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CD23, the low affinity receptor for IgE on B cells, exists in membrane and soluble 
forms. CD23 also binds CD21 with a distinct binding site to IgE. Soluble CD23 
(sCD23) fragments are released from trimeric membrane CD23 (mCD23) by the 
endogenous metalloprotease, ADAM10. It has been suggested that trimeric sCD23 
fragments can co-ligate membrane IgE (mIgE) and membrane CD21 (mCD21) on the 
surface of human B cells, in a similar way to C3d-antigen complexes and mIgM, to up-
regulate IgE synthesis and provoke allergic responses. 
To test this hypothesis, purified tonsil B cells were stimulated with IL-4 and anti-CD40 
to induce class switching to IgE in vitro. mCD23 was up-regulated and sCD23 
accumulated in the medium prior to IgE synthesis. IL-10 and IL-21 were shown to 
enhance IgE synthesis by increasing cell division and plasma cell differentiation. siRNA 
inhibition of CD23 synthesis or inhibition of mCD23 cleavage by an ADAM10 
inhibitor, GI254023X, were shown to suppress IgE synthesis. Addition of a 
recombinant trimeric sCD23, triCD23, enhanced IgE synthesis. This occurred even 
when endogenous mCD23 was protected from cleavage by GI254023X, indicating that 
IgE synthesis is positively controlled by sCD23. triCD23 was shown to bind to cells co-
expressing mIgE and mCD21 and caused capping of these proteins on the B cell 
membrane. triCD23-mediated up-regulation of IgE secretion and capping of mCD21 
was blocked in the presence of an anti-CD21 monoclonal antibody.  
Up-regulation of IgE secretion by sCD23 occurred after class switch recombination and 
the effects were isotype-specific. Together, these results suggest that mIgE and mCD21 
co-operate in the sCD23-mediated positive regulation of IgE synthesis by IgE-
committed B cells. 
These results have improved our understanding of the regulation of IgE in human B 
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Chapter 1. Introduction 
1.1. Asthma & allergy 
 The prevalence of allergic disease has trebled in the last 20 years and now 
affects 44% of British adults. Of these 21 million sufferers, almost half say they suffer 
from more than one allergy. Asthma costs the NHS £1 billion per year and accounts for 
the loss of more than 18 million working days each year (Asthma-UK 2011).  
  Conditions which fall into the category of allergic disease include allergic 
rhinitis (hayfever), eczema, food allergies and asthma. Asthma can be defined as a 
complex inflammatory disease of the lung, characterised by „reversible‟ 
bronchoconstriction, airway hyper responsiveness (AHR), infiltration of the bronchial 
mucosa with inflammatory cell types (mast cells, lymphocytes and eosinophils), as well 
as goblet cell hyperplasia and thickening of the submucosa. It is these cellular changes 
that cause the physiological changes associated with asthma; variable airflow 
obstruction and AHR (Wills-Karp 1999). 
 Asthma can be classified as atopic (extrinsic) or non-atopic (intrinsic) based on 
whether symptoms are precipitated by allergens or not. Beyond this, asthma is classified 
by severity from intermittent to severe persistent. The interactions between 
environmental and genetic factors, which cause asthma, are complex and not fully 
understood. Aside from atopy, other factors have been shown to increase the risk of 
developing asthma include obesity, exposure to air pollutants, viral respiratory 
infections and smoking. In 2007, results from the first genome-wide association study 
(GWAS) on asthma showed a strong association between the ORMDL3 locus and 
childhood asthma (Moffatt, Kabesch et al., 2007). In 2010, the world-wide GABRIEL 
consortium reported the results of the largest study to date on the genetics of asthma. 





The study replicated the ORMDL3 results and also discovered IL1RL1/IL18R1, HLA-
DQ, IL33, SMAD3 and IL2RB loci to be significantly associated with asthma (Moffatt, 
Gut et al., 2010).  
 
1.2. Immunoglobulins 
Immunoglobulin molecules consist of two functionally distinct parts: the variable 
region for antigen recognition and binding; and the constant region responsible for 
effector function (Figure 1.1). There are five classes of immunoglobulin molecules 
(IgM, IgD, IgG, IgA and IgE) determined by differences in the amino acid sequences in 
the constant region of the heavy chains. During B cell development in the bone marrow, 
the rearrangement of the variable region genes V (variable), D (diversity) and J (joining) 
and the nine different heavy chain constant (C) region genes takes place. B cells exiting 
into the periphery initially express IgM on their surface (Cµ heavy chain constant 
region) (Edry and Melamed 2004).  
Upon antigen stimulation and T cell help, B cells proliferate and differentiate into 
cells producing other immunoglobulin classes in a process known as class switch 
recombination (CSR). In this process, an intervening DNA segment between the two 
recombining switch regions is deleted from the chromosome, termed a „switch circle‟. 
„Switch circle‟ production is controlled by the enzyme activation induced cytidine 
deaminase (AID), through the creation of DNA breaks (Kaminski and Stavnezer 2004; 
Yu, Chedin et al., 2003).  
 
 






Figure 1.1. The domain structures of IgE and IgG. 
Both IgE and IgG contain a variable (V) region, constant (C) region, two heavy (VH and C) and 
two light (VL and CL) chains. IgE contains an extra immunoglobulin domain (Cε2) in place of 
the hinge region found in IgG. 
From (Gould and Sutton 2008). 
 
 
1.3. Class switch recombination to IgE 
 Allergic disease, such as asthma and allergic rhinitis, can be caused by the over-
production of IgE antibodies to foreign antigens which are harmless to non-allergic 
individuals. Originally thought to only occur in germinal centres, local CSR and 
synthesis of IgE has been shown to take place at local sites of inflammation in the nasal 
mucosa of allergic rhinitis patients (Durham, Smurthwaite et al., 2000; KleinJan, Vinke 
et al., 2000; Takhar, Smurthwaite et al., 2005) and the bronchial mucosa of asthmatics 
(Fiset, Cameron et al., 2005; Takhar, Corrigan et al., 2007; Ying, Humbert et al., 2001). 
 CSR to IgE is induced by the Th2 cytokines, IL-4 and IL-13, and CD40L 
(ligand) expression (Figure 1.2). IL-4 and IL-13 induce the activation of JAK kinases 





and the transcription factor STAT6 which binds to the ε germline gene promoter and 
activates transcription of the gene. CD40L expressed on activated T cells can ligate the 
B cell receptor CD40. This ligation event is required for JNK activation, which is 
important for AID activity required for CSR (Jabara and Geha 2005). These signalling 
events result in the transcription of ε germline gene transcripts (εGLT) and CSR to IgE. 
During recombination from IgM to IgE, the µ and ε switch regions, which contain 
potential DNA breakpoints, are broken and recombined to express ε chain mRNA and 
protein (Gould, Takhar et al., 2006). IgE exerts it effects through the receptors FcεRI 
and FcεRII (CD23), which are discussed in further detail in the following sections. 
 
1.4. The ‘high affinity’ IgE receptor (FcεRI) 
 FcεRI is expressed on a wide range of cells including monocytes, macrophages, 
basophils, mast cells, APCs, epithelial cells and smooth muscle cells. The Cε2 and Cε3 





permanently coating cells with IgE. This “sensitisation” enables very rapid activation 
upon allergen re-exposure (Gould, Sutton et al., 2003). When IgE binds to FcεRI on 
APCs, allergen cross-linking leads to presentation to allergen-specific Th2 cells (Figure 
1.2). This induces IL-4 secretion and CD40 cross-linking, promoting further Th2 cell 
differentiation and CSR to IgE in neighbouring B cells, as described in Section 1.3 
(Jabara, Fu et al., 1990). Allergen can also cross-link IgE bound to FcεRI on the surface 
of mast cells to induce an immediate type I hypersensitivity reaction resulting in 
degranulation and release of pro-inflammatory mediators, including histamine (Figure 
1.2). Repeated exposure to allergens leads to increased allergen-specific Th2 cells and 





IgE antibodies which initiate a secondary immune response upon subsequent allergen 
exposure (Williams and Galli 2000). 
 Anti-IgE monoclonal antibodies (mAb) have been shown to down-regulate 
FcεRI expression on human basophils in vivo (MacGlashan, Bochner et al., 1997) and 
in vitro (MacGlashan, McKenzie-White et al., 1998). Omalizumab (Xolair, Novartis 
Pharmaceuticals Ltd) is an anti-IgE antibody therapy used in the treatment of refractory 
moderate to severe asthma (Figure 1.2). It binds to and neutralises free IgE to prevent 
binding to FcεRI on mast cells and APCs (Holgate, Bousquet et al., 2001). However, 
omalizumab is very expensive to produce and, therefore, discovery of a small molecule 
inhibitor of the IgE-FcεRI interaction is in great demand as an alternative therapeutic 
approach with lower costs and a wider range of applications. 
 
 






Figure 1.2. The role of IgE and IgE receptors (FcεRI and CD23) in the allergic 
response. 
Following class switch recombination, IgE binds to FcεRI on APCs to sensitise cells to allergen. 
Upon allergen cross-linking of mIgE on APCs, recruited Th2 cells produce IL-4, IL-13 and 
CD40L, stimulating B cells to produce more IgE. Allergen also cross-links mIgE bound to 
FcεRI on mast cells, inducing degranulation and pro-inflammatory mediator release, initiating 
the allergic response. The B cell IgE receptor, CD23, is shown in the membrane and soluble 
form, with the co-receptor CD21. 
From (Gould and Sutton 2008).  





1.5. The ‘low affinity’ IgE receptor (FcεRII/CD23) 
The focus of this thesis is an investigation into the IgE receptor FcεRII (CD23). The 
information provided below relates to human CD23, unless otherwise stated. 
1.5.1. Distribution of CD23 
 Following the identification of CD23 as an IgE receptor on monocytes and B 
cells (Melewicz, Plummer et al., 1982), many cell types have been subsequently found 
to express CD23. These include T cells, NK cells, eosinophils, platelets, macrophages, 
follicular dendritic cells (Delespesse, Suter et al., 1991) and structural cells, such as 
airway smooth muscle cells (Belleau, Gandhi et al., 2005). 
1.5.2. Structure of CD23 
 Human CD23 is initially expressed as a 45 kDa type II integral membrane 
protein consisting of 321 amino acids. Unlike all other Fc receptors which belong to the 
Ig superfamily, CD23 is a member of the C-type (calcium-dependent) lectin family 
(Conrad 1990; Soilleux, Barten et al., 2000). Membrane CD23 (mCD23) contains a C-
type lectin „head‟ domain, a triple-stranded coiled-coil stalk and a C-terminal „tail‟ in 
the extracellular sequence (Figure 1.3A) (Gould and Sutton 2008; Spiegelberg 1991). 
The „tail‟ is not present in murine CD23 (Dierks, Bartlett et al., 1993). 
 CD23 is assembled into a trimer (Figure 1.3B) (Beavil, Graber et al., 1995), the 
predominant form in the B cell membrane, by way of the α-helical coiled-coil stalk that 
links the three lectin „head‟ and „tail‟ domains to their transmembrane and cytoplasmic 
sequences (Beavil, Edmeades et al., 1992). Structures of the CD23 lectin „head‟ solved 
by NMR (Hibbert, Teriete et al., 2005) and X-ray crystallography (Wurzburg, 
Tarchevskaya et al., 2006), revealed binding sites for IgE and CD21. Following 





observations in mice (Dierks, Bartlett et al., 1993), it was discovered that although a 







Ghirlando et al., 1997), a trimer of human mCD23 is capable of binding IgE with high 






). This is due to an avidity effect when the three lectin „heads‟ 
are brought together (Gould, Sutton et al., 1991). Binding of CD23 to IgE and CD21 is 





Figure 1.3. Structure of human membrane CD23. 
(A) The structure of full length mCD23 is comprised of the lectin „head‟ domain, coiled-coil 
stalk region and cytoplasmic tail region. The a-form and b-form are shown to differ by 6-7 
amino acids in the cytoplasmic sequence. α helices (α), β sheets (β) and loops (L) are indicated. 
Red arrows indicate cleavage sites for production of sCD23 fragments with the corresponding 
molecular weights. (B) Model of three mCD23 molecules assembled into a trimer. 
Adapted from (Kijimoto-Ochiai 2002) and (Gould and Sutton 2008). 
 
  





 Human CD23 is expressed as two isoforms, CD23a and CD23b, resulting from 
alternative transcription initiation sites and differing only by six or seven amino acids in 
the intracellular N-terminal cytoplasmic sequence (Figure 1.3A) (Yokota, Kikutani et 
al., 1988). CD23a is expressed on antigen-activated B cells, while CD23b expression is 
up-regulated on a wide variety of cells, particularly by IL-4 (Ewart, Ozanne et al., 
2002). 
1.5.3. Cleavage of CD23 
 The extracellular stalk region of mCD23 is susceptible to proteolysis, releasing a 
soluble form of CD23 (sCD23) (Sarfati, Nakajima et al., 1987). sCD23 fragments can 
vary in molecular weight due to several potential cleavage sites (Table 1.1 and Figure 
1.3A). All sCD23 fragments contain the lectin „head‟ domain and, therefore, retain the 
ability to bind IgE, albeit at lower affinity (Beavil, Graber et al., 1995). Larger sCD23 
fragments still have the tendency to form trimers, depending on the length of the 
remaining stalk region (Schulz, Sutton et al., 1997).  
 Members of the ADAM (A Disintegrin And Metalloprotease) family have been 
identified as the cleavage enzymes responsible for the production of 37 kDa and 33 kDa 
sCD23 (Table 1.1). ADAM10 is the principal sheddase of mCD23 both in vitro 
(Lemieux, Blumenkron et al., 2007; Weskamp, Ford et al., 2006) and in vivo (Gibb, El 
Shikh et al., 2010; Mathews, Ford et al., 2011; Weskamp, Ford et al., 2006). In a B cell 
specific ADAM10 knock-out mouse model, sCD23 production was reduced by 70% 
(Gibb, El Shikh et al., 2010). This same study, for the first time, showed ADAM10 to 
be essential for the initiation of Notch2 signalling (Gibb, El Shikh et al., 2010). The 
Notch2 signalling pathway is known to regulate the development of the marginal zone 





B cell lineage (Tanigaki and Honjo 2007) and plays a role in B cell activation by 
enhancing B cell receptor (BCR) and CD40 signalling (Thomas, Calamito et al., 2007).  
ADAM8 and ADAM33 have also been shown to produce sCD23 in vitro (Table 
1.1). However, whether these enzymes contribute to sCD23 production in vivo is 
uncertain. ADAM8 and ADAM33 knock-out mice show no alteration in sCD23 
production (Weskamp, Ford et al., 2006) and human immune cells, including B cells, 
have been shown to express very low levels of ADAM8 and undetectable levels of 
ADAM33 (Richens, Fairclough et al., 2007; Umland, Garlisi et al., 2003).  
 sCD23 can subsequently degrade into smaller fragments with molecular weights 
of 25-27 kDa (Table 1.1 and Figure 1.3A). This has been observed in cell culture 
supernatants and human serum (Letellier, Sarfati et al., 1989; Sarfati, Bron et al., 1988). 
The smallest sCD23 fragment, termed derCD23, results from cleavage by the house 
dust mite allergen, Der p I, a cysteine protease (Figure 1.3A). The resulting 16 kDa 
monomer contains only the lectin „head‟ domain and ten amino acids of the C-terminal 
„tail‟ (Gough, Schulz et al., 1999; Schulz, Sutton et al., 1997). 
 In addition to extracellular processing, sCD23 can be produced by intracellular 
proteolytic processing of newly synthesised CD23. This results in the secretion of 
sCD23 fragments with molecular weights of 28-29 kDa (Table 1.1) (Lee, Simmons et 
al., 1989). A recent study found mCD23 and ADAM10 inside endosomal compartments 
of murine and human B cells. This suggests a pathway of mCD23 internalisation and 
partial cleavage by ADAM10, prior to being secreted from the cell, as an alternative 
source of sCD23 (Mathews, Gibb et al., 2010).  
 
 





MW (kDa) Origin Enzyme 




in vivo: ADAM10 and MMP9 
in vitro: ADAM10, ADAM8 
and ADAM 33 




in vivo: ADAM10 and MMP9 
in vitro: ADAM10, ADAM8 
and ADAM 33 
28-29 Intracellular processing of newly synthesised 
CD23 protein 
Not defined 
25-27 Proteolytic cleavage/degradation products of 
33 kDa and 37 kDa sCD23 
Not defined 







Table 1.1. The variety of soluble CD23 fragments 
The locations of cleavage sites are shown on the structure of CD23 in Figure 1.3. From (Platzer, 
Ruiter et al., 2011). 
 
  Shedding of mCD23 can be prevented by stabilisation through conformational 
changes which reduce the accessibility of the cleavage sites to ADAM10. This can 
occur upon binding to IgE or through the use of CD23 mAbs (Conrad, Ford et al., 2007; 
Gould, Sutton et al., 1991). The human anti-CD23 mAb lumiliximab (IDEC-152, 
Biogen Idec Ltd) is thought to inhibit production of sCD23 through stabilisation of 
mCD23 (Rosenwasser, Busse et al., 2003). The resulting clinical impacts of 
lumiliximab treatment are discussed in Section 1.9. 
 
1.6. The interactions of CD23 
1.6.1. Interaction of CD23 with IgE 
 Upon binding to the high affinity receptor FcεRI, IgE undergoes a 
conformational change involving the Cε2 and Cε3 domains that is believed to be 
responsible for the high affinity interaction and slow dissociation rate as previously 
discussed in Section 1.4. This information was obtained from crystal structures of IgE 
Fc (Holdom, Davies et al., 2011; Wan, Beavil et al., 2002). No crystal structure has 





been published of the CD23-IgE complex. NMR analysis of the interaction between 
derCD23 and IgE identified a number of residues in the Cε3 domain that are implicated 
in CD23 binding (Hibbert, Teriete et al., 2005). Ultracentrifugation studies showed 
there to be two binding sites for CD23 on IgE, suggesting that one molecule of IgE may 
bind two lectin „heads‟ of the same molecule of CD23 or that one molecule of IgE may 
bind to two lectin „heads‟, each on separate CD23 molecules, leading to large cross-
linked networks (Hibbert, Teriete et al., 2005; Shi, Ghirlando et al., 1997).  
 The kinetics and binding sites for IgE on CD23 were introduced in Section 1.5.2, 
however, the requirement of calcium for this interaction was not previously discussed. 
CD23 contains two calcium binding sites, a principal binding site conserved among C-
type lectins and a non-conserved site (Weis, Drickamer et al., 1992). NMR analysis 
following a calcium titration showed the second non-conserved calcium binding site to 
be occupied and that calcium is not required to stabilise the lectin „head‟ for derCD23 to 
bind to IgE (Hibbert, Teriete et al., 2005). In contrast, the crystal structure of the lectin 
„head‟ in the presence of calcium revealed calcium binding at only the principal calcium 
binding site. In the crystal structure without calcium present, the principal calcium 
binding site is occupied by an arginine from a neighbouring loop (Wurzburg, 
Tarchevskaya et al., 2006). The calcium-induced conformational change is in areas 
shown to be important in binding to IgE Fc (Bettler, Maier et al., 1989). 
1.6.2. Interaction of CD23 with CD21 
 CD21 is a type I membrane glycoprotein with a molecular mass of ~145 kDa. 
The protein consists of a large extracellular portion made up of 15-16 short consensus 
repeat (SCR) domains, a transmembrane region and a short cytoplasmic tail (Gilbert, 
Asokan et al., 2006; Weis, Drickamer et al., 1992). CD21 (also known as complement 





receptor 2), associated with CD19, is the receptor for C3dg complement fragments, 
several copies of which covalently bind antigen. This lowers the threshold to initiate an 
immune response by two or three orders of magnitude. On antigen-specific B cells, 
C3dg co-ligates membrane IgM (mIgM) and the antigen receptor to form a „signalling 
platform‟ to stimulate proliferation and antibody production. Downstream signalling 
events from mIgM and CD21 co-ligation lead to Bcl-xL and Bcl-2 synthesis, reducing 
apoptosis and promoting B cell survival, proliferation and antibody production 
(Cherukuri, Cheng et al., 2001; Fearon and Carter 1995; Pierce 2002; Roberts and Snow 
1999).  
Twenty years ago, Bonnefoy et al incorporated recombinant CD23 into 
fluorescent liposomes and used this as a probe to first identify CD21 as a co-receptor for 
CD23 (Aubry, Pochon et al., 1994; Aubry, Pochon et al., 1992). Of the sixteen possible 
extracellular SCR domains of CD21, they mapped CD23 binding to SCR1-2 and SCR 
5-8. On CD23, structural studies have mapped the CD21 binding site to the C-terminal 
„tail‟ (Figure 1.4) (Hibbert, Teriete et al., 2005). 
 NMR studies by Hibbert et al showed the CD21 and IgE binding sites on CD23 
to be distinct from each other and from the trimerisation interface (Figure 1.4). This 
study also showed the capability of the 16 kDa monomeric sCD23 fragment, derCD23, 
to simultaneously bind both IgE and CD21 to form a tri-molecular complex (Hibbert, 
Teriete et al., 2005). The implications of an IgE-sCD23-CD21 complex are discussed in 
greater detail in Section 1.7.2. 






Figure 1.4: The structure of the CD23 trimer and its interactions with IgE and CD21. 
(A) An overhead view of the proposed trimer of CD23, coloured according to electrostatic 
charge, with IgE interaction residues shown in green. (B) Ligand binding sites on the top and 
side of trimeric CD23. Oligomerisation sites are coloured blue and red, the IgE interaction sites 
green, the CD21 binding sites cyan and the calcium binding sites yellow.  
From (Hibbert, Teriete et al., 2005). 
 
1.6.3. Other interactions of CD23 
 Human CD23 has also been shown to interact with the monocyte-expressed β2 
subfamily integrins CD11b and CD11c. These integrins pair with the β subunit CD18 to 
form the complement receptors αMβ2 (macrophage-1 antigen or CR3) and αXβ2 (CR4) 
(Bajorath and Aruffo 1996). CD23 binding activates nitric oxide synthase to induce the 
production of inflammatory cytokines such as IL-6, IL-8 and TNFα (Aubry, Dugas et 
al., 1997; Lecoanet-Henchoz, Gauchat et al., 1995). Human CD23 can also bind to the 
vitronectin receptor (αvβ3 integrin), associated with CD47, on monocytes to induce pro-
inflammatory cytokine release (Hermann, Armant et al., 1999). 
 
 





1.7. The role of CD23 in IgE homeostasis 
 As only 0.0001% of all serum immunoglobulins are IgE in normal donors (at 
~0.1µg/ml), 10
4 
less than that of IgG (Waldmann, Iio et al., 1976), the secretion of IgE 
must be a tightly regulated process. The interaction of CD23 with CD21, as described in 
Section 1.6.2, has been shown to be a key component in the regulation of IgE (Aubry, 
Pochon et al., 1994). CD23 has been implicated in both the up- and down-regulation of 
IgE synthesis, depending on its structural form. The ability of CD23 to both increase 
and decrease IgE suggests different forms of CD23 may act as a two-way switch in IgE 
homeostasis (Figure 1.5). 
1.7.1. The role of mCD23 in IgE homeostasis 
 It has long been known that CD23 negatively regulates the synthesis of IgE 
(Cho, Kilmon et al., 1997; Yu, Kosco-Vilbois et al., 1994). The most compelling 
evidence comes from CD23 knock-out mice, which exhibit greatly increased levels of 
antigen-specific IgE after immunisation (Cho, Kilmon et al., 1997; Yu, Kosco-Vilbois 
et al., 1994).  
 IgE synthesis is also inhibited in human B cells by anti-CD23 antibodies 
(McCloskey, Hunt et al., 2007; Nakamura, Kloetzer et al., 2000; Sherr, Macy et al., 
1989) and antigen-IgE complexes which bind to mCD23 (Figure 1.5) (Conrad, Ford et 
al., 2007). This stabilises mCD23 and prevents the formation of sCD23 allowing a 
negative feedback pathway to dominate. Neither free IgE nor antibody Fab fragments 
have this inhibitory activity, suggesting that cross-linking of mCD23 is required for the 
inhibition (Sherr, Macy et al., 1989). These observations suggest that mCD23 may act 
in a negative feedback mechanism on IgE synthesis to terminate allergen-specific IgE 
secretion (Figure 1.5). 





1.7.2. The role of sCD23 fragments in IgE homeostasis 
 IL-4 and CD40L have been shown to synergistically promote CD23 expression 
and sCD23 production which, in turn, leads to an increase in IgE secretion from IgE-
committed B cells. IL-4 and CD40L activate the transcription factors STAT6 and 
NFκB, respectively, to induce ε-germline gene expression and DNA recombination 
(Iciek, Delphin et al., 1997; Jabara, Fu et al., 1990; Linehan, Warren et al., 1998). 
Although these studies showed a link between sCD23 and IgE up-regulation, the exact 
mechanisms still remain unclear. 
 In a similar mechanism to co-ligation of mIgM and CD21 by C3dg, as described 
in Section 1.6.2, it has been proposed that trimeric sCD23 can co-ligate mIgE and CD21 
on the surface of IgE-committed B cells, stimulating proliferation of IgE-secreting 
plasma cells and increasing IgE secretion (Figure 1.5) (Gould, Beavil et al., 1997). This 
hypothesis is based on experiments in which the hen egg lysozyme (HEL)-specific BCR 
and CD21 were cross-linked with a C3d-HEL fusion protein. This lowered the B cell 
activation threshold, resulting in cell proliferation and IgM secretion (Dempsey, Allison 
et al., 1996; Dempsey and Fearon 1996). In human CD23, the binding site for CD21 
resides in the C-terminal „tail‟ (Hibbert, Teriete et al., 2005). This „tail‟ is not present in 
murine CD23 (Dierks, Bartlett et al., 1993), which may explain why sCD23 expressed 
in transgenic mice does not up-regulate IgE during immunisation, leaving only down-
regulation through mCD23 (Lamers and Yu 1995; Texido, Eibel et al., 1994; Yu, 
Kosco-Vilbois et al., 1994). 
1.7.3. In vitro studies of the effect of sCD23 on IgE 
 A number of studies have shown recombinant sCD23 fragments to either up- or 
down-regulate IgE synthesis in primary human B cells. Addition of recombinant 





oligomeric CD23 (lzCD23 or exCD23) has been shown to up-regulate IgE synthesis and 
derCD23 has been shown to down-regulate IgE synthesis (Aubry, Pochon et al., 1992; 
Bowles, Jaeger et al., 2011; Mayer, Bolognese et al., 2000; McCloskey, Hunt et al., 
2007; Sarfati, Bettler et al., 1992). These studies suggest the ability of sCD23 fragments 
to up-regulate IgE synthesis depends on their ability to form trimers. Despite the 
inability of derCD23 to oligomerise, distinct binding sites for CD21 and IgE have been 
identified (Hibbert, Teriete et al., 2005). Dual binding to both mIgE and CD21 is not 
thought to be possible in vivo due to the relative sizes of the molecules and their 
positioning on the cell surface. This may explain the down-regulation of IgE following 
addition of monomeric derCD23 (Sarfati, Bettler et al., 1992). 
 Several studies have utilised pharmacological inhibitors of ADAM10 (e.g. 
GI254023X) to inhibit mCD23 cleavage and, therefore, reduce sCD23 production 
(Lemieux, Blumenkron et al., 2007; Mathews, Ford et al., 2011; Mayer, Bolognese et 
al., 2000; Weskamp, Ford et al., 2006). Mayer et al showed inhibition of mCD23 
cleavage to correlate with inhibition of IL-4-stimulated IgE production in human 
peripheral blood lymphocytes (PBL) and human PBL-reconstituted SCID mice. In this 
study, progressively later additions of the mCD23 processing inhibitor in the 14 day 
culture period resulted in less inhibition of both sCD23 production and IgE secretion 
(Mayer, Bolognese et al., 2000). Mayer et al concluded that inhibition of mCD23 











Figure 1.5. CD23-mediated regulation of IgE synthesis. 
In this model, mCD23 is cleaved by ADAM10 to release trimeric sCD23 which co-ligates both 
mIgE and mCD21 on the surface of IgE-committed B cells to up-regulate IgE synthesis, 
triggering the onset of allergic symptoms. The inset shows the proposed formation of a large 
signalling network. Negative regulation occurs when the membrane form of CD23 is stabilised 
either through allergen-IgE complexes or certain anti-CD23 mAbs that bind the lectin „head‟ 
domain (e.g. lumiliximab). 
Adapted from (Gould and Sutton 2008). 
 
 
1.8. Other functions of CD23 
 Allergen-IgE complexes can bind to CD23 on allergen-activated B cells, leading 
to antigen presentation to T cells in a process known as facilitated antigen presentation 
(FAP) (Carlsson, Hjelm et al., 2007; Getahun, Hjelm et al., 2005). Following 
internalisation of whole antigen, a range of peptides are displayed by HLA-DR 
molecules (Karagiannis, Warrack et al., 2001) resulting in the generation of T cells with 
different epitope specificities, in a process known as „epitope spreading‟ (Mudde, 
Bheekha et al., 1995).  
 sCD23 can act as a B cell growth factor through the promotion of proliferation 
of IgE-specific plasmablasts. sCD23, together with IL-1, has been shown to rescue 





germinal centre B cells from apoptosis through the up-regulation of Bcl-2 (Liu, Cairns 
et al., 1991). 
 
1.9. CD23 as a biomarker and clinical target 
 High sCD23 levels are observed in a wide variety of diseases such as 
haematopoietic cancers, auto-immune diseases and allergic disease. Chronic 
lymphocytic leukaemia (CLL) is currently the only disease in which sCD23 is used as a 
clinical biomarker. High plasma sCD23 concentrations correlate with CLL severity and 
progression (Meuleman, Stamatopoulos et al., 2008; Reinisch, Willheim et al., 1994; 
Sarfati, Chevret et al., 1996; Schwarzmeier, Shehata et al., 2002).  
 In the case of allergic disease, there is debate as to whether enhanced serum 
sCD23 is a predictive marker for diagnosing allergy or whether it is simply a 
consequence of the disease. Several studies have shown a correlation between elevated 
serum IgE and levels of both mCD23 and sCD23 in allergic patients (Aberle, Gagro et 
al., 1997; Di Lorenzo, Drago et al., 1999; Lorenzo, Mansueto et al., 1996; Yanagihara, 
Sarfati et al., 1990), whilst others have found no statistically significant correlation 
(Rogala and Rymarczyk 1999; Wilhelm, Klouche et al., 1994). 
 The anti-CD23 mAb, lumiliximab, down-regulates IgE synthesis in human B 
cells in vitro (McCloskey, Hunt et al., 2007). A phase I clinical trial of lumiliximab in 
patients with mild-to-moderate persistent allergic asthma reduced serum IgE levels 
(Rosenwasser, Busse et al., 2003; Rosenwasser and Meng 2005). In 2004, lumiliximab 
in combination with chemotherapy drugs (fludarabine and cyclophosphamide) and 
rituximab (anti-CD20), entered a six year Phase I/II clinical trial for patients with 
relapsed CD23
+
 B cell CLL (Byrd, Kipps et al., 2010). Phase II randomised multi-





centre studies shortly followed, in patients with previously untreated CLL (clinical trial 
#NCT00801060) and relapsed CLL (clinical trial #NCT00391066). However, both of 
these trials were terminated in 2010. 
 sCD23, as well as mCD23, may be a promising target for therapy, as the work in 
this thesis shows. The use of selective ADAM10 inhibitors is considered a potential 
therapy for asthma, based on a recent pre-clinical trial in mice where intranasal 
administration of selective ADAM10 inhibitors led to reduced eosinophilia in the 
bronchoalveolar lavage fluid and reduced AHR (Mathews, Ford et al., 2011). In support 
of this therapeutic potential, it is known that asthmatics express high levels of ADAM10 
in the lung (Dijkstra, Postma et al., 2009).  
 
  





1.10. Hypothesis & Aims of the thesis 
  Due to the multiple forms of CD23, multiple ligands and various activities of the 
different complexes, the mechanisms involved in IgE regulation by CD23 are still 
poorly understood. The main aim of this thesis is to therefore investigate the role of 
different forms of CD23 in the regulation of IgE in primary human B cells.  
 The hypothesis that sCD23 can form a tri-molecular complex by binding to both 
mIgE and mCD21 to induce the up-regulation of IgE synthesis will be tested through 
the aims described below. 
 Isolated human tonsil B cells will be cultured with IL-4 and anti-CD40 to induce 
CSR to IgE, expression of mCD23 and mCD21 and production of sCD23 and 
secretion of IgE. sCD23 levels will be reduced through siRNA-mediated 
inhibition of CD23 or ADAM10 inhibition using GI254023X.  
 In contrast, sCD23 levels will be increased through addition of recombinant 
trimeric and monomeric sCD23 fragments.  
 In all cases, the loss of mCD23 from the B cell surface, the appearance of sCD23 
in the supernatant and the expression and secretion of IgE, as a function of time 
for up to 12 days, will be analysed by flow cytometry and ELISA.  
 The expression patterns of mIgE and mCD21, during the incubation of tonsil B 
cells with recombinant monomeric or trimeric sCD23, will be visualised by 
confocal microscopy. 
 An improved understanding of the regulation of IgE in human B cells may 
provide potential new therapeutic targets in the treatment of allergic disease. 





Chapter 2. Materials & Methods 
2.1. Materials  
2.1.1. Buffers & Media 
All chemicals were purchased from Sigma-Aldrich and diluted in deionised water 
unless otherwise stated. 
 
BrdU Staining Buffer: 3% FCS (Invitrogen) + 0.09% sodium azide in PBS 
Cell Culture Media: RPMI 1640, penicillin (100IU/ml), streptomycin (100µg/ml), 
glutamine (2mM) (Invitrogen), 10% FCS (Hyclone; Perbio Biosciences), transferrin 
(35µg/ml) and insulin (5µg/ml) 
ELISA Carbonate Buffer: 0.2M NaCO3 + 0.2M NaHCO3 (pH 9.8) 
FACS Buffer: 5% normal goat serum (Invitrogen) in PBS 
FACS Fix Buffer: 4% paraformaldehyde (EMS Ltd) in PBS 
FACS Permeabilisation Buffer: 0.05% Triton
®
 X-100 + 0.5% saponin in PBS 
Microscopy Fix Buffer: 4% paraformaldehyde in PBS 
Microscopy Wash Buffer: 0.05% Triton
®
 X-100 in PBS 
PBS-T: 0.05% Tween
®
 20 in PBS  






Application Antibody Manufacturer Conjugated Concentration  
used 











Alexa 594 1:500 
FACS Mouse anti-human 
ADAM10 
R&D Systems PE 1:50 
FACS Monoclonal mouse 
anti-human CD3 
Dako PE 1:50 
FACS Monoclonal mouse 
anti-human CD20 
Dako FITC 1:50 
FACS Monoclonal mouse 
anti-human CD21 
(HB-5) 
eBioscience APC 1:50 
FACS Mouse anti-human 
CD23 (EBVCS-5) 
BioLegend APC 1:50 
FACS Mouse anti-human 
CD23 (MHM6) 
Dako FITC 1:50 
FACS Monoclonal mouse 
anti-human CD38 
Dako FITC 1:50 
FACS Monoclonal mouse 
anti-human CD38 
Dako PE 1:50 
FACS Monoclonal mouse 
anti-human CD138 
AbD Serotec PE 1:10 






FACS Monoclonal mouse 
anti-human IgG 
Miltenyi Biotec APC 1:50 
FACS Mouse anti-human 
BrdU 
BD Biosciences APC 1µl 
 
ELISA Polyclonal mouse 
anti-human IgE 
Dako - 1:7000 





ELISA Mouse anti-human 
IgE 
Dako HRP 1:1000 
ELISA Polyclonal goat anti-
human IgG 
AbD Serotec - 1:1000 
ELISA Goat anti-human 
IgG 
Sigma-Aldrich HRP 1:1000 
Luminex Streptavidin Millipore PE 25µl/well 
 
Table 2.1. Antibodies used 
 
 
2.2. Isolation of human tonsil B cells 
 Following informed written consent, with ethical approval from Guy‟s Research 
Ethics Committee, human tonsils from donors undergoing routine tonsillectomies were 
obtained. The allergic status of the donor was determined by verbal communication 
with the parents at the time of consent. A list of tonsil donors, their allergic status and 
any medication the patients were taking is listed in Appendix 1. The tonsil donors used 
for each experiment is indicated in each figure legend. Mononuclear cells were 
separated by density on a Ficoll gradient (GE Healthcare) and B cells isolated using 
AET-treated sheep red blood cells (TCS Biosciences). The remaining cells were 
routinely >98% CD20
+
 and <2% CD3
+
, as determined by flow cytometry (Figure 2.1). 
  






Figure 2.1. Purity of freshly isolated human tonsil B cells. 
B cells were isolated from human tonsils by density centrifugation as described in Section 2.2. 
The expression of CD20 (B cell marker) and CD3 (T cell marker) were analysed by flow 
cytometry. 
Data shown from 1 donor (tonsil number 2), representative of 35 (tonsil numbers 1-35). 
 
 
2.3. Small interfering RNA (siRNA) transfection  
 Total B cells were transfected with the appropriate siRNA (3µg/960nM) 
(Thermo Scientific Dharmacon) as shown in Table 2.2 using the Amaxa™ Human B 
cell Nucleofector
™
 kit and Nucleofector
™
 II Device (Lonza), according to the 
manufacturer‟s instructions. Transfection efficiency, 30 minutes after transfection, was 
determined using a fluorescent non-functional siRNA (siGLO
®
 Red) (Thermo Scientific 
Dharmacon). The efficiency of CD23 knockdown was quantified by qPCR (described in 
Section 2.8). Although siRNA is designed to be specific to the gene of interest, the 









Target siRNA details 
Control 
(Non-targeting) 
ON-TARGETplus Non-targeting siRNA Pool #1 (D-001206-13-05) 
GAPDH ON-TARGETplus GAPD Control siRNA (DZD11400120) 
  









 Red Transfection Indicator DY-547 (D-001630-02-05) 
 
 
Table 2.2. siRNA reagents 
 
2.3.1. Post-transfection cell sorting 
 To separate positively and negatively transfected cells, human B cells were co-
transfected with siGLO
®





 cells were then separated using a FACS Aria™ Cell Sorter (BD 
Biosciences). 
 
2.4. Cell Culture 
 B cells were cultured in 24-well plates (Nunc) at 0.5x10
6
 cells/ml in Cell Culture 
Media. Cells were activated with IL-4 (200IU/ml) (R&D Systems) and anti-CD40 
antibody (1µg/ml) (G28.5; ATCC) for up to 12 days. 
2.4.1. ADAM10 inhibitor (GI254023X) 
 The ADAM10-specific hydroxamate-based small molecule inhibitor, 
GI254023X, was kindly provided by B Schmidt and B Drung from Technische 





Universität Darmstadt, Germany. GI254023X ((R)-N-((S)-3,3-dimethyl-1-
(methylamino)-1-oxobutan-2-yl)-2-((S)-1-(N-hydroxyformamido)ethyl)-5-
phenylpentanamide)) was purified on a CombiFlash Rf
®
 (Teledyne ISCO) system 
(column: RediSep Rf, 4 g silica; flow rate: 18ml/min; solvent: acetonitrile; tR: 10 min). 
HPLC analysis at 220nm confirmed a purity ≥98% (Hoettecke, Ludwig et al., 2010). 
Cells were grown for 5 days, to allow the up-regulation of CD23 and CSR to IgE, 
before addition of the inhibitor (0.25µM–15µM). 
2.4.2. Recombinant CD23 proteins 
 Monomeric derCD23 (16145 Da) was made as previously described (Hibbert, 
Teriete et al., 2005). lzCD23, made as previously described (McCloskey, Hunt et al., 
2007), was modified to produce the more stable trimer triCD23 (84414 Da), consisting 
of residues 131-321 of human CD23 prefixed by the trimerisation motif (IAAIESK)4 
and expressed and refolded from inclusion bodies using the Escherichia coli vector 
pET151. This additionally provided N-terminal HIS6 and V5 epitope tags and a TEV 
enzyme cleavage site that has been left uncleaved in the final product (designed by 
Rebecca Beavil and produced by Michael Wen-Pin Kao) (manuscript in preparation). 
Recombinant CD23 proteins were dialysed into PBS and sterile-filtered before addition 
to human B cell cultures. Concentrations were selected to be close to the calculated KD 
value for trimeric CD23 binding to IgE (10
-7
M) (Hibbert, Teriete et al., 2005; 
McCloskey, Hunt et al., 2007) and used at a weight ratio of 1:3 (triCD23:derCD23) to 









2.4.3. Anti-CD21 mAb 
 Mouse anti-human CD21 mAb (HB-5) (Santa Cruz) was added to cells at 0.1, 1 
or 10µg/ml. Epitope analysis has shown this clone to bind to SCRs 3-4 on CD21 and 
partially inhibit CD23 binding to CD21 (Aubry, Pochon et al., 1994). 
 
2.5. Flow cytometry 
2.5.1. Analysis of cell viability 
 Cell viability was quantified using flow cytometry with the proportion of live 
cells determined by gating on forward versus side scatter.  
2.5.2. Membrane and intracellular staining 
 At the appropriate timepoints, cells were collected into FACS tubes and washed 
in FACS Buffer. Antibodies to detect membrane-expressed markers (as shown in Table 
2.1) were added and incubated on ice in the dark for 45 minutes. Cells were then 
washed in FACS Buffer, fixed with 500µl FACS Fix Buffer and incubated at room 
temperature for 15 minutes. Cells were then washed in FACS Buffer and resuspended in 
200µl FACS Permeabilisation Buffer for 15 minutes. Intracellular antibodies were 
added (as shown in Table 2.1) and incubated on ice in the dark for 45 minutes. 
Collection of flow cytometry data was conducted using a FACS Calibur
TM
 (BD 









2.5.3. CFSE labelling for analysis of cell division 
 Cells were washed and resuspended at 1x10
6 
cells/ml in 2ml of RPMI 
(Invitrogen). CellTrace™ CFSE (5µM) (Invitrogen) in DMSO was added in 2ml of 
RPMI, for a final concentration of 2.5µM. Cells were incubated for 10 minutes at room 
temperature, washed twice in Cell Culture Media and counted. Cells were then cultured 
as described in Section 2.4 and CFSE content analysed by flow cytometry on day 7. 
2.5.4. BrdU incorporation for proliferation analysis 
 Using the APC BrdU Flow kit (BD Pharmingen), cells were labelled with BrdU 
(1mM) by direct addition to a well containing 1ml of cells (final concentration of 
10µM) and pulsed for 24 hours at 37°C. Cells were then washed in FACS tubes with 1 x 
Perm/Wash Buffer, resuspended in 100µl Cytofix/Cytoperm Buffer and incubated for 
15-30 minutes at room temperature. Cells were then washed and resuspended in 100µl 
Cytoperm Plus Buffer and incubated for 10 minutes on ice. Cells were then washed, 
resuspended in 100µl Cytofix/Cytoperm Buffer and incubated for 5 minutes at room 
temperature. Next, cells were resuspended in 100µl of DNase solution (30µg) and 
incubated for 1 hour at 37°C. Cells were then washed and resuspended in 50µl 
Perm/Wash Buffer containing anti-human BrdU-APC. Finally, cells were resuspended 
in 1ml Staining Buffer and BrdU incorporation measured by flow cytometric analysis, 
at no more than 400 events/second. 
 
  







 Maxisorp plates (Nunc) were coated with mouse anti-human IgE, in ELISA 
Carbonate Buffer, overnight at 4°C. Unbound sites were blocked with 2% milk powder 
in PBS-T for 1 hour at room temperature. Supernatant samples were then added at 
appropriate dilutions and plates incubated overnight at 4°C. Human serum IgE (NIBSC) 
was used to construct a standard curve. IgE binding was detected by mouse anti-human 
IgE-HRP in 1% milk in PBS-T for 2 hours at 37°C. The colour reaction was developed 
with OPD (Sigma-Aldrich) and analysed at 492nm using an automated plate reader 
(Titertek). Accumulated IgE concentrations were calculated from the standard curve 
using GraphPad Prism 5.03 software (San Diego, USA), with a minimum detectable 
concentration of 2ng/ml.  
2.6.2. IgG 
 Maxisorp plates were coated with goat anti-human IgG, in ELISA Carbonate 
Buffer, overnight at 4°C. Unbound sites were blocked with 2% milk powder in PBS-T 
for 1 hour at room temperature. Supernatant samples were then added at appropriate 
dilutions and plates incubated overnight at 4°C. Human serum IgG (Sigma) was used to 
construct a standard curve. IgG binding was detected by goat anti-human IgG-HRP in 
1% milk in PBS-T for 2 hours at 37°C. The colour reaction was developed with OPD 
and analysed at 492nm using an automated plate reader. Accumulated IgG 
concentrations were calculated from the standard curve using GraphPad Prism 5.03 
software, with a minimum detectable concentration of 2ng/ml.  
  






 Human sCD23 EASIA
™
 ELISA kits (BioSource International) were used 
according to the manufacturer‟s instructions. Briefly, supernatants were added to 
microtiter plates pre-coated with a mixture of monoclonal anti-CD23 antibodies and 
anti-CD23-HRP was added for 2 hours at room temperature. The colour reaction was 
developed with TMB and analysed at 450 nm using an automated plate reader. The kit 
recognises the 16, 25, 29 and 37 kDa fragments of sCD23. Accumulated sCD23 
concentrations were calculated from the standard curve using GraphPad Prism 5.03 
software, with a minimum detectable concentration of ~200pg/ml. 
 
2.7. MILLIPLEX® MAP Human Cytokine Assay 
 A MILLIPLEX
®
 MAP Human Cytokine 96-well Plate Assay (Millipore) was 
custom-made for the simultaneous quantification of human IL-2, IL-6, IL-10, IL-13 and 
IFNγ and used according to the manufacturer‟s instructions. Briefly, supernatants, 
controls and standards were added in duplicate to the 96-well filter plate with 25µl 
mixed antibody-immobilised beads per well and incubated on a plate shaker for 1 hour 
at room temperature. The fluid was removed by vacuum and the plate washed twice. 
25µl biotinylated detection antibodies were added per well and incubated on a plate 
shaker for 30 minutes at room temperature. Next, 25µl streptavidin-PE was added per 
well and incubated on a plate shaker for 30 minutes at room temperature. The fluid was 
removed by vacuum and the plate washed twice. 150µl of PBS was added per well and 
the beads resuspended on a plate shaker for 5 minutes. The plate was run on a 
FLEXMAP 3D
®
 machine (Luminex Corporation, Texas, USA) and the cytokine 





concentrations were calculated from analysis of MFI values. The minimum detection 
level for all cytokines was 0.4pg/ml. 
 
2.8. Quantitative PCR (qPCR) 
 Total RNA was isolated from cells using RNeasy Mini kits (Qiagen), primed 
with oligo(dT) and random hexamers and reverse transcribed using Superscript II 
(Invitrogen). qPCR was performed using TaqMan
®
 MGB gene expression assays (Table 
2.3) and TaqMan
®
 Universal PCR Master Mix on a 7900HT Real-Time PCR machine 
(Applied Biosystems). Gene expression was normalised to an endogenous reference 
gene (β2-microglobulin) and quantified by ∆∆ threshold cycle (Ct) analysis (SDS 2.1 
software). All reactions were carried out in triplicate. 
 
Target gene Assay details/oligo sequence 
β2-microglobulin 4310886E 
CD23 Hs00233627_m1  
εGLT F: 5‟ CTGTCCAGGAACCCGACAGA 3‟ 
R: 5‟ TGCAGCAGCGGGTCAAG 3‟ 
Probe: 6FAM-AGGCACCAAATG-MGB 
GAPDH Hs02786624_g1  
 









2.9. PyroGene™ Recombinant Factor C assay for endotoxin detection 
 The Pyrogene™ Recombinant Factor C (rFC) Endpoint Fluorescent Assay 
(Lonza) was used according to the manufacturer‟s instructions. Briefly, 100µl of 
samples and endotoxin standards were added in triplicate to the 96-well plate and 
incubated at 37ºC for 10 minutes. rFC enzyme solution, assay buffer and fluorogenic 
substrate were mixed at a ratio of 1:4:5 and 100µl was added per well. The fluorescence 
at time zero and at 1 hour was analysed at 380nm using an automated plate reader. 
Endotoxin concentration was calculated from the standard curve using GraphPad Prism 
5.03 software. 
 
2.10. Confocal microscopy 
 Human tonsillar B cells were stimulated for 8 days with IL-4 and anti-CD40, 
harvested and dead cells removed by density on a Ficoll gradient. 3x10
5
 cells were 
stimulated with either media alone, derCD23 (3µM/48µg/ml), triCD23 (1µM/84µg/ml) 
or anti-CD21 mAb (10µg/ml) at 37ºC for 30 minutes. Cells were fixed with Microscopy 
Fix Buffer, washed with Microscopy Wash Buffer, mounted onto poly-L-lysine-coated 
coverslips and fixed again. Coverslip-mounted cells were stained with goat anti-human 
IgE-FITC and mouse anti-human CD21 for 1 hour, washed, and secondary goat anti-
mouse-Alexa 594 was added for 45 minutes. The nuclear stain Hoescht 33258 
(1:20,000) (Molecular Probes, Invitrogen) was added for 10 minutes, cells were washed 
3 times and immunofluorescence visualised with an SP2 confocal microscope (Leica 
Microsystems). Multi-colour overlay images were created using ImageJ software 
(National Institutes of Health, USA). 
 





2.11. Statistical analysis 
 Flow cytometry and ELISA data are shown relative to control-treated cells 
(either transfected with control siRNA or stimulated with IL-4 and anti-CD40 alone, 
depending on the experiment), to compensate for inter-donor variation. Data from the 7 
out of 32 donors that failed to respond to IL-4 and anti-CD40, with undetectable levels 
of IgE expression and secretion by day 12, were excluded from selected figures. 
 Data are summarised as mean SEM. For comparisons between two non-paired 
groups, statistical analysis was performed using the Mann-Whitney U test. For 
comparisons between two paired groups, statistical analysis was performed using the 
Wilcoxon matched-pairs signed rank test. For comparisons between multiple groups, 
statistical analysis was performed using ANOVA with Bonferroni correction. The post-
test for linear trend was used to analyse dose-dependent trends. In all cases, a p-value of 
<0.05 was considered significant (ns = non-significant, * = <0.05, ** = <0.01, *** = 
<0.001). Significance to control conditions is indicated above data and significance 
between two conditions is shown between data. Correlation analysis was performed 
using Spearman‟s rank correlation coefficient.  





Chapter 3. Improving in vitro CSR to IgE in human B cells 
3.1. Introduction 
 Isotype class-switching to IgE in human B cells is induced by the interaction 
with Th2 cells. In the lymph nodes, Th2 cells secrete IL-4 and IL-13 and express 
CD40L which can co-ligate CD40 on B cells. Together, this promotes further Th2 cell 
differentiation and CSR to IgE (Jabara, Fu et al., 1990). To re-create this scenario in 
vitro, primary human tonsillar B cells were stimulated with recombinant human IL-4 
and an anti-CD40 mAb (aCD40). This chapter describes the in vitro model for induction 
of IgE expression and secretion from primary human B cells and how this can be 
enhanced by the inclusion of the additional cytokines IL-10 and IL-21.  
 
3.2. CSR to IgE in vitro requires IL-4 and anti-CD40  
 In order to initially determine the correct functioning of this system, primary 
human B cells were cultured for up to 12 days, in culture media alone or in the presence 
of IL-4 and anti-CD40. Surface and intracellular expression of IgE was assessed by 
flow cytometry (as described in Section 2.5.1) and secreted IgE (sIgE) levels assessed 
by ELISA (as described in Section 2.6.1). Figure 3.1 shows one example, from 32 
donors, of how IgE expression and secretion were modulated by the addition of IL-4 
and anti-CD40. As expected, the presence of both IL-4 and anti-CD40 were essential for 
cell survival and up-regulation of IgE from human B cells, levels of which could be 
detected from day 4 onwards (Figure 3.1).  
 







Figure 3.1. Human B cells require IL-4 and anti-CD40 for IgE expression and 
secretion. 
Total B cells were cultured for 12 days in the presence or absence of IL-4 (200IU/ml) and anti-
CD40 (1µg/ml) and monitored for the expression of membrane and intracellular IgE by flow 
cytometry and sIgE by ELISA. (A) % of live IgE
+
 cells measured by flow cytometry (white 
bars, left y-axis) and sIgE production by ELISA (blue bars, right y-axis), on days 4, 7 and 12, 
from cells stimulated with IL-4 and anti-CD40. Error bars represent SEM from experimental 
triplicates. Photographs show the proliferation and clumping of B cells over the culture period. 
(B) IgE expression 7 days after stimulation with or without IL-4 and anti-CD40, where % 
values shown represent the % of live IgE
+
 cells.  
Data shown from 1 (tonsil number 5) of 32 donors. 
 
 A titration of IL-4 and anti-CD40 was carried out to dissect the individual roles 
of each stimulation on human B cells. Cells were stimulated with either 100%, 50% or 
25% of the normal IL-4 and anti-CD40 concentrations (as described in Section 2.4) and 
cultured for 12 days before analysis of viability, IgE expression and IgE secretion. 
Figure 3.2A and Figure 3.2B show that the addition of IL-4 was more important for 
maintaining cell viability than the addition of anti-CD40. IgE expression was vastly 





reduced with decreasing concentrations of IL-4 (Figure 3.2C) and IgE secretion was 




     
Figure 3.2. IgE expression and secretion are dependent on both IL-4 and anti-CD40. 
Total B cells were cultured for 12 days in the presence of reducing concentrations of either IL-4 
or anti-CD40 and monitored for the expression of membrane and intracellular IgE by flow 
cytometry and sIgE by ELISA. (A) Day 12 cell viability and IgE expression of cells cultured 
with IL-4 at 100% (200IU/ml), 50% (100IU/ml) or 25% (50IU/ml) and 100% anti-CD40 
(1µg/ml), relative to cells cultured with 100% IL-4 and anti-CD40. (B) Day 12 cell viability and 
IgE expression of cells cultured with anti-CD40 at 100% (1µg/ml), 50% (500ng/ml) or 25% 
(250ng/ml) and 100% IL-4 (200IU/ml), relative to cells cultured with 100% IL-4 and anti-
CD40. (C) Day 12 IgE expression in cells cultured with sub-optimal IL-4 concentrations and 
100% anti-CD40. (D) IgE secretion by day 12 from cells cultured with sub-optimal IL-4 or anti-
CD40 concentrations. Error bars represent SEM from experimental triplicates. 
n=1 (tonsil number 16).  





3.2.1. IgE secretion from non-allergic versus allergic donors 
 Since May 2009 it became possible to question the parents of tonsil donors on 
the allergic status of their child. Before this date, due to ethical restrictions, the allergic 
status of tonsil donors was unknown and, therefore, it was not possible to correlate in 
vitro IgE expression and secretion with allergic status. Figure 3.3A shows the range of 
IgE secretion from human B cells cultured for 12 days with IL-4 and anti-CD40 (n=29). 
Excluding the 5 donors which did not produce any detectable sIgE by day 12, sIgE 
levels varied from 2 – 2742ng/ml (mean = 573 ± 151ng/ml, n=24). There was no 
significant difference between the levels of IgE secretion from non-allergic donors 
versus allergic donors. Figure 3.3B shows the range of IgG secretion from human B 
cells cultured for 12 days with IL-4 and anti-CD40 (n=21). Less donors are shown in 
Figure 3.3B compared to Figure 3.3A due to not enough supernatants available to test 
for both IgE and IgG. The difference of 8 donors is, therefore, not due to the fact that no 
IgG was detected in these particular donors. There was no significant difference 
between the levels of IgG secretion from non-allergic donors versus allergic donors. 
 It is of interest that the level of in vitro IL-4 and anti-CD40-stimulated IgE 
secretion does not appear to correlate with allergic severity. Specific allergies or allergic 
conditions are annotated on Figure 3.3, with the most atopic patient (allergic rhinitis, 
eczema, egg and nut allergy) producing the least sIgE of all the allergic patients (only 
15ng/ml by day 12). This indicates that any differences seen in IgE secretion in future 
experiments cannot be attributed to the allergic status of the patient from which the 
tonsil and B cells were isolated. 
 
  







Figure 3.3. Levels of in vitro IgE and IgG secretion are not associated with allergic 
status. 
Total B cells, from either non-allergic (○) (n=23) or allergic donors (□) (n=6), were cultured 
with IL-4 (200IU/ml) and anti-CD40 (1µg/ml) and (A) IgE secretion (n=29, tonsil numbers 4-
32) and (B) IgG secretion (n=21, tonsil numbers 8, 11-15, 17-25 & 27-32) were analysed by 
ELISA on day 12. Specific allergies or allergic conditions are annotated by each allergic donor.  
Error bars represent SEM and statistical analysis was performed using the Mann-Whitney U 
test. 





3.3. Increasing IgE production with the addition of IL-10 and IL-21 
 The induction of class switching to IgE in human B cells in vitro was already a 
well established protocol within the group. However, IgE levels often varied hugely 
between donors and it was a regular occurrence to detect no IgE expression or secretion 
after 12 days in culture, as demonstrated in Figure 3.3. Designing a reliable system 
which would consistently result in high IgE expression and secretion would greatly 
benefit my own studies and others working within the group, especially for future 
assays which aim to decrease IgE levels. In view of this, the addition of IL-10 and IL-21 
into the culture media was investigated. 
 IL-10 is considered a suppressive agent in the immune response and, therefore, it 
would seem important to investigate its effect on the regulation of IgE. It is well 
documented that IL-10 increases cell division in the murine system (Hasbold, Lyons et 
al., 1998; Hodgkin, Lee et al., 1996) and, more recently, an IL-10-mediated association 
between CSR to IgG and cell division was shown in the human in vitro (Tangye, Avery 
et al., 2003; Tangye, Ferguson et al., 2002). However, similar studies on human IgE 
have been restricted due to low IgE production from primary human B cells in vitro. 
Conflicting reports surround this field, with some reports stating that IL-10 inhibits IL-4 
and anti-CD40-stimulated IgE production from PBMCs (Milovanovic, Heine et al., 
2009; Punnonen, de Waal Malefyt et al., 1993) and purified B cells (Akdis, Blesken et 
al., 1998), whilst other reports show an increase in IgE due to increased proliferation 
and plasma cell differentiation (Kobayashi, Nagumo et al., 2002; Rousset, Peyrol et al., 
1995). Differences appear to be most likely due to the source of B cells and the chosen 
method to stimulate CD40 signalling. 





 IL-21, a recently identified type I cytokine produced by CD4
+
 T cells and NKT 
cells, is known to enhance B cell proliferation (Parrish-Novak, Dillon et al., 2000). Like 
IL-10, conflicting reports exist on whether IL-21 up-regulates (Caven, Shelburne et al., 
2005; Caven, Sturgill et al., 2007) or down-regulates (Pene, Guglielmi et al., 2006; 
Wood, Bourque et al., 2004) IgE production from human B cells in vitro. These 
differences are most likely due to the concentration of IL-21 and B cell density. It has 
been reported that IL-21 up-regulates IgE production from human B cells through the 
promotion of plasma cell differentiation (increase in BLIMP-1, XBP-1 and CD38
hi
 
cells) and enhancement of AID expression, working in synergy with IL-10 (Caven, 
Shelburne et al., 2005; Caven, Sturgill et al., 2007; Kobayashi, Nagumo et al., 2002; 
Kobayashi, Haruo et al., 2009). This signalling pathway has been shown to involve 
STAT3 (Avery, Ma et al., 2008) and Bcl-6 (Kitayama, Sakamoto et al., 2008). 
3.3.1. IL-10 and IL-21 increase IgE and IgG expression 
 Initially, the effect of IL-10 and IL-21 on the expression of IgE and IgG was 
investigated in human B cells. Cells were isolated and stimulated with IL-4 and anti-
CD40 alone, plus the addition of IL-10, IL-21 or a combination of IL-10 & IL-21, and 
cultured for up to 12 days. The population size (% positive cells) and mean fluorescence 




 cells were analysed by flow cytometry (as described in 
Section 2.5.1) on days 5, 7 and 12 and compared to cells cultured with IL-4 and anti-
CD40 alone.  
 Under the normal culture conditions of IL-4 and anti-CD40 alone, the population 
size of IgE
+
 cells increased over the 12 day culture period. The majority of this 
expansion took place between days 7 and 12 (Figure 3.4A). The addition of IL-10 ± IL-
21 caused an increase in the percentage and MFI of IgE
+
 cells on days 5 and 7. By day 





12, the presence of the additional cytokines no longer resulted in a larger proportion of 
IgE
+
 cells or higher MFI, compared to cells cultured with IL-4 and anti-CD40 alone. 
However, none of these differences reached statistical significance (Figure 3.4).  
 Figure 3.5 shows flow cytometric analysis of IgG expression following 
stimulation with IL-4 and anti-CD40 alone, plus the addition of IL-10, IL-21 or IL-10 & 
IL-21. Unlike the IgE
+
 population, the IgG
+
 population size decreased over the 12 day 
culture period, in cells cultured with IL-4 and anti-CD40 alone, presumably as CSR to 
other isotypes was taking place (Figure 3.5A). By days 5 and 7, the addition of either 
IL-10, IL-21 or IL-10 & IL-21 all caused an increase in the size of the IgG
+
 population 
and MFI of IgG
+
 cells. The addition of both IL-10 & IL-21 resulted in a statistically 
larger IgG
+
 population by day 7 (p=0.006, n=6) (Figure 3.5A). With similarity to the 
effects on IgE expression, IgG expression was no longer elevated by day 12 in cells 
stimulated with IL-21 or IL-10 & IL-21.  
 It appears that the stronger the stimulus to increase IgE and IgG expression at 
the early timepoints, the larger the decrease in expression by day 12. The mechanisms 










      
 
Figure 3.4. The addition of IL-10 or IL-21 increases early IgE expression. 
Total B cells were cultured for up to 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml), with the addition of IL-10 (2.7µM/50ng/ml or 5.4µM/100ng/ml), IL-21 
(1.0µM/30ng/ml or 1.9µM/60ng/ml) or combinations of IL-10 & IL-21. The expression of 
membrane and intracellular IgE was analysed on days 5, 7 and 12 by flow cytometry. (A) The 
% of live IgE
+
 cells, relative to cells cultured with IL-4 and anti-CD40 alone at day 7 (100%). 
(B) The MFI of live IgE
+
 cells, relative to cells cultured with IL-4 and anti-CD40 alone at day 7 
(100%). 
Error bars represent SEM and statistical analysis was performed using ANOVA with Bonferroni 
correction (n=9, tonsil numbers 4-7, 9, 10, 12, 15 & 17).       





       
 
Figure 3.5. The addition of IL-10 or IL-21 increases early IgG expression. 
Total B cells were cultured for up to 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml), with the addition of IL-10 (2.7µM/50ng/ml or 5.4µM/100ng/ml), IL-21 
(1.0µM/30ng/ml or 1.9µM/60ng/ml) or combinations of IL-10 & IL-21. The expression of 
membrane and intracellular IgG was analysed on days 5, 7 and 12 by flow cytometry. (A) The 
% of live IgG
+
 cells, relative to cells cultured with IL-4 and anti-CD40 alone at day 7 (100%). 
(B) The MFI of live IgG
+
 cells, relative to cells cultured with IL-4 and anti-CD40 alone at day 7 
(100%). 
Error bars represent SEM and statistical analysis was performed using ANOVA with Bonferroni 
correction (n=6, tonsil numbers 7, 9, 12, 15 & 17). * p<0.05, ** p<0.01  





3.3.2. IL-21 generates an IgEhi population 




 cells due to the addition of IL-10 
and/or IL-21 (Figure 3.4B and Figure 3.5B) required further investigation. Figure 3.6A 
shows raw flow cytometry data of this phenomenon, also shown as a histogram in 
Figure 3.6B. By day 7, in this particular donor, 0.37% of live cells were positive for 
IgE. This increased to 0.51% with IL-10, 2.75% with IL-21 and 2.36% with IL-10 & 
IL-21. IL-21 was particularly potent at causing the expansion of an IgE
hi
 population in 
this donor (Figure 3.6A and Figure 3.6B). The behaviour and properties of this IgE
hi 
population are discussed later in this chapter. 
 
Figure 3.6. IL-10 and IL-21 generate an IgE
hi
 population. 
Total B cells were cultured for 7 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml), with the addition of IL-10 (5.4µM/100ng/ml), IL-21 (1.9µM/60ng/ml) or a 
combination of IL-10 & IL-21. The expression of membrane and intracellular IgE and IgG were 
analysed on day 7 by flow cytometry. (A) IgE and IgG expression on day 7, represented as dot 




 (x-axis) cells. (B) IgE 




 cells separated by dotted 
lines. The IgE
-
 (negative) cells are excluded from this histogram for clarity. 
Data shown from 1 (tonsil number 9) of 9 donors. 





3.3.3. IL-10 and IL-21 increase early IgE secretion 
 Following on from the increase seen in IgE expression shown in Figure 3.4, sIgE 
levels were analysed by ELISA (as described in Section 2.6.1) on days 5, 7 and 12 
following stimulation with IL-4 and anti-CD40 alone, plus the addition of IL-10, IL-21 
or IL-10 & IL-21 (Figure 3.7).  
 By day 5, the addition of IL-10 or IL-21 led to a small increase in IgE secretion, 
compared to cells cultured with IL-4 and anti-CD40 alone. The combination of IL-10 & 
IL-21 resulted in a synergistic 2-fold increase in IgE secretion (Figure 3.7A). In cells 
cultured with IL-4 and anti-CD40 alone, the majority of IgE secretion (59 ± 14%, n=9) 
took place during days 8 to 12 in the culture period (Figure 3.7A and Figure 3.7B). The 
addition of IL-10 or IL-21 caused IgE secretion to begin earlier and in larger volumes. 
 By day 7, IgE secretion from cells cultured with IL-10 was 7-fold higher than 
from cells cultured with IL-4 and anti-CD40 alone. Addition of IL-21 increased IgE 
secretion by only 2.5-fold and addition of the combination of IL-10 & IL-21 increased 
IgE secretion by 4-fold (Figure 3.7A). In cells cultured with IL-21 present, a larger 
proportion of IgE secretion took place between days 0-7, compared to cells stimulated 
with IL-4 and anti-CD40 alone (Figure 3.7B).  
 By day 12, only cells cultured with the addition of IL-10 continued to secrete 
more IgE (2.7-fold higher) than cells cultured with IL-4 and anti-CD40 alone. Whilst 
cells stimulated with IL-21 or IL-10 & IL-21 did still continue to secrete IgE between 
days 8 and 12, the level of secretion was lower than from cells stimulated with IL-4 and 
anti-CD40 alone by day 12 (Figure 3.7A). In similarity to the pattern of IgE expression 
shown in Figure 3.4, it appears that the stronger the stimulus to increase IgE secretion at 





the early timepoints, the smaller the increase in IgE secretion by day 12. The 
mechanisms by which this occurs will be discussed later in this chapter. 
  It is important to remember that the data in Figure 3.7A is shown as fold change 
in IgE secretion, relative to the level of IgE secreted from cells cultured with IL-4 and 
anti-CD40 alone by day 7. The data is not shown as sIgE (in ng/ml) due to the large 
inter-donor variation in the levels of IgE secretion. However, the fold-changes in IgE 
secretion were of similar magnitudes between donors (Figure 3.7A). The method of data 
presentation in Figure 3.7A does not provide any information on the raw accumulated 
levels of IgE secreted into the supernatant (in ng/ml). By looking at the raw data, donors 
appeared to fall into three categories of IgE secretion: undetectable levels of IgE; 
medium levels of IgE (up to 500ng/ml); or high levels of IgE (above 500ng/ml). The 
addition of IL-10 and/or IL-21 was capable of increasing IgE secretion from the first 
two groups. However, in cells which went onto secrete already high levels of IgE with 
IL-4 and anti-CD40 alone, the addition of IL-10 or IL-21 did not further enhance the 
level of IgE secretion by day 12 (Figure 3.8).   







Figure 3.7. IL-10 and IL-21 increase the level and rate of IgE secretion. 
Total B cells were cultured for up to 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 (1µg/ml), 
with the addition of IL-10, IL-21 or a combination of IL-10 & IL-21. IgE secretion was analysed by 
ELISA on days 5, 7 and 12. (A) Fold change in accumulated IgE secretion, relative to cells cultured with 
IL-4 and anti-CD40 alone at day 7, with the addition of IL-10 (2.7µM/50ng/ml or 5.4µM/100ng/ml), IL-
21 (1.0µM/30ng/ml or 1.9µM/60ng/ml) or combinations of IL-10 & IL-21. Error bars represent SEM and 
statistical analysis was performed using ANOVA with Bonferroni correction. (B) Accumulated IgE 
secretion was separated into days 0-5, 6-7 and 8-12 for cells cultured with IL-4 and anti-CD40 alone, with 
the addition of IL-10 (5.4µM/100ng/ml), IL-21 (1.9µM/60ng/ml) or a combination of IL-10 & IL-21. The 
% values shown represent the proportion of IgE secretion which took place during each time period. % 
values are expressed as mean ± SEM. 
n=9 (tonsil numbers 4-7, 9, 10, 12, 15 & 17). 





   
Figure 3.8. IL-10 and IL-21 cannot increase IgE secretion from cells already 
secreting high levels of IgE. 
Total B cells were cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml), with the addition of IL-10 (2.7µM/50ng/ml or 5.4µM/100ng/ml), IL-21 
(1.0µM/30ng/ml or 1.9µM/60ng/ml) or combinations of IL-10 & IL-21. IgE secretion was 
analysed by ELISA on day 12. (A) IgE secretion from a donor (tonsil number 7) with a low IgE 
secretion baseline (IL-4 and anti-CD40 alone) and (B) a high IgE secretion baseline (tonsil 
number 12).   
Error bars represent SEM from experimental triplicates. Data shown from 2 of 9 donors.  
 
3.3.4. IL-10 and IL-21 support early cell growth 
 Having established that IL-10 and IL-21 are capable of rapidly up-regulating IgE 
and IgG expression and IgE secretion from human B cells, the mechanism by which this 
may occur was then investigated. 
 Cell viability was assessed by flow cytometry with live cell gating determined 
by forward versus side scatter. Figure 3.9 shows cell viability on days 5, 7 and 12 
following stimulation with IL-4 and anti-CD40 alone or with the addition of 
combinations of IL-10 and IL-21. Figure 3.9A shows the raw flow cytometry data of the 
percentage of viable cells and Figure 3.9B shows this same data expressed relative to 





cells cultured with IL-4 and anti-CD40 alone at each timepoint (100%). In cells cultured 
with IL-4 and anti-CD40 alone, cell viability was 35 ± 3% by day 5, 30 ± 4% by day 7 
and 20 ± 4% by day 12 (n=9) (Figure 3.9A). By day 5, the addition of IL-10, IL-21 or 
IL-10 & IL-21 improved cell viability by up to 20% with IL-21 or a combination of 
both IL-10 & IL-21.  
 By day 7, only the addition of IL-10 alone continued to improve cell viability 
from that of cells cultured with IL-4 and anti-CD40 alone. Cells cultured with IL-21 
began to rapidly die between days 5 and 7, with cell viability halved to only 15 ± 5% 
(n=9) in cells cultured with the top concentration of IL-10 & IL-21, compared to cells 
cultured with IL-4 and anti-CD40 alone (Figure 3.9A).  
 By day 12, this effect was even more prominent, with relative cell viability 
significantly lower in cells cultured with IL-21 or IL-10 & IL-21 (p=0.0004, n=9), 
compared to IL-4 and anti-CD40 alone (Figure 3.9B).  
  






Figure 3.9. IL-10 and IL-21 promote early cell survival followed by rapid cell death. 
Total B cells were cultured for up to 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml), with the addition of IL-10 (1.3µM/25ng/ml, 2.7µM/50ng/ml or 5.4µM/100ng/ml), IL-
21 (1.0µM/30ng/ml or 1.9µM/60ng/ml) or combinations of IL-10 & IL-21. The % of viable 
cells was analysed by flow cytometry with live cell gating determined by forward versus side 
scatter. Cell viability is displayed as (A) the % of viable cells and (B) the % of viable cells 
relative to cells cultured with IL-4 and anti-CD40 alone at each timepoint (100%).  
Error bars represent SEM and statistical analysis was performed using ANOVA with Bonferroni 
correction (n=9, tonsil numbers 4-7, 9, 10, 12, 15 & 17). *** p<0.001 
 
3.3.5. IL-10 and IL-21 increase cell proliferation 
 The effect of IL-10 and IL-21 on the proliferation of total human B cells was 
next investigated. BrdU is a synthetic analogue of thymidine, which can incorporate 
into newly synthesised DNA during the S (synthesis) phase of the cell cycle. Following 
DNase treatment to expose the labelled epitopes, a fluorescent anti-BrdU antibody was 
then used to detect the incorporated BrdU as a measure of proliferating cells (as 





described in Section 2.5.4). Total B cells were cultured for 7 days with IL-4 and anti-
CD40, with or without the addition of IL-10 and IL-21, and then pulsed for 24 hours 
with BrdU. Cells were stained with anti-BrdU-APC and incorporation detected by flow 
cytometry. Figure 3.10 shows the percentage of BrdU
+ 
cells, relative to cells cultured 
with IL-4 and anti-CD40 alone, in 3 different donors. The level of BrdU incorporation 
varied between the three donors. In two of the three donors, addition of IL-10 and/or IL-
21 resulted in increased proliferation (Figure 3.10). The increased proliferation rate in 
these two donors was associated with a large increase in IgE expression and secretion 
(data not shown). 
 
           
 
Figure 3.10. IL-10 and IL-21 increase human B cell proliferation. 
Total B cells were cultured for 7 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml), with the addition of IL-10 (2.7µM/50ng/ml or 5.4µM/100ng/ml), IL-21 
(1.0µM/30ng/ml or 1.9µM/60ng/ml) or combinations of IL-10 & IL-21. Cells were pulsed for 
24 hours with BrdU then stained with anti-BrdU-APC (S phase) and 7-AAD for cell cycle 
analysis by flow cytometry. (A) An example of cell cycle analysis in cells cultured with IL-4 
and anti-CD40 only (tonsil number 7). A: apoptotic/sub G0 phase; M: mitosis (cell division); S: 
synthesis. (B) % of cells in S phase (BrdU
+
), relative to cells cultured with IL-4 and anti-CD40 
alone (100%), in three separate donors (n=3, tonsil numbers 4, 7 & 10). 





3.3.6. IL-10 and IL-21 increase cell division  
 In the late 1990s, Hodgkin et al showed that multiple rounds of cell division are 
required for isotype switching to IgG (3 divisions) and IgE (5 divisions) in IL-4 and 
anti-CD40-stimulated human B cells in vitro. Cell division is also associated with a loss 
of surface IgM and IgD (Hasbold, Lyons et al., 1998; Hodgkin, Lee et al., 1996). 
Following on from this work, they showed addition of IL-10 increases the number of 
cell divisions and, therefore, isotype switching to IgG (Tangye, Ferguson et al., 2002). 
The combination of IL-10 and IL-21 has also been reported to synergistically increase 
isotype switching to IgE through increasing cell division (Caven, Shelburne et al., 
2005). 
 The effect of IL-10, IL-21 or IL-10 & IL-21 on cell division-associated isotype 
switching to IgE was investigated in primary human tonsil B cells. Total B cells were 
isolated and stained with CFSE, a fluorescent marker which reduces in concentration 
upon cell division (as described in Section 2.5.3), before stimulation for 7 days with 
either IL-4 and anti-CD40 alone or with the addition of combinations of IL-10 and IL-
21. Figure 3.11 shows flow cytometric analysis on day 7, from one donor, with the 
lower histograms showing individual CFSE peaks and the upper dot plots showing co-
staining of CFSE with IgE. In cells cultured with IL-4 and anti-CD40 alone, 47% of live 
cells remained undivided by day 7, represented by the brightest CFSE peak on the far 
right. 0.25% of live cells were positive for IgE, and it was clear that the IgE
+
 cells were 
the cells which had undergone the most rounds of cell division (~4 or 5 divisions) 
(Figure 3.11). When IL-10 was included in the cell culture, only 16% of live cells 
remained undivided by day 7. As previously discussed in Section 3.3.1 and shown in 
Figure 3.4, the addition of IL-10 increased IgE expression. Building on this observation, 
Figure 3.11 shows that the expansion of IgE
+
 cells takes place following 5 or more 





rounds of cell division (60% of divided cells). In cells stimulated with IL-21 present, 
even less cells remained undivided (8-11%). However, a smaller proportion of cells 
reached the stage of 5 or more cell divisions with two thirds of the divided cells having 
only divided 1-4 times (Figure 3.11). This correlates with less IgE expression as, in this 
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Figure 3.11. Increased IgE expression with IL-10 and IL-21 is associated with 
increased rounds of cell division.  
Total B cells were stained with CFSE and cultured for 7 days in the presence of IL-4 
(200IU/ml) and anti-CD40 (1µg/ml), with the addition of IL-10 (5.4µM/100ng/ml), IL-21 
(1.9µM/60ng/ml) or a combination of IL-10 & IL-21. Cell division and IgE expression were 
analysed by flow cytometry on day 7, with each peak of decreased fluorescence representing a 
round of cell division. The table summarises the relationship between the proportion of 
undivided, highly divided (5 or more divisions) and IgE
+
 cells.  
n=1 (tonsil number 9).  





3.3.7. IL-10 and IL-21 drive rapid plasma cell differentiation 
 The phenotype of cells stimulated with or without the addition of IL-10 and IL-
21 was next investigated. Flow cytometric analysis of CD38, highly expressed on the 
surface of plasma cells, was carried out on days 5, 7 and 12 and is summarised in Figure 
3.12. Cells cultured with IL-4 and anti-CD40 alone expressed low levels of CD38, even 
by day 12 (17 ± 7%, n=4).  
 By day 5, the proportion of CD38
+
 cells increased 5-fold with the addition of IL-
10, 6-fold with the addition of IL-21 and up to 7.5-fold with IL-10 & IL-21 in 
combination (Figure 3.12A). By day 7, there was no further increase in the proportion 
of CD38
+
 cells with the addition of IL-10, compared to day 5. With the stronger 
stimulations of IL-21 or IL-10 & IL-21, CD38 expression continued to rise, with the 
highest concentrations of IL-10 & IL-21 leading to significantly higher levels of CD38 
compared to IL-4 and anti-CD40 alone (p=0.037, n=4) (Figure 3.12A). By day 12, 
CD38 expression had continued to increase in cells cultured with IL-10. However, cells 
cultured in the presence of IL-21 expressed lower levels of CD38, compared to day 7. 
 In addition to a larger proportion of cells expressing CD38, the MFI of CD38
+
 
cells also increased with the addition of IL-10 or IL-21. Figure 3.12B shows the MFI of 
CD38
+
 cells on days 5, 7 and 12. In cells cultured with IL-4 and anti-CD40 alone, the 
MFI remained constant over the 12 day period.  
 With increasing strengths of cytokine addition, from IL-10 alone up to IL-10 & 
IL-21 in combination, the MFI increased accordingly. This increase was most 
prominent at day 7 (Figure 3.12C). By day 12, the MFI of CD38
+
 cells cultured with IL-
10 or IL-21 had reduced to the level on cells cultured with IL-4 and anti-CD40 alone. 










Figure 3.12 is continued on the following page. 
 










Total B cells were cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml), with the addition of IL-10 (2.7µM/50ng/ml or 5.4µM/100ng/ml), IL-21 
(1.0µM/30ng/ml or 1.9µM/60ng/ml) or combinations of IL-10 & IL-21. The expression of 
surface CD38 was analysed on days 5, 7 and 12 by flow cytometry. Data is shown as (A) the % 
of live CD38
+
 cells and (B) the MFI of live CD38
+
 cells. Error bars represent SEM and 
statistical analysis was performed using ANOVA with Bonferroni correction (n=4, tonsil 
numbers 7, 9, 10 & 12). * p<0.05 (C) CD38 expression on day 7, represented as dot plots, 
where % values shown represent the % of live CD38
+ 
cells in cells cultured with IL-4 and anti-
CD40 alone, with the addition of IL-10 (5.4µM/100ng/ml), IL-21 (1.9µM/60ng/ml) or a 
combination of IL-10 & IL-21. Data shown from 1 (tonsil number 12) of 4 donors. 
 
 CD138 (syndecan-1) is an integral membrane protein, encoded by the SDC1 
gene, which plays a role in cell proliferation, migration and apoptosis. Expression of 
CD138 is also a useful marker for the detection of mature plasma cells as it is not 
expressed on plasmablasts (Ala-Kapee, Nevanlinna et al., 1990; Mali, Jaakkola et al., 
1990; van Zaanen, Vet et al., 1995). Figure 3.13 shows flow cytometric analysis of 
CD38 and CD138 expression on cells cultured either with IL-4 and anti-CD40 alone, or 
with the addition of IL-10, for 12 days. In the absence of IL-10, a very small proportion 
of CD138
+





 plasma cells (2.9%) were present in cells cultured with the addition of 
IL-10 (Figure 3.13).  










 plasma cell population. 
Total B cells were cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml) alone or with the addition of IL-10 (5.4µM/100ng/ml). Cells were stained with 
antibodies against CD38 (y-axis) and CD138 (x-axis) on day 12 and analysed by flow 

















 plasma cells are highlighted in the red box. The far right dot plot 
shows an overlay of cells stimulated with IL-4/anti-CD40 alone (black) or with the addition of 
IL-10 (red).  
n=1 (tonsil number 12). 
  






 The key objectives of this chapter were to firstly establish the in vitro assay for 
inducing CSR to IgE in primary human tonsillar B cells. Expression and secretion of 
IgE was shown to be dependent upon the addition of anti-CD40 mAb and IL-4, which 
were also important for cell viability (Figure 3.1 and Figure 3.2). Under the normal cell 
culture conditions cell viability was shown to reduce rapidly over the 12 day period 
(Figure 3.9). It is, therefore, important to consider the possible effects of this when 
analysing data throughout the culture period. It became apparent that the level of IgE 
secretion would vary widely between donors, although this did not correlate with the 
allergic status of the donor (Figure 3.3). This confirmed that any changes seen in sIgE 
levels in future chapters, which will aim to modify the secretion of IgE, cannot be 
attributed to the donor‟s allergic status.  
 As cells from some donors did not express or secrete any IgE by day 12, the 
addition of extra cytokines was investigated as a means to overcome this. As explained 
in Section 3.1, there are many conflicting reports as to whether the addition of IL-10 
and IL-21 can increase IgE synthesis in human B cells in vitro. In our hands, the 
addition of these cytokines led to an early increase in the expression of IgE and IgG, 
indicating an overall increase in the level of CSR. By day 12, the latest timepoint 
examined, the presence of these additional cytokines resulted in less IgE and IgG 
expression, compared to cells cultured with IL-4 and anti-CD40 alone (Figure 3.4 and 
Figure 3.5). In accordance with this, the additional cytokines were capable of rapidly 
increasing IgE secretion at early timepoints. However, this effect had worn off by day 
12 (Figure 3.7). It was subsequently shown that the presence of the additional cytokines, 
for long periods of time, led to very poor cell viability, particularly the combination of 
both IL-10 & IL-21 (Figure 3.9).  





 It was shown that addition of IL-10 ± IL-21 could not further enhance IgE 
secretion from donors which secreted a high level of IgE with IL-4 and anti-CD40 alone 
(Figure 3.8). This may explain why B cells isolated from the highly atopic tonsil donor 
shown in Figure 3.3 (tonsil number 23) were only capable of secreting very low levels 
of IgE. In vivo, B cells from this donor would be secreting high levels of IgE. Perhaps 
this means that they could not be stimulated by IL-4 and anti-CD40 to continue to 
secrete more IgE when in vitro.  
 The mechanisms by which IL-10 and IL-21 were capable of increasing CSR 
were next investigated. These cytokines were shown to increase cell proliferation and 
division, increasing rounds of which were shown to correlate with increased IgE 
expression (Figure 3.10 and Figure 3.11). Increasing strength of cytokine stimulation 
(from IL-10 alone, to IL-21 alone and then the combination of both) was shown to 
induce rapid B cell differentiation, as measured by the B cell differentiation marker 





 plasma cells were detected following stimulation with IL-10 (Figure 
3.13). 
 In summary, the addition of IL-10 and IL-21 served as a useful experimental 
tool to reliably stimulate IgE secretion from human B cells, including those which 
would have otherwise not secreted any IgE by day 12. For short in vitro cultures of 
human B cells (up to 7 days), the combination of both IL-10 & IL-21 can be added to 
greatly increase the expression and secretion of IgE, cell division and CD38 expression. 
This would be particularly useful for subsequent isolation of IgE
+
 cells for a variety of 
purposes. However, for longer cultures up to 12 days, the presence of IL-21 leads to 
very poor cell viability. In this case, addition of IL-10 alone, or a lower concentration of 
IL-21, may be a more appropriate stimulation. 





3.4.1. Further experiments 
 It would be of interest to conduct more experiments to investigate whether the 
population of IgE
hi
 cells also co-express CD138. qPCR could be utilised to detect 
plasma cell differentiation markers such as BLIMP-1 and XBP-1. To definitively 
confirm that IL-10 and IL-21 are increasing CSR in human B cells, switch circles could 
be measured by PCR and AID and εGLT levels by qPCR (Takhar, Corrigan et al., 
2007).  
 





Chapter 4. siRNA-mediated inhibition of CD23 
4.1. Introduction 
 Discovery of an ancient endogenous defence mechanism of plants against 
viruses (Napoli, Lemieux et al., 1990; van der Krol, Mur et al., 1990) led to the 
development of a novel gene silencing technique using small interfering RNA (siRNA). 
In this chapter, this technique was utilised to target CD23 in primary human B cells. 
 
4.2. Optimisation of siRNA conditions 
4.2.1. Transfection efficiency 
 Since the procedure of human B cell transfection with siRNA (as described in 
Section 2.3) had not been attempted before within the research group, it was first 
necessary to optimise the assay conditions. To assess whether it was possible to 
transfect human B cells by nucleofection, the transfection indicator siGLO
®
 Red was 
utilised. This reagent contains fluorescent oligonucleotides that localise to the nucleus 
to allow flow cytometric analysis of transfection uptake into cells. Figure 4.1 shows that 
at 30 minutes following transfection a very high proportion of cells were positive for 
siGLO
®
 Red (97%), indicating a high transfection efficiency.  
 








 Red enters B cells following electroporation.  
Total B cells were transfected with either siGLO
®
 Red (3µg/960nM) (red) or cell culture media 
alone (black) by electroporation. Transfection efficiency was analysed by flow cytometry 30 
minutes following transfection. The % of live cells positive for siGLO
®
 Red is indicated on the 
histogram.  
Data shown from 1 donor (tonsil number 17), representative of 11 (tonsil numbers 4, 8, 11-15, 
17, 19, 21 & 22). 
 
4.2.1. siGLO® Red cell sorting 
 To avoid any untransfected cells, albeit only a small percentage, from 
contaminating the cell cultures and possibly skewing results, cell sorting using a FACS 
Aria™ was utilised to separate siGLO- and siGLO+ cells (as described in Section 2.3.1). 





cell populations were placed into culture with IL-4 and anti-CD40 (as described 
in Section 2.4). The sorting procedure resulted in very poor cell viability with only 5% 
of siGLO
+ 
and 11% of siGLO
-
 cells remaining live 24 hours after sorting (Figure 4.2B). 
The average viability of un-sorted transfected cells, 24 hours after transfection, was 
31% (n=13) as shown in Figure 4.3. By day 9, in the sorted cell cultures, no live cells 
could be detected by flow cytometry (data not shown). 
 
 






Figure 4.2. siGLO cell sorting results in very poor cell viability. 
Total B cells were transfected with siGLO
®
 Red (3µg/960nM) by electroporation. 30 minutes 
following transfection, cells were sorted with a FACS Aria™ into tubes containing siGLO+ and 
siGLO- cells, according to gates set using untransfected cells as a guide. (A) The % of live 
siGLO+ and siGLO- cells are indicated on the dot plots. (B) Cells were subsequently cultured in 
the presence of IL-4 (200IU/ml) and anti-CD40 (1µg/ml) and the cell viability after 24 hours is 
indicated on the dot plots. 
n=1 (tonsil number 17). 
 
 





4.2.2. Effect of siRNA transfection on cell viability  
 In the process of electroporation approximately 50% of the cells were killed 
(data not shown). It was therefore necessary to make sure that the viability of the 
electroporated cells, and also those transfected with siRNA, would be high enough to 
survive the necessary 12 day culture period. To test this, cells were transfected with 
control siRNA (scrambled), GAPDH siRNA or CD23 siRNA (as described in Section 
2.3). Cells which had been electroporated without siRNA (EP only) and cells which had 
not been electroporated (untreated) were included as control conditions.  
 Figure 4.3 shows cell viability measured by flow cytometry at 24 hours, 48 
hours, 5 days, 7 days and 12 days after transfection. It is clear to see that the process of 
electroporation caused a reduction in cell viability. This reduction was most significant 
at 24 hours following transfection when cells electroporated and transfected with 
control siRNA were 44% less viable than untreated cells (p=<0.0001, n=12) (Figure 
4.3). Over the 12 day period, cell viability declined at a faster rate in untreated cells, 
compared with electroporated cells, until there was no significant difference in cell 
viability between untreated and control siRNA-transfected cells by day 12 (Figure 4.3). 
 Importantly, there was no additional reduction in viability when cells were 
electroporated with siRNA, compared to electroporation alone (EP only). This indicates 
the reduction in cell viability was due to the procedure of electroporation and not the 
presence of siRNA. In addition, there were no differences in cell viability between cells 
transfected with control, GAPDH or CD23 siRNA (Figure 4.3). 
  
  






Figure 4.3. Electroporation, but not the addition of siRNA, reduces cell viability. 
Total B cells were transfected with either control siRNA (red), GAPDH siRNA (green) or CD23 
siRNA (blue) by electroporation and cultured for up to 12 days in the presence of IL-4 
(200IU/ml) and anti-CD40 (1µg/ml). For comparison, cells which had been electroporated with 
no siRNA (EP only) (grey) and cells which had not been electroporated (untreated) (white) are 
also shown. The % of viable cells was analysed by flow cytometry with live cell gating 
determined by forward versus side scatter.  
Error bars represent SEM and statistical analysis was performed using ANOVA with Bonferroni 
correction (n=13, tonsil numbers 1, 2, 4, 8, 11-15, 17, 19, 21 & 22). Statistics in red indicate 
significance compared to control siRNA-transfected cells at each timepoint and statistics in 




4.3. Validation of siRNA knockdowns 
4.3.1. CD23 siRNA reduces mRNA levels 
 Before investigating the ability of siRNA to inhibit the mRNA levels of target 
genes, it was important to check that electroporation alone did not cause a reduction in 
the mRNA levels of GAPDH and CD23, given the reduction observed in cell viability 
(Figure 4.3). Cells were electroporated, cultured with IL-4 and anti-CD40 and qPCR 
performed (as described in Section 2.8) to quantify GAPDH and CD23 mRNA levels. 





Figure 4.4 shows that the procedure of electroporation did not significantly alter 
GAPDH or CD23 mRNA levels. 
 
 
Figure 4.4. Electroporation alone does not decrease GAPDH or CD23 mRNA levels. 
Total B cells were either transfected with control siRNA (black) by electroporation or 
electroporated alone (white) and cultured for up to 56 hours in the presence of IL-4 (200IU/ml) 
and anti-CD40 (1µg/ml). Cell samples were harvested at the times indicated and qPCR was 
performed to quantify (A) GAPDH mRNA levels and (B) CD23 mRNA levels. Expression 
levels were calculated by ∆∆Ct analysis, normalised against the endogenous reference gene β2-
microglobulin and expressed relative to control siRNA-transfected cells at each timepoint. 
Error bars represent SEM and statistical analysis was performed using ANOVA with Bonferroni 
correction (n as indicated, max n=6, tonsil numbers 1, 4 & 11-14). 
 
 Following this, human tonsillar B cells were transfected with siRNA to 
specifically target GAPDH or CD23. The level of knockdown was quantified by qPCR, 
relative to cells transfected with control siRNA, from 5 hours to 5 days following 
transfection. Figure 4.5A and Figure 4.5B show there was a significant decrease in 
GAPDH mRNA levels in cells transfected with GAPDH siRNA, with no significant 
effect on CD23 mRNA. The largest decrease in GAPDH mRNA was observed at 18 
hours (75 ± 10%, n=2) and 24 hours (69 ± 4%, n=8) following transfection.  





 Figure 4.5C and Figure 4.5D show there was a significant knockdown of CD23 
mRNA levels in cells transfected with CD23 siRNA, with no significant effect on 
GAPDH mRNA. The maximum knockdown of CD23 (70 ± 0.1%, n=11) occurred 
between 18 and 24 hours following transfection. From 24 hours onwards, in both 
GAPDH- and CD23 siRNA-transfected cells, mRNA levels began to recover to that of 
control siRNA-transfected cells highlighting the transient nature of this knockdown 
technique.   






Figure 4.5. GAPDH siRNA specifically reduces GAPDH mRNA levels and CD23 
siRNA specifically reduces CD23 mRNA levels. 
Total B cells were transfected with either control siRNA, GAPDH siRNA or CD23 siRNA by 
electroporation and cultured for up to 5 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). Cell samples were harvested at the times indicated and qPCR was performed to 
quantify (A) GAPDH mRNA levels in cells transfected with GAPDH siRNA, (B) CD23 mRNA 
levels in cells transfected with GAPDH siRNA, (C) GAPDH mRNA levels in cells transfected 
with CD23 siRNA and (D) CD23 mRNA levels in cells transfected with CD23 siRNA. 
Expression levels were calculated by ∆∆Ct analysis, normalised against the endogenous 
reference gene β2-microglobulin and expressed relative to control siRNA-transfected cells at 
each timepoint (black bars). 
Error bars represent SEM and statistical analysis was performed using ANOVA with Bonferroni 
correction (n as indicated, max n=11, tonsil numbers 1, 4, 8, 11-15, 17, 19 & 21). *** p<0.001 





4.3.2. CD23 siRNA reduces mCD23 expression 
 After having confirmed that CD23 siRNA could successfully reduce CD23 
mRNA levels, the knock-on effect of this on mCD23 expression was next investigated. 
Human tonsil B cells were transfected and cultured, as previously described, for up to 
12 days. Cell samples were taken after 18 hours, 24 hours, 48 hours, 5 days, 7 days and 
12 days, stained for mCD23 expression and analysed by flow cytometry (as described in 
Section 2.5.1). Figure 4.6A shows an example of flow cytometric analysis of mCD23 
levels from 18 hours to 12 days following transfection with either control siRNA or 
CD23 siRNA. In control siRNA-transfected cells, mCD23 expression increased 
gradually over the first 48 hours and reached a peak on day 5 (88 ± 2.8%, n=8, data not 
shown graphically). mCD23 expression was dramatically decreased in CD23 siRNA-
transfected cells.  
 Figure 4.6B shows pooled data from multiple donors, expressed relative to 
mCD23 expression on control siRNA-transfected cells. The percentage of mCD23
+
 
cells was reduced following transfection with CD23 siRNA. The maximum inhibition 
was observed at 18 hours after transfection (69%), although this timepoint was only 
recorded in one donor. The reduction remained statistically significant until day 7, 
although was largely recovered by 48 hours (19 ± 2%, n=6). Figure 4.6C shows the 
level of mCD23 expression on cells, as measured by the MFI, was significantly lower 
on cells transfected with CD23 siRNA, compared to control siRNA. This reduction also 
remained statistically significant until day 7 but the MFI was suppressed to a greater 
degree (66 ± 6% inhibition after 48 hours, n=6) than the percentage of mCD23
+
 cells 
and took longer to recover. In summary, despite the short-term inhibition of CD23 
mRNA shown in Figure 4.5, the inhibition of mCD23 expression by CD23 siRNA 
remained significant until day 7.  








Figure 4.6. CD23 siRNA significantly reduces mCD23 expression for up to 7 days 
following transfection. 
Total B cells were transfected with either control siRNA or CD23 siRNA by electroporation and 
cultured for up to 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 (1µg/ml). The 
expression of mCD23 was analysed at the times indicated by flow cytometry. (A) Overlay of 
mCD23 expression on cells transfected with control siRNA (red) or CD23 siRNA (blue). % of 
mCD23
+
 cells are indicated below each dot plot. Data shown from 1 (tonsil number 8) of 11 
donors. Pooled multiple donor data for cells transfected with CD23 siRNA (○), relative to 
control siRNA (∆) at each timepoint, is shown for (B) % of mCD23+ cells and (C) CD23+ MFI. 
Error bars represent SEM and statistical analysis was performed using ANOVA with Bonferroni 
correction (n=11, tonsil numbers 4, 8, 11-15, 17, 19, 21 & 22). ** p<0.01, *** p<0.001 
  





4.3.3. CD23 siRNA reduces sCD23 production 
 sCD23 is produced by cleavage of mCD23, initially by the membrane-bound 
metalloprotease ADAM10 (Weskamp, Ford et al., 2006). In the same experiments as 
described in the previous section, supernatants were harvested at 18 hours, 24 hours, 48 
hours, 5 days, 7 days and 12 days after transfection and the sCD23 content was analysed 
by ELISA (as described in Section 2.6.3). sCD23 was first detectable in the supernatant 
4 days after transfection with control siRNA (data not shown) and reached levels of 13 
– 102ng/ml (mean = 58 ± 4ng/ml, n=32) by day 12 (Figure 4.8). In accordance with the 
reduced mCD23 levels shown in Figure 4.6, sCD23 production decreased significantly 
following CD23 siRNA transfection (Figure 4.7). By day 12, sCD23 levels were, on 
average, 17.4 ± 5.7% (p=0.13, n=6) lower in supernatants from cells transfected with 
CD23 siRNA, compared to control siRNA. No significant reduction was seen at the 
earlier timepoints of day 5 or day 7.  
  






Figure 4.7. CD23 siRNA reduces sCD23 production by day 12. 
Total B cells were transfected with either control siRNA (∆) or CD23 siRNA (○) by 
electroporation and cultured for up to 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). Supernatants were analysed for sCD23 content by ELISA on the days indicated, 
relative to control siRNA-transfected cells (100%). Error bars represent SEM and statistical 
analysis was performed using ANOVA with Bonferroni correction (n=10, tonsil numbers 1, 8, 
11, 13-15, 17, 19, 21 & 22). * p<0.05 
 
 
4.4. CD23 siRNA-mediated effects on IgE and IgG 
 Having shown that the transfection of human B cells with CD23 siRNA resulted 
in a reduction in the levels of CD23 mRNA, mCD23 expression and sCD23 production, 
the effect of these reductions on switching to, and expression of, IgE was next 
investigated. As introduced in Section 1.9, there are conflicting opinions as to whether 
there is a clinical relationship between elevated sCD23 levels, IgE levels and severity of 
allergic symptoms (Aberle, Gagro et al., 1997; Di Lorenzo, Drago et al., 1999; Lorenzo, 
Mansueto et al., 1996; Rogala and Rymarczyk 1999; Wilhelm, Klouche et al., 1994; 
Yanagihara, Sarfati et al., 1990). 
 





4.4.1. Correlation between sCD23 and sIgE 
 It was first necessary to show whether there was a correlation between sCD23 
production and IgE secretion in the in vitro human tonsillar B cell cultures. Figure 4.8 
shows the relationship between sCD23 and sIgE levels measured in the supernatant 
following 12 days stimulation with IL-4 and anti-CD40. In Figure 4.8A, the sCD23 
concentrations are indicated in both ng/ml and µM to facilitate comparisons with the 
known KD values of interaction with IgE and CD21 (discussed in Sections 1.5.2 and 
2.4.2). Figure 4.8A shows a significant positive correlation between sCD23 and sIgE 
levels (r=0.79) as determined by Spearman‟s rank correlation coefficient (p=<0.0001, 
n=32). There appears to be two phases in the relationship. Only a slight increase in sIgE 
was observed at low sCD23 concentrations, up to 60ng/ml (concentrations calculated 
for the 37 kDa fragment). However, above this threshold in the range of 60-100ng/ml of 
sCD23, there was a steep rise in sIgE with increasing concentrations of sCD23 (Figure 
4.8).  
 Figure 4.8B shows the same data as Figure 4.8A. However, the concentration of 
sCD23 is plotted against the log concentration of sIgE (in ng/ml). This form of data 
analysis clearly shows the positive correlation between sIgE and sCD23 (r=0.75, n=28). 
Four donors did not secrete any IgE by day 12 (tonsil numbers 1, 8, 13 & 14) and are, 
therefore, excluded from Figure 4.8B as it is not possible to log a value of zero. 
 
  









Figure 4.8. sCD23 production positively correlates with IgE secretion. 
Total B cells were cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). sCD23 production and IgE secretion were analysed by ELISA on day 12. (A) Values 
are shown in ng/ml on the bottom x-axis and left y-axis and in µM on the top x-axis and right y-
axis (1µM 190kDa sIgE = 190ng/ml and 1µM 37kDa sCD23 = 37ng/ml) (n=32, tonsil numbers 
1-32). (B) Re-analysis of the data shown in (A) with the sIgE concentration shown in log ng/ml 
(n=28, tonsil numbers 2-7, 9-12 & 15-32). 
Correlation analysis was performed using Spearman‟s rank correlation coefficient (r values 
indicated on graphs). 
  





4.4.1. CD23 siRNA reduces IgE secretion 
 Having shown a positive correlation between the levels of sCD23 production 
and IgE secretion, the effect of reduced sCD23 production, due to CD23 siRNA 
transfection, on IgE secretion was analysed. Initially it was important to check the 
impact of electroporation and transfection with control siRNA on IgE secretion. Figure 
4.9 shows that cells which were left untreated (no electroporation or transfection with 
control siRNA) secreted significantly higher levels of IgE (p=0.031, n=6) after 12 days 
in culture with IL-4 and anti-CD40 (ranged from 38 – 1160ng/ml), compared to control 
siRNA-transfected cells (ranged from 36 – 729ng/ml). Despite this, control siRNA-
transfected cells were still able to secrete detectable levels of IgE by day 12. 
 
 
Figure 4.9. Electroporation reduces IgE secretion. 
Total B cells were either transfected with control siRNA (∆) or left untreated (no 
electroporation) (◊) and cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). IgE secretion was analysed by ELISA on day 12.  
Statistical analysis was performed using the Wilcoxon matched-pairs signed rank test (n=6, 
tonsil numbers 11, 15, 17, 19, 21 & 22). * p<0.05 
 





  Next, the levels of sIgE in the supernatants of cells transfected with control 
siRNA or CD23 siRNA were analysed and compared by ELISA. Low levels of sIgE 
were first detectable in the supernatant 5 days after stimulation with IL-4 and anti-CD40 
(data not shown). Figure 4.10 shows the relative levels of sIgE on days 5, 7 and 12 after 
transfection with control siRNA or CD23 siRNA. Of the ten donors analysed for sCD23 
production in Figure 4.7, four donors (tonsil numbers 1, 8, 13 & 14) did not produce 
any detectable sIgE by day 12 and so were excluded from the analysis shown in Figure 
4.10. By day 12, CD23 siRNA-transfected cells had secreted 47% (± 9.5%) less IgE 
than control siRNA-transfected cells. For comparison, the average IgE secretion from 
GAPDH siRNA-transfected cells was only 2.8% less than that of control siRNA-
transfected cells by day 12 (n=10, data not shown). Figure 4.11 shows there was no 
significant difference in the level of IgG secretion by day 12, between control siRNA- 
and CD23 siRNA-transfected cells. 
 
  






Figure 4.10. CD23 siRNA reduces IgE secretion by day 12. 
Total B cells were transfected with either control siRNA (∆) or CD23 siRNA (○) by 
electroporation and cultured for up to 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). Supernatants were analysed for sIgE content by ELISA on the days indicated, relative 
to control siRNA-transfected cells (100%). 
Error bars represent SEM and statistical analysis was performed using ANOVA with Bonferroni 
correction (n=6, tonsil numbers 11, 15, 17, 19, 21 & 22). *** p<0.001 
 
Figure 4.11. CD23 siRNA has no effect on IgG secretion by day 12. 
Total B cells were transfected with either control siRNA (∆) or CD23 siRNA (○) by 
electroporation and cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). Supernatants were analysed for sIgG content by ELISA on day 12, relative to control 
siRNA-transfected cells (100%). 
Error bars represent SEM and statistical analysis was performed using the Wilcoxon matched-
pairs signed rank test (n=8, tonsil numbers 1, 8, 11, 13, 14, 17, 19 & 21). 





  It is important to note that no significant reduction in IgE secretion was observed 
until after day 7 (Figure 4.10). From day 7 onwards, following transfection with CD23 
siRNA, mCD23 levels had returned to those of control siRNA-transfected cells (Figure 
4.6). Thus any CD23-mediated differences in IgE secretion between days 7 and 12 can 
be attributed to sCD23, rather than mCD23.   
 Although the average reduction in IgE secretion by day 12 from CD23 siRNA-
transfected cells was 47%, this included a range of IgE inhibition levels from 22% to 
76% (Figure 4.10). The extent to which sIgE levels were inhibited was not related to the 
amount of IgE the cells secreted (data not shown). Given the correlation between sCD23 
production and IgE secretion shown in Figure 4.8, the level of sIgE inhibition from the 
six donors in Figure 4.10 was plotted against the level of sCD23 inhibition from Figure 
4.7. Figure 4.12 shows that there was a strong positive correlation (r=0.94) between the 
level of sIgE inhibition and the inhibition of sCD23 production (p=0.017, n=6).  
 
Figure 4.12. The extent of sIgE inhibition correlates with the extent of sCD23 
inhibition. 
Total B cells were transfected with CD23 siRNA by electroporation and cultured for 12 days in 
the presence of IL-4 (200IU/ml) and anti-CD40 (1µg/ml). Day 12 sCD23 ELISA data from 
Figure 4.7 was plotted against day 12 sIgE ELISA data from Figure 4.10.  
Correlation analysis was performed using Spearman‟s rank correlation coefficient (r=0.94) 
(n=6, tonsil numbers 11, 15, 17, 19, 21 & 22). 





4.4.2. CD23 siRNA has no effect on IgE and IgG expression 
 Having now shown that reducing sCD23 production in human B cells with 
CD23 siRNA can consequently reduce IgE secretion, more investigation was required 
as to the exact mechanism by which this may occur. To establish whether the reduction 
in IgE was specific to the secreted form of IgE, membrane and intracellular expression 
of IgE and IgG was analysed by flow cytometry. Human B cells were transfected with 
either control siRNA or CD23 siRNA and cultured for up to 12 days with IL-4 and anti-





 cells and the MFI of these cell populations (as described in Section 2.5.1).  
 Figure 4.13A shows the increase in IgE expression between days and 7 and 12 
and the development of an IgE
hi
 population by day 12 (also previously shown in Figure 
3.6). The IgE expression pattern between cells transfected with control siRNA, 
compared to CD23 siRNA, was very similar. Figure 4.13B and Figure 4.13C show there 
was no significant difference between the percentage of IgE
+
 cells (or MFI) following 
transfection with control siRNA, compared to CD23 siRNA (n=6).  
 This was also the case for IgG expression, shown in Figure 4.14. Figure 4.14A 
shows how the expression of IgG decreased over time, due to switching to other 
isotypes. The IgG expression pattern between cells transfected with control siRNA, 
compared to CD23 siRNA, was very similar. Figure 4.14B and Figure 4.14C show there 
was no significant difference between the percentage of IgG
+
 cells (or MFI) of cells 
following transfection with control siRNA, compared to CD23 siRNA (n=6).  









Figure 4.13. CD23 siRNA does not alter the % or MFI of IgE
+
 cells. 
Total B cells were transfected with either control siRNA (black) or CD23 siRNA (white) by 
electroporation and cultured for up to 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). The expression of membrane and intracellular IgE was analysed on days 7 and 12 by 
flow cytometry. (A) An example of IgE expression levels on day 7 (dotted line) and day 12 
(solid line) for cells transfected with either control siRNA (red) or CD23 siRNA (blue). The % 
of IgE
+
 cells and MFI are indicated on the legend. Data shown from 1 (tonsil number 21) of 6 
donors. Pooled data from multiple donors is shown for (B) the % of live IgE
+
 cells and (B) the 
MFI of live IgE
+
 cells, relative to control siRNA-transfected cells at each timepoint (100%). 
Error bars represent SEM and statistical analysis was performed using ANOVA with Bonferroni 
correction (n=6, tonsil numbers 11, 15, 17, 19, 21 & 22).  









Figure 4.14. CD23 siRNA does not alter the % or MFI of IgG
+
 cells. 
Total B cells were transfected with either control siRNA (black) or CD23 siRNA (white) by 
electroporation and cultured for up to 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). The expression of membrane and intracellular IgG was analysed on days 7 and 12 by 
flow cytometry. (A) An example of IgG expression levels on day 7 (dotted line) and day 12 
(solid line) for cells transfected with either control siRNA (red) or CD23 siRNA (blue). The % 
of IgG
+
 cells and MFI are indicated on the legend. Data shown from 1 (tonsil number 21) of 6 
donors. Pooled data from multiple donors is shown for (B) the % of live IgG
+
 cells and (B) the 
MFI of live IgG
+
 cells, relative to control siRNA-transfected cells at each timepoint (100%). 
Error bars represent SEM and statistical analysis was performed using ANOVA with Bonferroni 
correction (n=6, tonsil numbers 11, 15, 17, 19, 21 & 22).  





4.5. Mechanism of action of CD23 siRNA 
 The CD23 siRNA-mediated reduction in IgE secretion shown in Figure 4.10 can 
be attributed to the reduction in sCD23 production shown in Figure 4.7. To confirm this, 
further experiments were required to ensure that CD23 siRNA did not affect other 
pathways which could also explain the reduction in sCD23 and sIgE. 
4.5.1. CD23 siRNA does not reduce ADAM10 expression 
 The metalloprotease ADAM10 is responsible for the initial cleavage of mCD23 
from the cell surface to produce a 37kDa fragment of sCD23 (Weskamp, Ford et al., 
2006). A reduction in the expression level of ADAM10 could therefore lead to 
decreased mCD23 cleavage and sCD23 production. To ensure the surface expression 
levels of ADAM10 were the same in cells transfected with either control siRNA or 
CD23 siRNA, cell samples were taken at 24 hours, 48 hours, 5 days, 7 days and 12 days 
after transfection for flow cytometric analysis (as described in Section 2.5.1). Figure 
4.15 shows there was no significant difference in the percentage of ADAM10
+
 cells 
following transfection with either control siRNA or CD23 siRNA (n=3), revealing that 
the loss of ADAM10 was not responsible for the decrease in sCD23 levels. 
 
 






Figure 4.15. ADAM10 expression levels are the same on cells transfected with control 
siRNA or CD23 siRNA. 
Total B cells were transfected with either control siRNA (∆) or CD23 siRNA (○) by 
electroporation and cultured for up to 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). The expression of ADAM10 was analysed at the times indicated by flow cytometry.  
Error bars represent SEM and statistical analysis was performed using ANOVA with Bonferroni 
correction (n=3, tonsil numbers 12-14). 
 
4.5.1. CD23 siRNA does not decrease εGLT levels 
 To shed light on the stage of IgE synthesis that is affected by CD23 siRNA, the 
effect on the level of ε germline transcripts (εGLTs) was investigated. The transcription 
of germline transcripts is essential for CSR and is the first step in the commitment of B 
cells to the synthesis of IgG, IgA and IgE (Bacharier, Jabara et al., 1998; Gould, Beavil 
et al., 2000).  
 To ensure the reduction seen in IgE synthesis following CD23 siRNA 
transfection (Figure 4.12) was due to reduced sCD23 levels and not a reduction in CSR 
to IgE, the levels of εGLTs were quantified by qPCR (as described in Section 2.8). Cells 
were harvested immediately following transfection with either control siRNA or CD23 
siRNA (0 hours) and at 5 hours, 18 hours, 24 hours, 48 hours and 5 days following 





transfection. Figure 4.16 shows the increase in εGLT levels over the period of 5 days in 
both control siRNA- and CD23 siRNA-transfected cells. No significant differences in 
εGLT levels were detected at either 24 or 48 hours following transfection. This 
indicates that CD23 siRNA does not reduce the induction of class switching to IgE. 
 
 
Figure 4.16. CD23 siRNA does not reduce εGLT levels. 
Total B cells were transfected with either control siRNA (black) or CD23 siRNA (white) by 
electroporation and cultured for up to 5 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). Cell samples were harvested at the times indicated and qPCR was performed to 
quantify RNA levels for εGLT. Expression levels were calculated by ∆∆Ct analysis, normalised 
against the endogenous reference gene β2-microglobulin and expressed relative to control 
siRNA-transfected cells at 24 hours.  
Error bars represent SEM and statistical analysis was performed using ANOVA with Bonferroni 
correction (n=1, unless indicated otherwise. Max n=7, tonsil numbers 4, 12-14, 17, 19 & 21). 
 
 
4.6. CD23 siRNA-mediated effects on B cell cytokine secretion 
 Although it is well known that B cells can produce cytokines, less is known 
about whether B cells can differentiate into effector subsets that secrete polarized arrays 





of cytokines. „Effector‟ B cells have been divided into three groups determined by their 
cytokine profile: B effector 1 (Be1) cells; B effector 2 (Be2) cells; and regulatory B 
cells. Be1 cells secrete IFNγ, IL-6 and IL-12 in response to priming by T cells, in 
combination with antigen and/or TLR stimulation, in the presence of Th1-type 
cytokines (e.g. IFNγ) (Harris, Goodrich et al., 2005; Harris, Haynes et al., 2000). Be2 
cells secrete IL-2, IL-4 and IL-13, in response to priming by T cells in combination with 
antigen, in the presence of Th2-type cytokines (e.g. IL-4). Both Be1 and Be2 cells 
secrete IL-5, IL-6, IL-10 and TNF (Harris, Goodrich et al., 2005; Harris, Haynes et al., 
2000). Regulatory B cells have been shown to secrete high levels of IL-10 (B10 cells) in 
response to a combined stimulation of antigen, CD40L and TLR ligands (Bouaziz, 
Yanaba et al., 2008; Fillatreau, Gray et al., 2008; Mauri and Ehrenstein 2008; Yanaba, 
Bouaziz et al., 2009). 
 Since the human B cells in the experiments described in this thesis are cultured 
with IL-4, it was hypothesised that it may be possible to detect the presence of Be2-type 
cytokines in the supernatants, despite the lack of T cells. A comparison could then be 
made between control siRNA- and CD23 siRNA-transfected cells to investigate 
whether a knockdown of CD23 has any impact on B cell cytokine secretion.  
 Human B cells were transfected with either control siRNA or CD23 siRNA and 
cultured for 12 days in the presence of IL-4 and anti-CD40. A custom-made 
MILLIPLEX
®
 MAP Human Cytokine Assay was used to simultaneously quantify the 
supernatant levels of IFNγ (Be1 cytokine), IL-2 (Be2 cytokine), IL-13 (Be2 cytokine), 
IL-10 (both Be1 and Be2 cytokine) and IL-6 (both Be1 and Be2 cytokine) on day 12 (as 
described in Section 2.7). Figure 4.17A shows the standard curves generated for each 
individual cytokine and Figure 4.17B shows that the control samples of known cytokine 
concentrations, provided as part of the kit, all fell within the expected ranges. 








Figure 4.17. Assay optimisation for multiplex cytokine analysis. 
(A) Using the MILLIPLEX
®
 MAP Human Cytokine Assay, standard curves were generated for 
the simultaneous quantification of IFNγ, IL-2, IL-6, IL-10 and IL-13 (10,000pg/ml-3.2pg/ml). 
(B) Low concentration (white) and high concentration (grey) control samples, of known 
concentrations, were analysed for the simultaneous quantification of IFNγ, IL-2, IL-6, IL-10 and 
IL-13. Calculated pg/ml values are indicated above each bar and the expected ranges indicated 
below each bar. Error bars represent SEM of individual duplicates. 
 
  






 Since IFNγ is a Be1 cytokine no detection was expected. Figure 4.18 shows that 
this was indeed the case in ten out of eleven donors. However, a small amount of IFNγ 
(4.6pg/ml) was detected in the supernatant of CD23 siRNA-transfected cells from one 
donor. 
 
Figure 4.18. IFNγ could not be detected in B cell supernatants by day 12 
Total B cells were transfected with either control siRNA (red) or CD23 siRNA (blue) by 
electroporation and cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). Cell supernatants were harvested on day 12 and the levels of IFNγ were quantified 
using a MILLIPLEX
®
 MAP Human Cytokine Assay. The minimum detection level is indicated 
by the dashed line. 
Error bars represent SEM of individual duplicates (n=11, tonsil numbers as indicated). 
 
4.6.1. IL-2 and IL-13  
 The detection of the cytokines IL-2 and IL-13 is shown in Figure 4.19. Only 
very low levels of IL-2 could be detected. IL-13 was detected in the supernatants from 
two donors. B cells from donor 4 produced 16pg/ml of IL-13 from control siRNA-





transfected cells and this increased to 50pg/ml from CD23 siRNA-transfected cells. B 






Figure 4.19. IL-2 and IL-13 could be detected in B cell supernatants by day 12 
Total B cells were transfected with either control siRNA (red) or CD23 siRNA (blue) by 
electroporation and cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). Cell supernatants were harvested on day 12 and the levels of IL-2 and IL-13 were 
quantified using a MILLIPLEX
®
 MAP Human Cytokine Assay. The minimum detection level is 
indicated by the dashed line. 
Error bars represent SEM of individual duplicates (n=11, tonsil numbers as indicated).  






 The detection of the cytokine IL-10 is shown in Figure 4.20. Figure 4.20A 
shows the raw data for the detection of IL-10 in pg/ml for all eleven donors. It is clear to 
see that there was a wide range in the levels of IL-10 secretion, from 2 – 98pg/ml. 
Figure 4.20B presents this data as relative IL-10 secretion, normalised to IL-10 levels 
from cells transfected with control siRNA in each donor. IL-10 secretion from CD23 
siRNA-transfected cells, compared to control siRNA-transfected cells, was elevated in 
five donors. Other donors showed either no difference between the two siRNA 
transfections or a slight decrease in IL-10 secretion from CD23 siRNA-transfected cells. 
Figure 4.20C summarises the data from all donors and shows the average increase in IL-
10 secretion from CD23 siRNA-transfected cells, compared to control siRNA-
transfected cells, was non-significant (p=0.123, n=11). 
  






Figure 4.20. Depending on the donor, CD23 siRNA either increased or decreased IL-
10 secretion. 
Total B cells were transfected with either control siRNA (red) or CD23 siRNA (blue) by 
electroporation and cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). Cell supernatants were harvested on day 12 and the levels of IL-10 were quantified 
using a MILLIPLEX
®
 MAP Human Cytokine Assay. Data is displayed from individual donors 
as (A) the concentration of IL-10 in pg/ml and (B) the % of IL-10 secretion relative to cells 
transfected with control siRNA (100%). Error bars represent SEM of individual duplicates 
(n=11). (C) Pooled data from multiple donors for the % of IL-10 secretion relative to cells 
transfected with control siRNA (100%). Error bars represent SEM and statistical analysis was 










 The detection of the cytokine IL-6 is shown in Figure 4.21. Figure 4.21A shows 
the raw data for the detection of IL-6 in pg/ml for all eleven donors. IL-6 secretion 
levels varied widely between donors from 60 – 5600pg/ml. Of the eleven donors, cells 
from three donors secreted very high levels of IL-6 above 2500pg/ml. Figure 4.21B 
presents this data as relative IL-6 secretion, normalised to IL-6 levels from cells 
transfected with control siRNA in each donor. IL-6 secretion from CD23 siRNA-
transfected cells, compared to control siRNA-transfected cells, was elevated in seven 
donors. Other donors showed no difference in IL-6 secretion between control siRNA- 
and CD23 siRNA-transfected cells. Figure 4.21C shows the average increase in IL-6 
secretion from CD23 siRNA-transfected cells, compared to control siRNA-transfected 
cells, was statistically significant (p=0.042, n=11). These results suggest a mechanism 
by which IL-6 secretion is enhanced as a result of siRNA-induced CD23 knockdown. 
This will be discussed further in the chapter summary (Section 4.7). 
 






Figure 4.21. IL-6 secretion was significantly higher from cells transfected with CD23 
siRNA compared to control siRNA. 
Total B cells were transfected with either control siRNA (red) or CD23 siRNA (blue) by 
electroporation and cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). Cell supernatants were harvested on day 12 and the levels of IL-6 were quantified 
using a MILLIPLEX
®
 MAP Human Cytokine Assay. Data is displayed from individual donors 
as (A) the concentration of IL-6 in pg/ml and (B) the % of IL-6 secretion relative to cells 
transfected with control siRNA (100%). Error bars represent SEM of individual duplicates 
(n=11). (C) Pooled data from multiple donors for the % of IL-6 secretion relative to cells 
transfected with control siRNA (100%). Error bars represent SEM and statistical analysis was 
performed using the Wilcoxon matched-pairs signed rank test (n=11, tonsil numbers as 
indicated). * p<0.05 
 
4.6.2. The relationship between IL-6, IL-10 and IgE secretion 
 IgE secretion from human B cells, induced by the combination of IL-4 and anti-
CD40 stimulation, has been previously shown to be preceded by a strong activation of 
NF-κB and an increase in IL-6 secretion (Jeppson, Patel et al., 1998). It was of interest 
to see if the wide range of IL-6 secretion levels shown in Figure 4.21 correlated with 





levels of IgE secretion. Figure 4.22A shows there was no correlation between IL-6 and 
IgE secretion from control siRNA-transfected human B cells following 12 days in 
culture with IL-4 and anti-CD40. 
 Since Figure 3.4 showed the addition of recombinant human IL-10 could 
increase IgE secretion from human B cells in vitro, it was of interest to see if 
endogenous B cell-secreted IL-10 would have the same effect. Figure 4.22B shows 
there was no correlation between IL-10 secretion and IgE secretion from control 
siRNA-transfected human B cells following 12 days in culture with IL-4 and anti-
CD40. 
 
     
Figure 4.22. No correlation was shown between IL-6, or IL-10, and IgE secretion. 
Total B cells were transfected with control siRNA by electroporation and cultured for 12 days in 
the presence of IL-4 (200IU/ml) and anti-CD40 (1µg/ml). (A) IL-6 secretion and (B) IL-10 
secretion were quantified using a MILLIPLEX
®
 MAP Human Cytokine Assay on day 12. IgE 
secretion was analysed by ELISA on day 12. 
Correlation analysis was performed using Spearman‟s rank correlation coefficient (r values 
indicated on graphs) (n=10, tonsil numbers 8, 11-15, 17, 19, 21 & 22). 
 
  






 This chapter described a series of experiments using siRNA in human B cells to 
study the effects of CD23 knockdown on IgE synthesis with the overall aim of 
dissecting the roles of different forms of CD23 in the regulation of IgE. 
 No work has ever been published on the use of CD23 siRNA so the protocol 
required extensive optimisation. After selecting the appropriate concentration of siRNA 
to be used, human B cells were successfully transfected by electroporation (Figure 4.1). 
As the process of electroporation was found to reduce cell viability (Figure 4.3), cells 
transfected with a scrambled control siRNA were used for comparison in all future 
experiments.  
 qPCR analysis following transfection with CD23 siRNA showed a specific and 
significant reduction in CD23 mRNA levels with the optimum knockdown at 18-24 
hours following transfection (Figure 4.5). This transient reduction in CD23 mRNA 
levels reduced the frequency and MFI of mCD23
+
 cells until day 7 following 
transfection. However, by day 12, mCD23 expression had recovered to that of control 
siRNA-transfected cells (Figure 4.6). As introduced in Section 1.5.3, sCD23 is 
produced by ADAM10-mediated cleavage of mCD23. By day 12, but not at the earlier 
timepoints of days 5 or 7, CD23 siRNA-transfected cells showed significantly reduced 
sCD23 production (Figure 4.7). Supporting the correlation shown between sCD23 and 
sIgE in Figure 4.8, reduced sCD23 levels on day 12 were associated with reduced IgE 
secretion at the same timepoint (Figure 4.10 and Figure 4.12). As mCD23 expression 
had returned to normal from days 7-12 following transfection with CD23 siRNA, any 
CD23-mediated differences in IgE secretion between days 7 and 12 can be attributed to 
sCD23. This reduction in IgE was shown to be specific to the secreted form of IgE, 





isotype-specific and not due to a reduction in the levels of CSR to IgE or ADAM10 
expression (Figure 4.11 - Figure 4.16).  
 Multiplex cytokine analysis of supernatants from control siRNA- and CD23 
siRNA-transfected cells revealed a significantly higher level of IL-6 secretion from 
CD23 siRNA-transfected cells (Figure 4.21). However, the range in the levels of IL-6 
secretion did not correlate with IgE secretion (Figure 4.22). More in depth experiments 
are required to establish whether B cell-secreted IL-6 plays a role in regulating IgE 
secretion (discussed in Section 4.7.1). Multiplex cytokine analysis also detected the 
secretion of IL-10 from human B cells, although there appeared to be no consistent 
pattern of whether IL-10 secretion was increased or decreased following transfection 
with CD23 siRNA, compared to control siRNA (Figure 4.20). IFNγ (Figure 4.18) and 
high levels of IL-13 (Figure 4.19) and IL-10 (Figure 4.20) were detected in the 
supernatant from tonsil number 12 (non-allergic donor), particularly from CD23 
siRNA-transfected cells. This mixed cytokine profile cannot be correlated with sIgE 
levels as no sIgE was detected by day 12, which may be interesting in itself. However, 
no IFNγ and only low levels of IL-13 and IL-10 were detected in the supernatants from 
the other tonsils which also secreted no IgE by day 12 (tonsil numbers 1, 8, 13 & 14).   
 In summary, these experiments utilised CD23 siRNA for the first time to show 
that a reduction in sCD23 is sufficient to reduce the secretion of IgE from primary 
human B cells in vitro (Cooper, Hobson et al., 2012). The relationship between sCD23 
and sIgE shown in Figure 4.8, may reflect the avidity of sCD23 in the tri-molecular 
complexes with mIgE and mCD21 at the surface of the fluid B cell membrane. An 
investigation into the role of mCD21 in sCD23-mediated regulation of IgE will be 
covered in Chapter 6.  





4.7.1. Further experiments 
 To truly show that reduced sCD23 production is sufficient to cause a reduction 
in IgE secretion it would be interesting to transfect cells with CD23 siRNA and then add 
sCD23 back in, in the form of recombinant CD23 or sCD23-containing supernatants, to 
see if the IgE secretion can be restored.  
 Experiments are currently underway to investigate the downstream cellular 
effects by which CD23 controls the synthesis of IgE. qPCR could be utilised to measure 
a selection of B cell signalling molecules, transcription factors and survival factors in 
cells transfected with control siRNA compared to CD23 siRNA. Another interesting 
experiment would be to optimise the knockdown of CD21 using siRNA (this was 
attempted but no knockdown was observed) and to see whether reduced mCD21 levels 
would also lead to reduced IgE secretion due to disruption of the mIgE-sCD23-mCD21 
cross-linking network.  
 It would be interesting to continue the experiments investigating B cell cytokine 
secretion and how this is altered upon transfection with CD23 siRNA. As a very large 
panel of cytokines and chemokines are available to create custom multiplex cytokine 
assays, it would be useful to screen supernatants from control siRNA and CD23 siRNA-
transfected cells for levels of many more cytokines. If a particular cytokine was found 
to be consistently down-regulated following CD23 siRNA transfection, this would give 
an indication of the signalling pathways through which sCD23 increases IgE secretion 
from human B cells. 
  





Chapter 5. Inhibition of ADAM10 with GI254023X 
5.1. Introduction 
 Since CD23 siRNA transfection reduced sCD23 through the early reduction of 
mCD23 expression (Chapter 4), a different approach was taken that would aim to 
reduce sCD23 levels through preventing mCD23 shedding, thus maintaining mCD23 
levels. The ADAM10-specific small molecule inhibitor, GI254023X, was utilised to 
achieve this. 
 
5.2. The ADAM10 inhibitor, GI254023X, does not affect cell viability 
 It was first necessary to ascertain whether addition of GI254023X into the B cell 
cultures would have any effect on cell viability. Human tonsil B cells were cultured for 
5 days with IL-4 and anti-CD40 before addition of the ADAM10 inhibitor (1µM-15µM) 
as described in Section 2.4.1. Figure 5.1 shows cell viability on days 6, 7 and 12, 
relative to cells cultured with no inhibitor present at each timepoint. The viability of 
cells, cultured with no inhibitor present, was 29 ± 4% on day 6, 22 ± 5% on day 7 and 
13 ± 4% on day 12 (n=6). Figure 5.1 clearly shows that the presence of the inhibitor did 
not cause a significant increase or decrease in cell viability at any timepoint in the 
culture period. 
  






Figure 5.1. The ADAM10 inhibitor, GI254023X, does not affect cell viability. 
Total B cells were cultured for up to 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). GI254023X (1µM-15µM) was added on day 5 and the % of viable cells was analysed 
on days 6, 7 and 12 by flow cytometry, with live cell gating determined by forward versus side 
scatter. Cell viability is displayed as the % of viable cells, relative to cells cultured with no 
inhibitor at each timepoint (100%).  
Error bars represent SEM and statistical analysis was performed using ANOVA with Bonferroni 
correction (n=6, tonsil numbers 20, 22-25 & 31). 
 
 
5.3. ADAM10 inhibition with GI254023X increases mCD23 expression 
 To assess the ability of GI254023X to inhibit the ADAM10-mediated cleavage 
of mCD23, flow cytometry was utilised to quantitate the expression levels of mCD23 
(as described in Section 2.5.1). Human tonsil B cells were cultured for up to 12 days 
with IL-4 and anti-CD40 with addition of GI254023X (0.25µM-15µM) on day 5. Cell 
samples were taken on days 6, 7 and 12, stained for mCD23 expression and analysed by 
flow cytometry. Figure 5.2A shows an example of mCD23 expression levels on the 
surface of cells cultured with no GI254023X present or with the addition of GI254023X 
(15µM). In this example, the addition of GI254023X led to an increase in the 
percentage and MFI of mCD23
+
 cells, most evident at the latest timepoint of day 12.  





 Figure 5.2B and Figure 5.2C show pooled mCD23 expression data from multiple 
donors on day 12 with addition of a concentration range of GI254023X on day 5. This 
data is expressed relative to mCD23 expression on cells cultured with no GI254023X 
present. Figure 5.2B shows a small increase in the percentage of mCD23
+
 cells with 
increasing concentrations of GI254023X but this did not reach statistical significance. 
However, Figure 5.2C shows a significant dose-dependent accumulation (p<0.0001) of 
mCD23 on the surface of CD23
+
 cells as measured by the MFI. With the addition of the 
highest concentration of GI254023X (15µM), the MFI of mCD23
+
 cells increased by an 
average of 53 ± 13% (p=0.0009, n=6). 
  







     
 
  
Figure 5.2. GI254023X increases the level of mCD23 expression on mCD23
+
 cells. 
Total B cells were cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). GI254023X (0.25µM-15µM) was added on day 5 and the expression of mCD23 was 
analysed by flow cytometry on days 6, 7 and 12. (A) Overlay of mCD23 expression on cells 
cultured with GI254023X (15µM) (blue) or with no inhibitor (red). % of mCD23
+
 cells and 
mCD23
+
 MFI are indicated below each dot plot. Data shown from 1 (tonsil number 22) of 6 
donors. Pooled multiple donor data for cells cultured with GI254023X (0.25µM-15µM), relative 
to cells cultured with no inhibitor (100%), is shown for (B) % of mCD23
+
 cells and (C) CD23
+
 
MFI. Error bars represent SEM and statistical analysis was performed using ANOVA with 
Bonferroni correction (n=6, tonsil numbers 20, 22-25 & 31). ** p<0.01, *** p<0.001 
 
  





5.4. ADAM10 inhibition with GI254023X reduces sCD23 production in a time-
dependent manner 
 Since Figure 5.2 showed the accumulation of mCD23 through the use of an 
ADAM10 inhibitor it was expected that this would also be accompanied by a reduction 
in the levels of sCD23 in the supernatant. In the same experiments as described in the 
previous section, supernatant samples were taken on day 12 for analysis of sCD23 
content by ELISA (as described in Section 2.6.3). Figure 5.3 shows a dose-dependent 
inhibition of sCD23 production when GI254023X was added on day 5. The addition of 
10µM GI254023X resulted in a 28.3 ± 9.9% reduction in sCD23 production (p=0.048, 
n=6). Due to a larger error bar for the 15µM GI254023X data point, the observed 
reduction in sCD23 production (26.4 ± 11.3%) did not reach statistical significance 
(p=0.06, n=6) (Figure 5.3). 
 To assess the mechanism of action of GI254023X in more detail, a comparison 
was made between the levels of sCD23 inhibition when the inhibitor was added on days 
5, 8 or 10. The level of sCD23 inhibition was analysed on day 12 and is shown in 
Figure 5.3. When the inhibitor was added progressively later in the incubation period 
the level of sCD23 inhibition decreased accordingly, resulting in higher levels of sCD23 
detected in the supernatant. This was due to the shorter time period in which 
GI254023X was able to inhibit mCD23 shedding. Despite this, even the addition of 
GI254023X (15µM) as late as day 10 was still able to cause a small reduction in sCD23 
production (10%, n=1) when analysed 2 days later on day 12. Taking the mean values, 
there was a significant dose-dependent trend in the reduction of sCD23 with increasing 
concentrations of ADAM10 inhibitor (p=0.012). 






Figure 5.3. GI254023X decreases sCD23 production and the level of inhibition is 
dependent on the day of addition. 
Total B cells were cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). GI254023X (1µM-15µM) was added on either day 5 (○), 8 (∆) or 10 (◊) and the 
production of sCD23 was analysed by ELISA on day 12, relative to cells cultured with no 
inhibitor (100%). 
Error bars represent SEM and are shown downwards for day 5 data and upwards for day 8 data 
(no error bars for day 12 data). Statistical analysis was performed using ANOVA with 
Bonferroni correction (n=6, tonsil numbers 20, 22-25 & 31). * p<0.05 
 
 
5.5. ADAM10 inhibition with GI254023X reduces IgE secretion in a time-
dependent manner 
 In the same experiments as described in the previous section, supernatant 
samples were taken on day 12 for analysis of sIgE content by ELISA (as described in 
Section 2.6.1). Figure 5.4 shows a dose-dependent inhibition of IgE secretion when the 
inhibitor was added on day 5. The addition of both 10µM and 15µM GI254023X 
resulted in a significant decrease in sIgE levels. The maximum inhibition of IgE 
secretion (64.9 ± 7.2%) was observed in cells cultured with 10µM GI254023X 
(p=0.007, n=6).  





 To assess the mechanism of action of GI254023X in more detail, as discussed in 
the previous section for sCD23 inhibition, a comparison was made between the levels of 
sIgE inhibition when the inhibitor was added on days 5, 8 or 10. The level of sIgE 
inhibition was analysed on day 12 and is shown in Figure 5.4. When the inhibitor was 
added progressively later in the incubation period the level of sIgE inhibition decreased 
accordingly, resulting in higher levels of sIgE detected in the supernatant. Despite this, 
even the addition of GI254023X (15µM) as late as day 10 was still able to cause a large 
reduction (44%, n=1) in sCD23 production when analysed 2 days later on day 12. This 
complements the pattern of sCD23 inhibition when GI254023X was added 
progressively later in the incubation period (Figure 5.3). Taking the mean values, there 
was a significant dose-dependent trend in the reduction of sIgE with increasing 
concentrations of ADAM10 inhibitor (p=0.0002). 
  






Figure 5.4. GI254023X decreases IgE secretion and the level of inhibition is 
dependent on the day of addition. 
Total B cells were cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). GI254023X (1µM-15µM) was added on either day 5 (○), 8 (∆) or 10 (◊) and the 
secretion of IgE was analysed by ELISA on day 12, relative to cells cultured with no inhibitor 
(100%). 
Error bars represent SEM and are shown downwards for day 5 data and upwards for day 8 data 
(no error bars for day 12 data). Statistical analysis was performed using ANOVA with 
Bonferroni correction (n=6, tonsil numbers 20, 22-25 & 31). ** p<0.01 
 
5.5.1. ADAM10 inhibition with GI254023X has no effect on IgG secretion 
 To assess whether the reduction in IgE secretion was isotype-specific, the effect 
of GI254023X addition on IgG secretion was analysed. In the same supernatant samples 
used for the analysis of sCD23 and sIgE content, day 12 sIgG levels were quantified by 
ELISA (as described in Section 2.6.2). Figure 5.5 shows that the addition of 1µM, 
10µM or 15µM GI254023X on day 5 did not significantly reduce the levels of sIgG by 
day 12 (n=6). 
 






Figure 5.5. GI254023X has no significant effect on IgG secretion. 
Total B cells were cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). GI254023X (1µM-15µM) was added on day 5 and the secretion of IgG was analysed 
by ELISA on day 12, relative to cells cultured with no inhibitor (100%). 
Error bars represent SEM and statistical analysis was performed using ANOVA with Bonferroni 
correction (n=6, tonsil numbers 20, 22-25 & 31). 
 
5.5.2. ADAM10 inhibition with GI254023X has no significant effect on IgE 
or IgG expression levels  
 Having now shown that reducing sCD23 production in human B cells, through 
the addition of an ADAM10 inhibitor, can consequently reduce IgE secretion, it was 
necessary to check whether this reduction was specific to the secreted form of IgE. To 
investigate this, cells were cultured in the presence of GI254023X (added on day 5) and 
the membrane and intracellular expression of IgE and IgG was analysed by flow 
cytometry on day 12 (as described in Section 2.5.1).  
 Figure 5.6A and Figure 5.6B show very similar expression patterns for IgE and 
IgG, on days 7 and 12, between cells cultured only with IL-4 and anti-CD40 or with the 
addition of GI254023X (15µM) on day 5. Figure 5.6C shows there appeared to be a 





slight reduction in the MFI of IgE
+
 cells on day 12, although this was not statistically 
significant (p=0.12 for 15µM GI254023X, n=6). Figure 5.6D shows there was no 




Figure 5.6. GI254023X has no significant effect on IgE or IgG expression levels. 
Total B cells were cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml) and GI254023X (1µM, 10µM or 15µM) was added on day 5. The expression of 
membrane and intracellular IgE and IgG was analysed on days 7 and 12 by flow cytometry. An 
example of (A) IgE and (B) IgG expression levels on day 7 (dotted line) and day 12 (solid line) 
for cells cultured with either IL-4/aCD40 only (red) or with the addition of GI254023X (15µM) 
(blue). The % of IgE
+
 cells and MFI are indicated on the legend. Data shown from 1 (tonsil 
number 25) of 6 donors. Pooled data from multiple donors is shown for the MFI of (C) live IgE
+
 
cells and (D) live IgG
+
 cells, relative to cells cultured with no inhibitor at each timepoint 
(100%). Error bars represent SEM and statistical analysis was performed using ANOVA with 
Bonferroni correction (n=6, tonsil numbers 20, 22-25 & 31).  






 Previously, Chapter 4 concluded that a reduction in sCD23 alone was sufficient 
to reduce IgE secretion from human B cells. In this present chapter, an alternative 
approach was taken to see if the same outcome could be achieved. Whilst the 
experiments in Chapter 4 decreased sCD23 through a reduction in mCD23 (via siRNA), 
this present chapter described experiments which decreased sCD23 through maintaining 
mCD23 on the cell surface through inhibition of ADAM10 with a specific small 
molecule inhibitor (GI254023X). It has previously been shown that inhibition of 
ADAM10 in vivo (Gibb, El Shikh et al., 2010; Sturgill, Mathews et al., 2011) and the 
addition of GI254023X to human tonsil B cells (Weskamp, Ford et al., 2006) results in 
decreased sCD23 production. However, subsequent effects on IgE were not analysed in 
these studies.  
 The results in this chapter showed how the addition of GI254023X to primary 
human B cells led to a significant dose-dependent increase in the MFI of mCD23
+ 
cells 
indicating the inhibitor was preventing the ADAM10-mediated cleavage of mCD23 
(Figure 5.2). In support of this, addition of the inhibitor was shown to reduce sCD23 
levels in the supernatant, the extent of which decreased when the inhibitor was added 
progressively later in the incubation period (Figure 5.3). This pattern of sCD23 
reduction was paralleled in the level of sIgE reduction with a maximum inhibition of 
65% (by day 12) following addition of GI254023X (10µM) on day 5 of the culture 
period (Figure 5.4). Adding GI254023X progressively later in the culture period and yet 
still observing a reduction in IgE secretion demonstrated that the inhibitor was 
regulating the secretion of IgE by a post-switch mechanism. There was no timepoint at 
which there appeared to be a committed pathway that could no longer be inhibited by 





addition of GI243023X. The GI254023X-mediated inhibition of IgE was shown to be 
isotype-specific and to only affect the secreted form of IgE (Figure 5.5 and Figure 5.6).   
 In summary, prevention of mCD23 shedding through addition of an ADAM10-
specific inhibitor led to a concentration-dependent decrease in sCD23 and sIgE. Since 
mCD23 was not cleaved but was actually elevated in these experiments, the observed 
inhibition of IgE synthesis firmly points to sCD23-mediated positive regulation. As in 
previous work with alternative matrix metalloprotease inhibitors and IL-4-stimulated 
human peripheral blood lymphocytes (Mayer, Bolognese et al., 2000), we conclude that 
sCD23 is required to maintain IgE synthesis in human B cells (Cooper, Hobson et al., 
2012). A recent pre-clinical trial in mice showed intranasal administration of selective 
ADAM10 inhibitors led to reduced eosinophilia in the bronchoalveolar lavage fluid and 
reduced AHR (Mathews, Ford et al., 2011). The work in this chapter provides further 
evidence to support ADAM10 and sCD23 as potential therapeutic targets in the 
treatment of asthma and allergic disease. 
5.6.1. Further experiments 
 It would be worthwhile confirming the results shown in this chapter by 
transfecting human B cells with siRNA targeted against ADAM10. If the same results 
were achieved as with GI254023X then this would confirm the specificity of 
GI254023X for ADAM10 and provide further evidence for the role of sCD23 in the up-










Chapter 6. Addition of recombinant CD23 and the role of mCD21 
6.1. Introduction 
 McCloskey et al previously showed that addition of oligomeric sCD23 
(lzCD23), above a certain threshold concentration, up-regulates IgE production from 
human tonsillar B cells. In contrast, monomeric derCD23 was shown to down-regulate 
IgE production (McCloskey, Hunt et al., 2007). The IgE-potentiating ability of the more 
stable triCD23 (produced as described in Section 2.4.2) will be explored in this chapter. 
Although not a naturally occurring fragment, triCD23 has been specifically designed to 
mimic the trimeric state of endogenous sCD23 when it is first cleaved off the membrane 
in allergic tissues (Figure 1.3). 
 
6.2. Assay Optimisation  
 First it was necessary to conduct preliminary tests to ensure the recombinant 
triCD23 protein contained no endotoxin and did not interfere with the detection of sIgE 
by ELISA. 
6.2.1. triCD23 does not contain endotoxin 
 To address the first concern, the PyroGene™ Recombinant Factor C Assay for 
endotoxin detection was utilised (as described in Section 2.9). Figure 6.1 shows the 
endotoxin concentrations calculated in samples of a positive control, IL-4 and triCD23. 
IL-4 and triCD23 did not contain any endotoxin. 
 






Figure 6.1. triCD23 does not contain any endotoxin. 
The Pyrogene™ Recombinant Factor C (rFC) Endpoint Fluorescent Assay was used according 
to the manufacturer‟s instructions. 100µl of the positive control, IL-4 and triCD23 were added 
in triplicate to the 96-well plate and incubated at 37ºC for 10 minutes. rFC enzyme solution, 
assay buffer and fluorogenic substrate were mixed at a ratio of 1:4:5 and 100µl was added per 
well. The fluorescence at time zero and 1 hour was analysed at 380nm and endotoxin 
concentration (EU/ml) was calculated from the standard curve. 
Error bars represent SEM of individual triplicates (n=1). 
 
6.2.2. triCD23 does not interfere with the detection of sIgE by ELISA 
 To address the second concern, human serum IgE was diluted to 100ng/ml in 
Cell Culture Media and triCD23 was titrated in doubling dilutions from 1185nM 
(100,000ng/ml) into the diluted IgE. 100ng/ml of IgE alone was included as a control. 
After 10 days incubation at 37ºC sIgE content in the supernatants was analysed by 
ELISA. Figure 6.2 shows that the presence of triCD23 did not interfere with the 
detection of IgE by ELISA.  
 






Figure 6.2. triCD23 does not interfere with the detection of sIgE by ELISA. 
triCD23 was titrated in doubling dilutions from 1185nM (100,000ng/ml) and added to 100ng/ml 
IgE WHO standard (red line). IgE at 100ng/ml was used as a control (labelled as 0ng/ml 
triCD23). Levels of IgE were analysed 10 days later by ELISA.  
Error bars represent SEM of individual triplicates (n=1). 
 
 
6.3. Addition of recombinant CD23 proteins 
6.3.1. triCD23 has no effect on cell viability 
 Following the completion of the preliminary tests the effects of adding 
recombinant CD23 proteins into the human B cell cultures were investigated. Human 
tonsillar B cells were isolated as described in Section 2.2 and recombinant CD23 
proteins were produced and cultured with the human B cells as described in Section 
2.4.2. Initially it was important to determine whether triCD23 and derCD23 would have 
any detrimental effects on B cell viability. To test this, cells were cultured for up to 12 
days with IL-4 and anti-CD40 alone plus the addition of triCD23 (1µM) or derCD23 
(3µM) on day 0. Cell viability was analysed on days 7 and 12 by flow cytometry with 
live cell gating determined by forward versus side scatter. Figure 6.3 shows that 





although cell viability decreased over time there was no additional reduction in the 
viability of cells cultured with triCD23 or derCD23, compared to cells cultured with IL-
4 and anti-CD40 alone (n=6). 
 
 
Figure 6.3. Addition of triCD23 or derCD23 does not significantly affect cell viability. 
Total B cells were cultured for up to 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml) alone or with the addition of triCD23 (1µM) or derCD23 (3µM) on day 0. The % of 
viable cells was analysed on days 7 and 12 by flow cytometry with live cell gating determined 
by forward versus side scatter.  
Error bars represent SEM and statistical analysis was performed using ANOVA with Bonferroni 
correction (n=6, tonsil numbers 18, 19, 25 & 30-32). 
 
6.3.2. triCD23 up-regulates IgE secretion 
 Since it was now confirmed that addition of triCD23 or derCD23 into the human 
B cell cultures did not reduce cell viability, the effect on IgE and IgG secretion could 
next be investigated. In order to do this, isolated human B cells were cultured for 12 
days with a concentration range of triCD23 or derCD23. Concentrations were selected 
to be lower than, equal to and above the calculated KD value for trimeric CD23 binding 
to IgE (10
-7
M) (Hibbert, Teriete et al., 2005; McCloskey, Hunt et al., 2007) and used at 





a weight ratio of 1:3 (triCD23:derCD23) to maintain the same number of mIgE/mCD21 
binding sites in each condition (Table 6.1).  
 























Table 6.1. Concentrations used of triCD23 and derCD23. 
Concentrations were selected to be lower than, equal to and above the calculated KD value for 
trimeric CD23 binding to IgE (10
-7
M) and used at a weight ratio of 1:3 (triCD23:derCD23) to 
maintain the same number of mIgE/mCD21 binding sites in each condition. Concentrations 
highlighted in red were selected as the routine concentrations of triCD23 and derCD23 to be 
used in subsequent experiments. 
 
 Supernatants were analysed by ELISA for sIgE content on day 12 and the results 
are shown in Figure 6.4. The addition of triCD23 resulted in a concentration-dependent 
increase in the secretion of IgE. In contrast, addition of derCD23 resulted in a 
concentration-dependent decrease in the secretion of IgE. This experiment was repeated 
in six donors for 1µM triCD23 and 3µM derCD23 („85 x‟ on Figure 6.4). At these 
concentrations IgE secretion increased 200.0 ± 27.2% in cells cultured with triCD23 
(1µM) compared to cells cultured with IL-4 and anti-CD40 alone (p=0.008, n=6). IgE 
secretion from cells cultured with derCD23 (3µM) reduced by 42.2 ± 5.7% compared to 
IL-4 and anti-CD40 alone (p=0.04, n=6) (Figure 6.4). These results confirm findings 
from previous studies using recombinant trimeric CD23 proteins (Bowles, Jaeger et al., 
2011; McCloskey, Hunt et al., 2007). However, triCD23 was around twice as effective 
at increasing IgE synthesis compared to the „trimeric‟ CD23 proteins used in previous 
studies (lzCD23 or exCD23). 






Figure 6.4. triCD23 increases and derCD23 decreases IgE secretion. 
Total B cells were cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml) alone or with the addition of triCD23 (●) or derCD23 (○) as described in Table 6.1. 
IgE secretion was analysed by ELISA on day 12, relative to cells cultured with IL-4/anti-CD40 
alone (100%). 
Error bars represent SEM and statistical analysis was performed using ANOVA with Bonferroni 
correction (n=6, tonsil numbers 18, 19, 25 & 30-32). * p<0.05, ** p<0.01, *** p<0.001 
 
6.3.1. triCD23 has no effect on IgG secretion 
 IgG secretion was analysed by ELISA to establish whether the increase in IgE 
secretion was isotype-specific. In the same supernatants used in Figure 6.4, Figure 6.5 
shows IgG secretion levels from cells cultured for 12 days with triCD23 (1µM) or 
derCD23 (3µM). No significant difference was seen in the levels of IgG secretion, 
compared to cells cultured with IL-4 and anti-CD40 alone, with addition of triCD23 or 
derCD23.  
 






Figure 6.5. Addition of triCD23 or derCD23 has no significant effect on IgG 
secretion. 
Total B cells were cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml) alone or with the addition of triCD23 (1µM) (●) or derCD23 (3µM) (○). IgG secretion 
was analysed by ELISA on day 12, relative to cells cultured with IL-4/anti-CD40 alone (100%). 
Error bars represent SEM and statistical analysis was performed using ANOVA with Bonferroni 
correction (n=6, tonsil numbers 18, 19, 25 & 30-32). 
 
6.3.2. triCD23 has no effect on IgE or IgG expression 
 To investigate whether the triCD23-mediated increase in IgE was specific to the 
secreted form of IgE, flow cytometry was utilised to quantify the expression levels of 
intracellular and membrane IgE (as described in Section 2.5.1). Human B cells were 
isolated and cultured for 12 days with IL-4 and anti-CD40 alone plus the addition of 
triCD23 (1µM) or derCD23 (3µM). Figure 6.6 shows the addition of neither triCD23 or 
derCD23 significantly altered the expression levels (as measured by MFI) of IgE or 
IgG. The increase in IgE secretion shown in Figure 6.4 was therefore not accompanied 
by an increase in the expression levels of IgE.  
 







   
Figure 6.6. Addition of triCD23 or derCD23 has no significant effect on IgE or IgG 
expression levels. 
Total B cells were cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml) alone or with the addition of triCD23 (1µM) or derCD23 (3µM). The expression of 
membrane and intracellular IgE and IgG was analysed on day 12 by flow cytometry. (A) An 
example of IgE expression levels on day 12 for cells transfected with IL-4/anti-CD40 alone or 




 cells and MFI are indicated on the plots. 
Data shown from 1 (tonsil number 25) of 6 donors. Pooled data from multiple donors is shown 
for (B) the MFI of live IgE
+
 cells (B) the MFI of live IgG
+
 cells, relative to cells cultured with 
IL-4/anti-CD40 alone (100%). Error bars represent SEM and statistical analysis was performed 
using ANOVA with Bonferroni correction (n=6, tonsil numbers 18, 19, 25 & 30-32). 
 
  





6.3.1. triCD23 can rescue GI254023X-mediated inhibition of IgE secretion 
 In Chapter 5, the ADAM10-specific small molecule inhibitor GI254023X was 
shown to decrease sCD23 production and IgE secretion from human B cells. The 
following experiment investigates the ability of triCD23 to rescue the GI254023X-
mediated reduction of sCD23 and sIgE. Cells were cultured for 12 days with IL-4 and 
anti-CD40 alone plus the addition of triCD23 (1µM), GI254023X (5µM) or triCD23 & 
GI254023X on day 0. As previously shown in Figure 6.4, the addition of triCD23 led to 
an up-regulation of IgE secretion (Figure 6.7). When cells were cultured with 
GI254023X a large reduction in IgE secretion occurred (Figure 6.7), previously shown 
to be due to a reduction in sCD23 production (Figure 5.3 and Figure 5.4). When cells 
were cultured with a combination of the ADAM10 inhibitor and triCD23, a partial relief 
from GI254023X-mediated IgE suppression was observed (2.3-fold increase, n=2) 
(Figure 6.7). This result confirms the positive regulation of IgE synthesis by sCD23. 
 
Figure 6.7. triCD23 rescues GI254023X-mediated inhibition of IgE secretion. 
Total B cells were cultured for 12 days in the presence of IL-4 (200IU/ml) and anti-CD40 
(1µg/ml) alone or with the addition of triCD23 (1µM), GI254023X (5µM) or triCD23 & 
GI254023X. IgE secretion was analysed by ELISA on day 12, relative to cells cultured with IL-
4/anti-CD40 alone (100%). 
Error bars represent SEM (n=2, tonsil numbers 25 & 31). 





6.4. The mechanism of action of triCD23 
 Having identified a role for sCD23 in the positive regulation of IgE synthesis, 
the possible mechanisms involved were investigated further. 
6.4.1. triCD23-mediated redistribution of mCD21 and mIgE 
 In 2005, structural studies showed the CD23-binding sites of IgE and CD21 to 
be in distinct locations on the lectin „head‟ domain (Hibbert, Teriete et al., 2005). With 
this in mind, confocal microscopy was utilised to assess whether triCD23 was capable 
of simultaneously binding to IgE and CD21, co-localising these molecules on the cell 
surface, to induce the up-regulation of sIgE (Gould, Beavil et al., 1997). 
 Human tonsillar B cells were cultured with IL-4 and anti-CD40 for 8 days; the 
optimum timepoint for the dual expression of mIgE and mCD21 (Figure 6.8). Dead 
cells were removed and the remaining cells stimulated for 30 minutes with media alone, 
derCD23 (3µM) or triCD23 (1µM). When analysing these cells by confocal 





cells could be detected on each slide. For the images shown in the following sections, 
only these double positive cells were imaged to analyse the ability of triCD23 to co-















Human tonsillar B cells were cultured for up to 10 days with IL-4 (200IU/ml) and anti-CD40 
(1µg/ml). mCD21 and mIgE expression were analysed by flow cytometry and the fold change 
plotted for the % of (A) mCD21
+





 cells (□), relative to Day 1. Error bars represent SEM and statistical analysis 
was performed using ANOVA with Bonferroni correction (n=5). * p<0.05, ** p<0.01, *** 
p<0.001 
Experimental work conducted by Dr M Jutton. 
 
 Figure 6.9A and Figure 6.9B show the even and uniform distribution of both 
mCD21 and mIgE on the surface of B cells incubated with either media alone or 
monomeric derCD23, respectively. The merged images in the bottom panels of Figure 
6.9A and Figure 6.9B show no yellow regions of mCD21 and mIgE co-localisation. 
Figure 6.9C shows the redistribution and co-localisation of mCD21 and mIgE following 
incubation with triCD23. Several distinct microclusters formed and particularly strong 
capping of mCD21 and mIgE is indicated on the merged image in the bottom panel of 
Figure 6.9C.   






Figure 6.9. triCD23 co-localises mCD21 and mIgE on the surface of human B cells. 
Human tonsillar B cells were cultured for 8 days with IL-4 (200IU/ml) and anti-CD40 (1µg/ml) 
and stimulated for 30 minutes with media alone, derCD23 (3µM/48µg/ml) or triCD23 
(1µM/84µg/ml). Following fixation, cells were stained for mCD21 (red), mIgE (green) and the 
nucleus (blue) and visualised by confocal microscopy. Images show a single field of view with 
the third row showing a three-colour overlay. The white arrow indicates strong capping of mIgE 
with mCD21.  
Data shown from 1 donor (tonsil number 18), representative of 3 (tonsil numbers 18, 25 & 32). 
 
 
6.5. The role of mCD21 in sCD23-mediated regulation of IgE 
 The role of mCD21 as a binding partner to sCD23 in the up-regulation of IgE 
synthesis was further investigated through the use of an anti-CD21 mAb which binds to 
SCRs 3-4 on CD21. Antibodies against human CD21 have been shown to up-regulate or 
down-regulate IgE synthesis, in anti-CD40-stimulated tonsil B cells, in an epitope-
dependent manner (Aubry, Pochon et al., 1992; Henchoz, Gauchat et al., 1994).  





6.5.1. Anti-CD21 mAb reduces IgE secretion 
 Human B cells were cultured with IL-4 and anti-CD40 plus the addition of 
increasing concentrations of an anti-CD21 mAb (HB-5 clone) (as described in Section 
2.4.3). Figure 6.10 shows the addition of the anti-CD21 mAb resulted in a dose-
dependent decrease in IgE secretion. When cells were cultured with a combination of 
anti-CD21 mAb (10µg/ml) and triCD23 (1µM), the IgE-enhancing effects of triCD23 
were blocked.  
 
 
Figure 6.10. Anti-CD21 mAb reduces IgE secretion and blocks the IgE-enhancing 
effects of triCD23. 
Human tonsillar B cells were cultured for 12 days with IL-4 (200IU/ml) and anti-CD40 
(1µg/ml) alone, + anti-CD21 mAb (0.1, 1 or 10µg/ml), + triCD23 (1µM) or + aCD21 mAb 
(10µg/ml) & triCD23. IgE secretion was analysed by ELISA on day 12, relative to cells cultured 
with IL-4/anti-CD40 alone (100%).  
Error bars represent SEM (n=2, tonsil numbers 31 & 32). 
  





6.5.2. Anti-CD21 mAb reduces sCD23 production 
 Figure 5.2 and Figure 5.4, in Chapter 5, showed the addition of an ADAM10 
inhibitor increased mCD23 expression levels through prevention of mCD23 cleavage, 
subsequently reducing sCD23 production and IgE secretion. Since addition of the anti-
CD21 mAb reduced IgE secretion, the effect on sCD23 production and mCD23 
expression were subsequently analysed.  
 Figure 6.11A shows sCD23 ELISA analysis on the same supernatants used in 
Figure 6.10. Addition of the anti-CD21 mAb reduced sCD23 production in a 
concentration-dependent manner. Figure 6.11B shows flow cytometric analysis of 
mCD23 and mCD21 expression on B cells following 12 days in culture with IL-4 and 
anti-CD40 alone plus the addition of increasing concentrations of anti-CD21 mAb. 
mCD21
+
 cells (~10%) could be detected following stimulation with IL-4 and anti-CD40 
alone (left panel, Figure 6.11B). In cells cultured with the anti-CD21 mAb present, no 
mCD21 expression could be detected as the fluorescent anti-CD21 detection antibody 
could no longer bind to mCD21. This proves that the anti-CD21 mAb was definitely 















Figure 6.11. Anti-CD21 mAb reduces sCD23 production. 
Total B cells were cultured for 12 days with IL-4 (200IU/ml) and anti-CD40 (1µg/ml) alone or 
with the addition of anti-CD21 mAb (0.1, 1 or 10µg/ml). (A) sCD23 production was analysed 
by ELISA on day 12, relative to cells cultured with IL-4/anti-CD40 alone (100%). Error bars 
represent SEM (n=2, tonsil numbers 31 & 32). (B) The expression of mCD23 and mCD21 was 
analysed on day 12 by flow cytometry. The % of mCD23
+
 cells (black) and mCD21
+
 cells (red) 
are indicated on each dot plot. Data shown from 1 (tonsil number 31) of 2 donors. 
  





6.5.3. Anti-CD21 mAb reduces the triCD23-mediated clustering of mCD21 
 Given that the anti-CD21 mAb had been shown to bind to mCD21 and prevent 
the triCD23-mediated up-regulation of IgE synthesis, confocal microscopy was utilised 
to visualise this process (as described in Section 2.10). Human B cells were cultured for 
8 days and stimulated for 30 minutes with either media alone, derCD23 (3µM), triCD23 
(1µM), anti-CD21 mAb (10µg/ml) or a 15 minute pre-treatment with anti-CD21 mAb, 
followed by triCD23. Figure 6.12A and Figure 6.12B show the uniform distribution of 
mCD21 on the surface of B cells stimulated with media alone or derCD23, respectively. 
As previously shown in Figure 6.9, with cells from a different donor, stimulation with 
triCD23 resulted in the formation of distinct microclusters of mCD21 (Figure 6.12C). A 
similar pattern of mCD21 expression was observed when cells were stimulated with the 
anti-CD21 mAb (Figure 6.12D). This was presumably due to the ability of the anti-
CD21 mAb to bind two molecules of mCD21 and, therefore, induce clustering. Figure 
6.12E shows an example of mCD21 expression on a cell which was pre-treated with the 
anti-CD21 mAb before stimulation with triCD23. The distinct triCD23-mediated 
redistribution of mCD21 shown in Figure 6.12C is far less pronounced due to the pre-
treatment with the anti-CD21 mAb (Figure 6.12E).   






Figure 6.12. Pre-treatment with anti-CD21 mAb reduces triCD23-mediated clustering 
of mCD21. 
Human tonsillar B cells were cultured for 8 days with IL-4 (200IU/ml) and anti-CD40 (1µg/ml) 
and stimulated for 30 minutes with (A) media alone, (B) derCD23 (3µM/48µg/ml), (C) triCD23 
(1µM/84µg/ml), (D) anti-CD21 mAb (10µg/ml) or (E) anti-CD21 mAb & triCD23. Following 
fixation, cells were stained for mCD21 (red) and the nucleus (blue) and visualised by confocal 
microscopy. Images show a single field of view with a two-colour overlay.  










 The experiments in this present chapter set out to confirm the findings from 
previous studies (Bowles, Jaeger et al., 2011; Mayer, Bolognese et al., 2000; 
McCloskey, Hunt et al., 2007) that the addition of recombinant trimeric sCD23 to 
primary human B cells can enhance IgE synthesis. For the purpose of these 
experiments, triCD23 was specifically designed to mimic the trimeric state of 
endogenous sCD23 when it is first cleaved off the membrane in allergic tissues. 
 After initial assay optimisation to confirm that the triCD23 preparation did not 
contain any endotoxin, interfere with sIgE detection by ELISA or reduce B cell viability 
(Figure 6.1 - Figure 6.3), the effects on IgE were analysed. Addition of triCD23 was 
shown to increase IgE secretion in a concentration-dependent manner with no effect on 
IgG secretion. triCD23 was shown to specifically increase the soluble form of IgE 
(Figure 6.6), confirming previous observations by other groups (Batista, Efremov et al., 
1995; Karnowski, Achatz-Straussberger et al., 2006; Saxon, Kurbe-Leamer et al., 
1991). As a control, monomeric derCD23 was shown to reduce IgE secretion (Figure 
6.4). These results indicate that only a trimeric complex of CD23 is capable of up-
regulating IgE secretion, hypothesised to be through post-CSR dual-binding to both 
mIgE and mCD21 (Gould and Sutton 2008; Hibbert, Teriete et al., 2005).  
 For the first time, experiments in this chapter showed that addition of 
recombinant trimeric CD23 can rescue GI254023X-mediated inhibition of sIgE, 
confirming the positive regulation of IgE synthesis by sCD23 (Figure 6.7). However, 
the level of IgE synthesis was not fully restored to that of cells cultured only with 
triCD23. This might be explained by off-target effects of the ADAM10 inhibitor, 
investigation of which would require further studies.  





 Confocal microscopy was utilised to visualise the expression patterns of mIgE 
and mCD21 in order to investigate the mechanism by which triCD23 is capable of up-
regulating IgE secretion. Stimulation with triCD23 caused a redistribution of mIgE and 
mCD21 from a uniform pattern into distinct clusters (Figure 6.9 and Figure 6.12). The 
observed capping revealed that there seems to be no topological constraints to prevent a 
trimeric CD23 molecule from co-ligating mIgE and mCD21 and forming the predicted 
multi-molecular network on the cell surface (Hibbert, Teriete et al., 2005). In cells 
where triCD23 binding to mCD21 was blocked with the addition of an anti-CD21 mAb, 
triCD23 was no longer able to increase IgE secretion (Figure 6.10). The cell surface 
clusters of mCD21, which formed following stimulation with triCD23 alone, could no 
longer be detected (Figure 6.12). 
 In summary, this chapter has provided further evidence for the positive 
regulation of IgE secretion by sCD23 in human B cells (Cooper, Hobson et al., 2012). 
Unlike Chapters 4 and 5, which investigated the inhibition of sCD23, the results in this 
present chapter showed that an increase in sCD23 can lead to an increase in IgE 
secretion. The recombinant trimeric sCD23, triCD23, was shown to be biologically 
active and able to restore IgE secretion from cells in which sCD23 and sIgE had been 
reduced due to the addition of an ADAM10 inhibitor. Confocal microscopy provided 
visual evidence for the proposed mechanism by which sCD23 must bind to both mIgE 
and mCD21 to create „signalling rafts‟, ultimately culminating in the up-regulation of 
IgE.  
6.6.1. Further experiments 
 Throughout this chapter it was assumed, from Surface Plasmon Resonance 
(SPR) assays completed by other members of the laboratory, that triCD23 could bind to 





mIgE. However, it would be useful to have a directly fluorescently-labelled triCD23 
protein to definitively show binding to mIgE on the surface of human B cells by flow 
cytometry and confocal microscopy. The collection of confocal microscopy data in this 
chapter could be improved upon by isolating IgE
+
 cells before stimulation with triCD23 





cells on each slide allowing for quantification of cells showing capping 
of mIgE and mCD21 and for statistical analysis to be performed. Visualising the 
binding of triCD23 to mIgE and CD21, inserted into artificial lipid bilayers, by Total 
Internal Reflection Fluorescence (TIRF) microscopy is currently underway in the 
laboratory. 
 The mechanism by which triCD23 is capable of increasing IgE secretion from 
human B cells requires further investigation. This includes measuring the effects on cell 
proliferation, division, apoptosis, differentiation and signalling pathways. It would also 
be interesting to investigate the effects of triCD23 on IgE mRNA, circle transcripts and 
GLTs by qPCR. Adding triCD23 progressively later in the 12 day incubation period 
may provide a greater understanding of when, and by what exact mechanism, triCD23 is 
targeting the cells to increase IgE synthesis. Work is currently underway in the 
laboratory to address these issues.  
 It would be interesting to cross-link an anti-IgE antibody and an anti-CD21 
antibody to mimic the binding capabilities of trimeric sCD23. The antibody complex 









Chapter 7. Overall Summary & General Discussion 
  This final chapter includes a general discussion on the importance of the results 
presented in this thesis and their contribution to the field of asthma and allergy research. 
 
7.1. CD23-mediated regulation of IgE synthesis 
 The cytokines IL-4 and IL-13 induce the CSR to all immunoglobulin isotypes 
downstream from Cµ in the heavy-chain locus on human chromosome 14. Since IL-4 is 
known to up-regulate CD23, the expression of CD23 and IgE are inextricably linked 
(Delespesse, Sarfati et al., 1992). The role of CD23 in the regulation of IgE in the 
human system appears to be much more complex than in the mouse (Gould and Sutton 
2008).  
 This thesis has described an investigation into the role of CD23 in the regulation 
of in vitro IgE synthesis from primary human B cells. The experiments aimed to shed 
light on a suggested mechanism by which sCD23 positively regulates IgE synthesis 
exclusively in human B cells (Hibbert, Teriete et al., 2005; McCloskey, Hunt et al., 
2007). In analysing this mechanism it is necessary to consider that there are multiple 
forms of sCD23, several potential ligands and various complexes with different 
affinities and topological constraints associated with binding to their ligands in solution 
and particularly on cells.   
 sCD23 is released from cells by the action of the endogenous metalloprotease 
ADAM10 (Lemieux, Blumenkron et al., 2007; Weskamp, Ford et al., 2006) and 
accumulates in the supernatant of B cells following IL-4 and anti-CD40-stimulated CSR 
to IgE (Christie, Barton et al., 1997; Mayer, Bolognese et al., 2000; Saxon, Ke et al., 





1990). The experiments described in this thesis used CD23 siRNA and an ADAM10-
specific inhibitor (GI254023X) to confirm that expression and cleavage of mCD23 to 
release sCD23 is required for the enhancement of IgE synthesis in primary human B 
cells (Cooper, Hobson et al., 2012).  
 Short-term inhibition of CD23 mRNA with siRNA led to a significant reduction 
in the frequency and MFI of CD23
+
 cells until day 7 following transfection. By day 12, 
but not at the earlier timepoints of days 5 or 7, CD23 siRNA-transfected cells showed 
significantly reduced sCD23 production. This correlated with reduced IgE secretion 
implicating sCD23 in the up-regulation of human IgE synthesis (Figure 4.6, Figure 4.7 
and Figure 4.10). 
 To further investigate the role of sCD23, ADAM10 was inhibited using a small 
molecule inhibitor (GI254023X). It has previously been shown that inhibition of 
ADAM10 in vivo (Gibb, El Shikh et al., 2010; Sturgill, Mathews et al., 2011) and the 
addition of GI254023X to human tonsil B cells (Weskamp, Ford et al., 2006) results in 
decreased sCD23 production. However, subsequent effects on IgE were not analysed in 
these studies. The experiments in this thesis showed the addition of GI254023X resulted 
in increased mCD23 expression levels, reduced sCD23 production and reduced IgE 
secretion. Inhibition of sCD23 production and IgE secretion could still be achieved even 
when GI254023X was added progressively later in the incubation period, albeit to lesser 
extents, indicating that the ADAM10 inhibitor was regulating secretion of IgE by a 
post-switch mechanism (Figure 5.3 and Figure 5.4). Since mCD23 was not cleaved but 
was actually elevated in these conditions, the observed inhibition of IgE synthesis 
firmly points to positive regulation mediated through sCD23.  





 When sIgE binds to mCD23 it blocks metalloprotease cleavage and the release 
of sCD23 (Conrad, Ford et al., 2007). However, this was not a complication in the 
present system as the sIgE concentrations in the medium (<10
-10
M) were well below the 
KD of the IgE-mCD23 interaction. As in previous studies with alternative matrix 
metalloprotease inhibitors and IL-4-stimulated human peripheral blood lymphocytes 
(Mayer, Bolognese et al., 2000) it can be concluded that sCD23 is required to maintain 
IgE synthesis in human B cells. 
 This thesis also confirms previous findings (Bowles, Jaeger et al., 2011; Mayer, 
Bolognese et al., 2000; McCloskey, Hunt et al., 2007) that addition of recombinant 
trimeric sCD23 to primary human B cells enhances IgE synthesis (Figure 6.4). Beyond 
this it has now been shown that when B cells are incubated with GI254023X in the 
presence of triCD23, a relief from GI254023X-mediated IgE suppression occurs (Figure 
6.7). This confirms the positive regulation of IgE synthesis by sCD23 (Cooper, Hobson 
et al., 2012). 
 
7.2. The role of mCD21 
 mIgE and mCD21 are the prime candidates for mediating the stimulatory effects 
of sCD23. mCD21 expression was shown to decline in the first few days of incubation 
with IL-4 and anti-CD40 and reached a plateau on day 5 (Figure 6.8). Loss of mCD21 is 
probably due to the shedding of soluble fragments (Fremeaux-Bacchi, Bernard et al., 
1996) and further shedding may be prevented by the binding of sCD23 to mCD21 and 
mIgE. Although the concentrations of endogenous sCD23 (Figure 4.8) were far lower 





respectively) (Hibbert, Teriete et al., 2005; McCloskey, Hunt et al., 2007), the avidity 





effect of binding of three sCD23 „heads‟ as a trimer to multiple mCD21 and/or mIgE 
molecules may dramatically enhance binding affinity at the cell surface. Prior binding 
of sCD23 to mIgE, the stronger ligand, may enable the recruitment of mCD21 into a tri-
molecular complex. The CD23 binding site for the two N-terminal domains of CD21 
lies in the C-terminal „tail‟ and is sufficiently distant from the IgE binding site to allow 
the simultaneous binding of both ligands in solution (Hibbert, Teriete et al., 2005). 
Indeed, the observed capping of mIgE and mCD21 on B cells stimulated with triCD23 
(Figure 6.9 and Figure 6.12) revealed that there are no topological constraints to prevent 
a trimeric CD23 molecule from co-ligating mIgE and mCD21 and forming the predicted 
multi-molecular network on the cell surface (Hibbert, Teriete et al., 2005). In cells 
where triCD23 binding to mCD21 was blocked with the addition of an anti-CD21 mAb, 
triCD23 was no longer able to increase IgE secretion (Figure 6.10). This confirms 
sCD23 binding to mCD21 as an essential component in the up-regulation of IgE 
secretion. 
 Figure 4.8 revealed that there was a remarkable relationship between the 
concentration of sCD23 and sIgE after incubation of human B cells with IL-4 and anti-
CD40 for 12 days. There appeared to only be a slight increase in sIgE at low sCD23 
concentrations up to 60ng/ml (1.6µM). However, above this threshold a steep rise in 
sIgE with increasing concentrations of sCD23 was observed. This co-operative 
relationship may reflect the avidity of sCD23 in the tri-molecular complexes with mIgE 









7.3. The mechanism of action of sCD23 
 Earlier work has shown that the incubation of PBMCs with sCD23 stimulates 
„ongoing‟ IgE synthesis rather than increasing CSR to IgE, which would require 
stimulation by IL-4 or IL-13 (Saxon, Ke et al., 1990). In the system described in this 
thesis using IL-4 and anti-CD40 stimulation, no difference in the expression of εGLT, 
an early marker for CSR, between control siRNA- and CD23 siRNA-transfected cells 
was observed (Figure 4.16). Neither inhibition of sCD23 through CD23 siRNA 
transfection or ADAM10 inhibition, nor addition of recombinant triCD23, altered the 




 cells when measured by flow cytometry (Figure 
4.13, Figure 4.14 and Figure 6.6).  
 Additional experiments with tonsil B cells have shown CSR to occur in the first 
few days of the incubations (Hobson et al., unpublished). However, recombinant sCD23 
can still increase IgE synthesis when added as late as day 9 in the incubation period 
(Jutton et al., unpublished). Results presented in this thesis showed that the addition of 
an ADAM10 inhibitor terminates incremental IgE synthesis after CSR has occurred 
(Figure 5.4) (Mayer, Bolognese et al., 2000). Taken together, these experiments indicate 
an isotype-specific role for sCD23 in promoting IgE synthesis through a post-switch 
mechanism. 
 Fearon and Carter showed that co-ligation of antigen-specific mIgM and the 
CD19-CD21-TAPA complex on naïve B cells by antigen, covalently linked to the C3d 
fragment of complement, stimulates B cell proliferation in the immune response 
(Fearon and Carter 1995). The effect of a blocking antibody against CD21 in vivo 
demonstrated the importance of this mechanism for a robust T cell-dependent immune 
response (Hebell, Ahearn et al., 1991). This mechanism operates by synergistic 





signalling through mIgM and mCD21 to augment the expression of the B cell survival 
factors Bcl-XL and Bcl-2, respectively (Roberts and Snow 1999). CD23 expressed in a 
fibroblast cell line can mimic the activity of the antigen-C3d complexes in lowering the 
threshold of B cell proliferation by an anti-IgM (surrogate antigen) (Reljic, Cosentino et 
al., 1997). However, it is not known whether mIgE can mimic mIgM in this mechanism. 
The cytoplasmic sequence of IgE, required for survival, differs from that of IgM (and 
other isotypes) (Achatz, Nitschke et al., 1997) although mIgE is associated with the 
same signal transduction proteins (the α and β subunits) as other isotypes 
(Venkitaraman, Williams et al., 1991). Evidently mIgE has some capacity for 
signalling, but nothing is known about the signal transduction pathways.  
 It is informative to consider the sequence of events after placing the B cells into 
culture with IL-4 and anti-CD40. At first, sCD23 can only bind to mCD21, which may 
elicit a proliferative response (Bohnsack and Cooper 1988). When IgE is expressed on 
the membrane, sCD23 appears to sequester the mIgE and mCD21 into raft-like 
structures (Figure 6.9 and Figure 6.12) (Hibbert, Teriete et al., 2005). These resemble 
the fate of cross-linked IgM-CD19-CD21-TAPA complexes in complement-enhanced 
IgM BCR activation (Fearon and Carter 1995; Pierce 2002). Whether formation of a 
mIgE-sCD23-mCD21 complex leads to similar functional consequences remains to be 
fully investigated.  
 
7.4. Overall Conclusion 
 In this thesis, two experimental approaches were taken to reduce sCD23 
production in primary human B cells. Both techniques culminated in reduced sCD23 
production and reduced IgE secretion, albeit through different actions on mCD23 





(reduced expression or inhibition of cleavage). Each approach had its limitations, but 
they were different from each other, and the combined results conclusively demonstrate 
that sCD23 stimulates IgE synthesis in human B cells. This was supported by 
contrasting experiments where addition of sCD23 led to an increase in the secretion of 
IgE. Together, these data support the hypothesis shown in Figure 7.1 whereby trimeric 
sCD23 molecules can bind both mIgE and mCD21 to stimulate IgE synthesis (Cooper, 
Hobson et al., 2012). 
 
 
Figure 7.1. Proposed mechanism of IgE up-regulation by trimeric soluble CD23. 
In this model, membrane CD23 (mCD23) is cleaved by ADAM10 to release trimeric soluble 
CD23 (sCD23), which co-ligates both membrane IgE (mIgE) and membrane CD21 (mCD21) on 
the surface of IgE-committed B cells to up-regulate IgE synthesis, triggering the onset of 
allergic symptoms. 
From (Cooper, Hobson et al., 2012). 
  





 The results in this thesis suggest that sCD23 may be an active partner, rather 
than an innocent bystander, in regulating IgE synthesis and, therefore, a promising 
therapeutic target for allergic disease. Two current strategies, the anti-CD23 mAb 
lumiliximab, which showed efficacy in lowering IgE levels in asthmatic patients 
(Rosenwasser, Busse et al., 2003; Rosenwasser and Meng 2005) and metalloprotease 
inhibitors, already tested in mice (Mathews, Ford et al., 2011), are aimed primarily at 
mCD23. The results described in this thesis, and those from others (Bowles, Jaeger et 
al., 2011; Mayer, Bolognese et al., 2000; McCloskey, Hunt et al., 2007; Sarfati and 
Delespesse 1988; Saxon, Ke et al., 1990), should encourage the rational design of 















Allergic condition Medication 
1 21/01/2009 (Could not ask)  
2 19/03/2009 (Could not ask)  
3 23/04/2009 (Could not ask)  
4 19/05/2009   
5 11/06/2009   
6 11/06/2009   
7 22/07/2009   
8 04/08/2009   
9 16/09/2009   
10 20/10/2009   
11 10/11/2009 Eczema  
12 09/12/2009   
13 03/02/2010   
14 04/03/2010   
15 28/04/2010   
16 02/06/2010 Asthma Very occasional steroid 
inhaler (bi-annual) 
17 06/07/2010   
18 21/07/2010 Allergic rhinitis Methylphenidate for ADHD 
19 07/09/2010 Antibiotic allergy  
20 27/10/2010   
21 02/11/2010 Antibiotic allergy  
22 09/12/2010   
23 12/01/2011 Allergic rhinitis, eczema, 
nut & egg allergy 
Cetirizine 
24 26/01/2011   
25 02/03/2011   
26 30/03/2011   
27 11/05/2011   
28 17/05/2011   
29 17/05/2011   
30 18/10/2011   
31 10/11/2011   
32 07/12/2011   
 
Appendix 1. Information on tonsil donors used in experiments. 
Information on the tonsil donors used in each experiment, the date of consent and any allergic 
conditions or medication which the patient was taking (n=32). Tonsil numbers used in each 
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Soluble CD23 Controls IgE Synthesis and Homeostasis in
Human B Cells
Alison M. Cooper,*,† Philip S. Hobson,*,† Mark R. Jutton,†,1 Michael W. Kao,*,†
Binia Drung,‡ Boris Schmidt,‡ David J. Fear,*,x Andrew J. Beavil,*,† James M. McDonnell,*,†
Brian J. Sutton,*,† and Hannah J. Gould*,†
CD23, the low-affinity receptor for IgE, exists in membrane and soluble forms. Soluble CD23 (sCD23) fragments are released from
membrane (m)CD23 by the endogenous metalloprotease a disintegrin and metalloprotease 10. When purified tonsil B cells are
incubated with IL-4 and anti-CD40 to induce class switching to IgE in vitro, mCD23 is upregulated, and sCD23 accumulates
in the medium prior to IgE synthesis. We have uncoupled the effects of mCD23 cleavage and accumulation of sCD23 on IgE syn-
thesis in this system. We show that small interfering RNA inhibition of CD23 synthesis or inhibition of mCD23 cleavage by an
a disintegrin and metalloprotease 10 inhibitor, GI254023X, suppresses IL-4 and anti-CD40–stimulated IgE synthesis. Addition of
a recombinant trimeric sCD23 enhances IgE synthesis in this system. This occurs even when endogenous mCD23 is protected
from cleavage by GI254023X, indicating that IgE synthesis is positively controlled by sCD23. We show that recombinant trimeric
sCD23 binds to cells coexpressing mIgE and mCD21 and caps these proteins on the B cell membrane. Upregulation of IgE by
sCD23 occurs after class-switch recombination, and its effects are isotype-specific. These results suggest that mIgE and mCD21
cooperate in the sCD23-mediated positive regulation of IgE synthesis on cells committed to IgE synthesis. Feedback regulation
may occur when the concentration of secreted IgE becomes great enough to allow binding to mCD23, thus preventing further
release of sCD23. We interpret these results with the aid of a model for the upregulation of IgE by sCD23. The Journal of
Immunology, 2012, 188: 000–000.
C
D23 is the low-affinity receptor for IgE on B cells. It is
initially expressed as a 45-kDa type II membrane protein
(membrane [m]CD23) containing a lectin head domain,
harboring the IgE binding site, and a C-terminal tail in the ex-
tracellular sequence (1, 2). CD23 is assembled into a trimer (3),
the predominant form in the B cell membrane, by way of an
a-helical coiled-coil stalk that links the three lectin head and tail
domains to their transmembrane and cytoplasmic sequences (4).
CD23 is expressed in two forms, CD23a and CD23b, resulting from
alternative transcription initiation sites and differing only by six or
seven amino acids in the intracellular N-terminal cytoplasmic se-
quence (5). CD23a is expressed on Ag-activated B cells, whereas
CD23b expression is upregulated by IL-4 in allergic inflammation
and is associated with elevated serum IgE (6–8). The anti-CD23
mAb lumiliximab downregulates IgE synthesis by human B cells
in vitro (9) and reduced human serum IgE levels in a phase I
clinical trial in patients with mild to moderate persistent allergic
asthma (10, 11). This provides proof of principle that mCD23 is
a valid target for therapy. Understanding the regulation of CD23 has
the potential to inspire a more cost-effective interventional strategy.
It has long been known that CD23 negatively regulates the syn-
thesis of IgE (12, 13). The most compelling evidence comes from
CD23 knockout mice, which exhibit greatly increased levels of
Ag-specific IgE after immunization (12, 13). IgE synthesis is also
inhibited in human B cells by anti-CD23 Abs (9, 14, 15) or Ag–IgE
complexes that bind to mCD23 (16). Neither free IgE nor Ab Fab
fragments have this inhibitory activity, suggesting that cross-linking
of mCD23 is required for the inhibition (15). These observations
suggest that mCD23 may act in a negative-feedback mechanism on
IgE synthesis.
mCD23 can be cleaved in the stalk region by the endogenous a
disintegrin and metalloprotease 10 (ADAM10) to release a 37-kDa
soluble fragment (soluble [s]CD23) both in vitro (17, 18) and in vivo
(18–20). After the initial cleavage by ADAM10, sCD23 is suscep-
tible to further cleavage by other proteases into fragments of various
sizes (33, 29, 25, and 16 kDa), eliminating additional parts of the
stalk and tail. These fragments lose the ability to independently
form trimers but retain the ability to bind IgE, albeit at lower affin-
ity (3). The 16-kDa fragment, termed derCD23, containing only the
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lectin domain and 10 aa of the tail, results from cleavage by the
house dust mite allergen, group I allergen of Dermatophagoides
pteronyssinus (21, 22). Whether sCD23, resulting from mCD23
cleavage, is involved in the positive regulation of IgE synthesis is
not as clear as the negative regulation by mCD23. A number of
studies have shown that sCD23 fragments either up- or down-
regulate IgE synthesis in human B cells (23, 24), depending on their
size and ability to form trimers (9, 25, 26). The use of selective
ADAM10 inhibitors is considered a potential therapy for asthma,
based on a recent preclinical trial in mice (19). Thus, sCD23, as well
as mCD23, may be promising targets for therapy.
Human CD23 binds not only to IgE, but also to CD21 (CR2)
(24), CD11b (CR3), CD11c (CR4) (27), the vitronectin receptor
(avb3) (28), and potentially other, as yet unidentified, proteins.
However, IgE and CD21 are the only known ligands on mature
B cells, with both binding sites distinct from each other and from
the interface between the head domains in the CD23 trimer (29).
Prior to the discovery of CD21 as the counterreceptor for CD23 on
B cells (24, 30), CD21 was already well characterized as the re-
ceptor for the C3d fragments of complement that play an impor-
tant role in the complement cascade and adaptive immunity (31,
32). In human CD23, the binding site for CD21 resides in the
C-terminal tail (29). This tail is not present in murine CD23 (33),
which may explain why sCD23 expressed in transgenic mice does
not upregulate IgE during immunization, leaving only downreg-
ulation through mCD23 (13, 34, 35). sCD21, shed from cell
membranes, is thought to inhibit IgE synthesis in human B cells
by binding to free trimeric sCD23, thereby preventing the binding
to mCD21 (26, 36). Abs against human CD21 modify IgE synthesis
in anti-CD40–stimulated tonsil B cells in an epitope-dependent
manner (24, 37). Hence, mCD21 is implicated in mediating the
effects of sCD23 on IgE synthesis.
Due to the multiple forms of CD23, multiple ligands, and various
activities of the different complexes, the mechanisms involved in
IgE regulation by CD23 are still poorly understood. In the current
study, we have focused on the positive regulation of IgE synthesis.
In 2000, Mayer et al. (23) showed that IL-4– and anti-CD40–
stimulated IgE synthesis in human PBMCs can be reduced by the
addition of metalloprotease inhibitors. It is uncertain whether this
is a direct effect on the B cells or whether it is due to inhibition of
mCD23 cleavage and, therefore, sCD23 production. If sCD23 acts
on B cells, are the stimulatory signals mediated by mCD21 or an
unidentified counterreceptor?
To gain further insight into this question, we have stimulated
purified human tonsil B cells with IL-4 and anti-CD40 and used
either small interfering RNA (siRNA) to inhibit CD23 synthesis or
an ADAM10 inhibitor (GI254023X) (38) to prevent cleavage of
mCD23, leading to a reduction in sCD23 levels through two dif-
ferent mechanisms. We have followed the loss of mCD23 from the
B cell surface, the appearance of sCD23 in the medium, and the
expression and secretion of IgE as a function of time for up to 12 d by
flow cytometry and ELISA. We have added a recombinant trimeric
sCD23 (triCD23) to the ADAM10-inhibited B cells to test its ability
to compensate for the reduction of endogenous sCD23. Finally, we
have followed the expression of mIgE and mCD21 during the in-
cubation of tonsil B cells with IL-4 and anti-CD40 and examined the
effects of triCD23 binding to these ligands by confocal microscopy.
Materials and Methods
Isolation of human tonsil B cells
Following informed written consent, with ethical approval from Guy’s
Research Ethics Committee, we obtained human tonsils from donors un-
dergoing routine tonsillectomies. The allergic status of the donor was
determined by verbal communication with the parents at the time of
consent. Mononuclear cells were separated by density on a Ficoll gradient
(GE Healthcare) and B cells isolated using 2-aminoethylisothiouronium
bromide-treated SRBCs (TCS Biosciences). B cells were routinely .98%
CD20+ and ,2% CD3+, as determined by flow cytometry (9).
siRNA transfection
Total B cells were transfected with CD23 siGENOME SMARTpool siRNA
(3 mg) (referred to as CD23 siRNA) or ON-TARGETplus Non-targeting
siRNA Pool #1 (3 mg) (referred to as control siRNA; Thermo Scientific
Dharmacon) using the Amaxa Human B cell Nucleofector kit and Nucle-
ofector II Device (Lonza), according to the manufacturer’s instructions.
Transfection efficiency, 30 min after transfection, was determined to be
97% using a fluorescent nonfunctional siRNA (siGLO Red; Thermo Sci-
entific Dharmacon). The efficiency of CD23 knockdown was quantified by
quantitative PCR (qPCR).
Cell culture
B cells were cultured in 24-well plates (Nunc) at 0.5 3 106 cells/ml in
RPMI 1640 with penicillin (100 IU/ml), streptomycin (100 mg/ml), glu-
tamine (2 mM; Invitrogen), 10% FCS (Hyclone; Perbio Biosciences),
transferrin (35 mg/ml), and insulin (5 mg/ml) (Sigma-Aldrich). Cells were
activated with IL-4 (200 IU/ml; R&D Systems) and anti-CD40 Ab (1 mg/
ml; G28.5; American Type Culture Collection) for up to 12 d. Mouse anti-
human CD21 mAb (HB5; Santa Cruz Biotechnology) was added to cells at
0.1, 1, or 10 mg/ml. Epitope analysis has shown this clone to inhibit CD23
binding to CD21 (30). The ADAM10 inhibitor GI254023X was purified on
a CombiFlash Rf (Teledyne ISCO) system (column: RediSep Rf, 4 g silica;
flow rate: 18 ml/min; solvent: acetonitrile; tR: 10 min). HPLC analysis at
220 nm confirmed a purity of $98% (38). Cells were grown for 5 d to
allow the upregulation of mCD23 and class-switch recombination (CSR)
to IgE before addition of the inhibitor (1–15 mM). Monomeric derCD23
(16145 Da) was made as previously described (29). lzCD23, made as
previously described (9), was modified to produce the more stable trimer
triCD23 (84414 Da), consisting of residues 131–321 of human CD23
prefixed by the trimerization motif (IAAIESK)4 and expressed and refol-
ded from inclusion bodies using the Escherichia coli vector pET151. This
additionally provides N-terminal HIS6 and V5 epitope tags and a TEV
enzyme cleavage site that has been left uncleaved in the final product
(M.W. Kao, J. Hunt, R.L. Beavil, M.N. Yahya, H.J. Gould, J.M. McDonnell,
B.J. Sutton, and A.J. Beavil, manuscript in preparation). rCD23 proteins
were dialyzed into PBS and sterile-filtered before addition to human B cell
cultures. Concentrations were selected to be close to the calculated KD
value for trimeric CD23 binding to IgE (1027 M) (9, 29) and used at a
weight ratio of 1:3 (triCD23/derCD23) to maintain the same number of
mIgE/mCD21 binding sites in each condition.
qPCR
Total RNAwas isolated from cells using RNeasy Mini kits (Qiagen), primed
with oligo(dT) and random hexamers, and reverse transcribed using Su-
perscript II (Invitrogen). qPCR was performed using TaqMan MGB gene
expression assays (see below) and TaqMan Universal PCR Master Mix on
a 7900HT real-time PCR machine (Applied Biosystems). Gene expression
was normalized to an endogenous reference gene (b2-microglobulin) and
quantified by ΔΔ threshold cycle (Ct) analysis (SDS 2.1 software): GAPDH,
Hs02786624_g1; b2-microglobulin, 4310886E; CD23, Hs00233627_m1;
ε germline transcript (εGLT) forward, 59-CTGTCCAGGAACCCGACA-
GA-39, and reverse, 59-TGCAGCAGCGGGTCAAG 39 with MGB probe
6FAM-AG GCACCAAATG-MGB.
Flow cytometry
B cells were stained for mCD23 expression with mouse anti-human CD23-
FITC (1:50; DakoCytomation) and membrane ADAM10 expression with
mouse anti-human ADAM10-PE (1:50; R&D Systems) and incubated on ice
in the dark for 45 min. For intracellular staining, cells were fixed with 4%
paraformaldehyde (ElectronMicroscopy Sciences) in PBS for 15min, washed,
and resuspended in permeabilization buffer (PBS, 0.05% Triton X-100, and
0.5% saponin [Sigma-Aldrich]) for 15min. Goat anti-human IgE-FITC (1:500;
Vector Laboratories) and monoclonal mouse anti-human IgG-APC (1:50;
Miltenyi Biotec) were added and incubated on ice in the dark for 45 min.
Collection of flow cytometry data was conducted using an FACSCalibur (BD
Biosciences), with gating on live cells determined by forward versus side
scatter, and events were analyzed using FlowJo software (Tree Star).
Ig ELISA
Maxisorp plates (Nunc) were coated with polyclonal mouse anti-human IgE
(1:7000; DakoCytomation) or polyclonal goat anti-human IgG (1:1000;













AbD Serotec) in pH 9.8 carbonate buffer (distilled water, 0.2 MNaCO3, and
0.2 M NaHCO3) overnight at 4˚C. Unbound sites were blocked with 2%
milk powder in PBS + 0.05% Tween 20 (Sigma-Aldrich) for 1 h at room
temperature. Supernatant samples were then added at appropriate dilutions
and plates incubated overnight at 4˚C. Human serum IgE (from 800 ng/ml;
NIBSC) or IgG (from 200 ng/ml; Sigma-Aldrich) were used to construct
standard curves. Binding was detected by mouse anti-human IgE-HRP
(1:1000; DakoCytomation) or goat anti-human IgG-HRP (1:1000; Sigma-
Aldrich) in 1% milk powder in PBS + 0.05% Tween 20 for 2 h at 37˚C. The
color reaction was developed with o-Phenylenediamine (Sigma-Aldrich)
and analyzed at 492 nm using an automated plate reader (Titertek). Ig
concentration was calculated from the standard curve using GraphPad
Prism 5.03 software (GraphPad, San Diego, CA), with a minimum de-
tectable concentration of ∼2 ng/ml. IgE secretion (by day 12) ranged from
2–1255 ng/ml (mean 401 6 71 ng/ml; n = 26). IgG secretion (by day 12)
ranged from 113–2264 ng/ml (mean 365 6 269 ng/ml; n = 8).
sCD23 ELISA
Human sCD23 EASIA ELISA kits (BioSource International) were used
according to themanufacturer’s instructions. Briefly, supernatantswere added
to microtiter plates precoated with a mixture of monoclonal anti-CD23 Abs,
and anti-CD23–HRP was added for 2 h at room temperature. The color re-
action was developed with tetramethylbenzidine and analyzed at 450 nm.
The kit recognizes the 16-, 25-, 29-, and 37-kDa fragments of sCD23, with
a minimum detectable concentration of ∼200 pg/ml. sCD23 production (by
day 12) ranged from 13–102 ng/ml (mean 58 6 4 ng/ml; n = 33).
Confocal microscopy
Human tonsillar B cells were stimulated for 8 d with IL-4 and anti-CD40,
harvested, and dead cells removed by density on a Ficoll gradient. A total of
3 3 105 cells was stimulated with media alone, derCD23 (3 mM/48 mg/
ml), triCD23 (1 mM/84 mg/ml), or anti-CD21 (10 mg/ml) at 37˚C for 30
min. Cells were fixed with 4% paraformaldehyde, washed (with PBS +
0.05% Triton X-100), mounted onto poly-L-lysine–coated coverslips, and
fixed again with 4% paraformaldehyde. Coverslip-mounted cells were
stained with goat anti-human IgE-FITC (1:200; Vector Laboratories) and
monoclonal mouse anti-CD21 (1:100; HB5 clone; Santa Cruz Biotech-
nology) for 1 h, washed, and secondary anti-mouse-Alexa 594 (1:500;
Molecular Probes, Invitrogen) was added for 45 min. The nuclear stain
Hoescht 33258 (1:20000; Molecular Probes, Invitrogen) was added for 10
min, cells were washed three times, and immunofluorescence visualized
with an SP2 confocal microscope (Leica Microsystems).
Statistical analysis
Flow cytometry and ELISA data are shown relative to control-treated cells
(either transfected with control siRNA or stimulated with IL-4 and anti-
CD40 alone) to compensate for interdonor variation. Data from 7 out of
33 donors who failed to respond to IL-4 and anti-CD40, with undetectable
levels of IgE expression and secretion by day 12, were excluded. Data are
summarized as mean 6 SEM. Statistical analysis was performed using
ANOVA with Bonferroni correction, unless otherwise stated. A p value of
, 0.05 was considered significant (*p , 0.05, **p, 0.01, ***p, 0.001).
Significance to control conditions is indicated above data, and significance
between two conditions is shown between data. Correlation analysis was
performed using Spearman’s rank correlation coefficient.
Results
siRNA-induced inhibition of CD23 mRNA, mCD23, sCD23,
and IgE secretion
Human tonsillar B cells were transfected with a pool of four siRNA
duplexes, directed against CD23, and stimulated with IL-4 and
anti-CD40 for up to 12 d. A significant inhibition of CD23 mRNA
expression was observed following transfection with CD23 siRNA
compared with control siRNA (Fig. 1A), but no effect was seen on
the expression of a nontargeted gene, GAPDH (Fig. 1B). The max-
imum knockdown of CD23 (70.0 6 0.1%) occurred between 18
and 24 h following transfection, after which CD23 mRNA levels
began to recover to that of control siRNA-transfected cells.
Despite the short-term inhibition of CD23 mRNA shown in Fig.
1, mCD23 protein levels were reduced following transfection with
CD23 siRNA. Fig. 2A shows a representative example of flow
cytometric analysis of mCD23 levels from 18 h to 12 d following
transfection with either control siRNA or CD23 siRNA. In control
siRNA-transfected cells, mCD23 expression reached a peak on
day 5 (88.4 6 2.8%, n = 8). Fig. 2B shows that the percentage of
mCD23+ cells was reduced following transfection with CD23
siRNA, and this reduction remained statistically significant until
day 7, although it was largely recovered by 48 h. The level of
mCD23 expression on cells, as measured by the mean fluores-
cence intensity (MFI), was significantly lower on cells transfected
with CD23 siRNA compared with control siRNA (Fig. 2C). This
reduction also remained statistically significant until day 7, but the
MFI was suppressed to a greater degree than the percentage of
mCD23+ cells and took longer to recover.
sCD23 is produced by cleavage of mCD23, initially by the
membrane-bound metalloprotease ADAM10 (18). sCD23 was first
detectable in the supernatant 4 d after transfection with either
control siRNA or CD23 siRNA (data not shown). In accordance
with the reduced mCD23 levels, sCD23 production decreased
significantly following CD23 siRNA transfection (Fig. 3A). By
day 12, sCD23 levels were, on average, 17.4% (6 5.7%) lower in
supernatants from cells transfected with CD23 siRNA compared
with control siRNA. No significant reduction was seen at the
earlier time points of days 5 and 7. The expression level of
ADAM10 was no different between control siRNA and CD23
siRNA-transfected cells at any time point during the culture
(Supplemental Fig. 1), which reveals that the loss of ADAM10
was not responsible for the decrease in sCD23 levels.
FIGURE 1. siRNA-induced inhibition of CD23 mRNA expression.
Human tonsillar B cells were transfected with either control siRNA (black
bars) or CD23 siRNA (white bars) and cultured for up to 5 d with IL-4
(200 IU/ml) and anti-CD40 (1 mg/ml). Cells were harvested at the times
indicated, and qPCR was performed to quantify mRNA expression levels
for CD23 (A) and GAPDH (B). Expression levels were calculated by ΔΔCt
analysis, normalized against the endogenous reference gene b2-micro-
globulin, and expressed relative to control siRNA-transfected cells at each
timepoint (n = 11). ***p , 0.001.













Because transfection with CD23 siRNA successfully resulted in
reduced sCD23 levels by day 12, we next investigated the asso-
ciation between reduced sCD23 production and IgE synthesis at
this time point. Secreted IgE (sIgE) was first detectable in the
supernatant 5 d after stimulation with IL-4 and anti-CD40 (data not
shown). Fig. 3A also shows the relative levels of sIgE 5, 7, and
12 d after transfection with control siRNA or CD23 siRNA. Of the
10 donors analyzed for sCD23 production, 4 donors did not pro-
duce any detectable sIgE by day 12 and so were excluded from the
analysis. CD23 siRNA-transfected cells secreted 47.4% (6 9.5%)
less IgE than control siRNA-transfected cells (Fig. 3A). The ex-
tent to which sIgE levels were inhibited was not related to the
amount of IgE the cells secreted. Fig. 3B correlates the level of
inhibition of sCD23 production with the level of inhibition of IgE
secretion. The positive correlation between sCD23 and sIgE is
statistically significant (r = 0.94; p = 0.0167), as determined by
FIGURE 2. Reduced mCD23 expression fol-
lowing CD23 siRNA transfection. (A) Human
tonsillar B cells were transfected with either
control siRNA (gray line) or CD23 siRNA (black
line) and cultured for up to 12 d with IL-4 (200
IU/ml) and anti-CD40 (1 mg/ml). mCD23 ex-
pression was analyzed by flow cytometry, and the
percent of mCD23+ cells (above isotype control as
indicated by horizontal marker) is indicated on the
histograms (n = 1, representative of 11). Multiple
donor data, relative to control siRNA-transfected
cells at each time point, are shown for percent
mCD23+ cells (B) and CD23+ MFI (C), at 18 h to
12 d following transfection (n = 11). **p , 0.01,
***p , 0.001.
FIGURE 3. Inhibition of sCD23
production by CD23 siRNA corre-
lates with reduced IgE secretion. Hu-
man tonsillar B cells were trans-
fected with either control siRNA or
CD23 siRNA and cultured for up to
12 d with IL-4 (200 IU/ml) and anti-
CD40 (1 mg/ml). (A) Supernatants
were harvested on days 5, 7, and 12,
and the percent inhibition of sCD23
production (d) (n = 10) and IgE se-
cretion (s) (n = 6) were analyzed by
ELISA, relative to control siRNA-
transfected cells. (B) Correlation be-
tween inhibition of IgE secretion and
inhibition of sCD23 production on
day 12 (n = 6). (C) Supernatants were
harvested on day 12, and the percent
inhibition of IgG secretion was ana-
lyzed by ELISA, relative to control
siRNA-transfected cells (n = 8). (D)
qPCR was performed to quantify
RNA levels for εGLT up to 5 d fol-
lowing transfection with either con-
trol (gray bars) or CD23 siRNA (white
bars). Expression levels were calcu-
lated by ΔΔCt analysis, normalized
against the endogenous reference gene
b2-microglobulin, and expressed rela-
tive to control siRNA-transfected cells
at 24 h (n = 1, unless indicated oth-
erwise). *p , 0.05, ***p , 0.001.













Spearman’s rank correlation coefficient (n = 6). Importantly,
CD23 siRNA transfection led to no significant changes in the
levels of IgG secretion by day 12 (Fig. 3C). From day 7 onwards,
following transfection with CD23 siRNA, mCD23 levels had re-
turned to those of control siRNA-transfected cells (Fig. 2B, 2C).
Thus, any CD23-mediated differences in IgE secretion between
days 7 and 12 can be attributed to sCD23 rather than mCD23.
Fig. 3D shows qPCR analysis of εGLT, an early marker of CSR
to IgE. No significant differences in εGLT levels were detected
between control siRNA and CD23 siRNA-transfected cells at
either 24 or 48 h following transfection, despite the inhibition of
IgE secretion shown in Fig. 3A. Membrane and intracellular
staining for IgE and IgG, analyzed by flow cytometry, showed no
significant changes in the percentage of IgE+ or IgG+ cells be-
tween control siRNA and CD23 siRNA-transfected cells at days
7 or 12 (Supplemental Fig. 2). In addition, there were no differ-
ences in general cell viability (live cell gating determined by
forward versus side scatter) or maturation (CD38 expression)
between control siRNA and CD23 siRNA-transfected cells (data
not shown).
ADAM10 inhibition with GI254023X reduces mCD23
shedding, sCD23 release, and IgE secretion
Because CD23 siRNA transfection reduced sCD23 through the
early reduction of mCD23 expression, a different approach was
taken that would reduce sCD23 levels through preventing mCD23
shedding, thus maintaining mCD23 levels. To achieve this, we
used the ADAM10 inhibitor GI254023X. Human tonsillar B cells
were stimulated with IL-4 and anti-CD40 for 5 d, after which
GI254023X was added at 1–15 mM. The addition of GI254023X
did not lead to a significant increase in the percentage of CD23+
cells, although a significant dose-dependent accumulation of mCD23
on the surface of CD23+ cells (as measured by MFI) was observed
by day 12 (Fig. 4A). With the addition of 10 mM GI254023X, this
was accompanied by a significant reduction in sCD23 production
(28.3 6 9.9%) (Fig. 4B) and a significant reduction in IgE se-
cretion (64.9 6 7.2%) (Fig. 4C), with no effect on IgG secretion
(data not shown).
To assess the mechanism of action, GI254023X was added at
days 8 or 10, in addition to day 5, and sCD23 and sIgE levels were
determined at day 12. Fig. 4B and 4C show that when the inhibitor
was added progressively later in the incubation period, the levels
of both sCD23 and sIgE were higher, due to the shorter time
period in which GI254023X could inhibit mCD23 shedding.
However, inhibition of sCD23 production and IgE secretion could
still be achieved even when GI254023X was added as late as day
10 in the incubation period. In further support of this association,
Fig. 4D shows the relationship between sCD23 and sIgE levels,
measured in the supernatant following 12 d stimulation with
IL-4 and anti-CD40. The sCD23 concentrations are indicated
in nanograms per milliliter, and also in micromoles, to facilitate
comparison with the known KD values of interaction with IgE and
CD21 (see Discussion). The positive correlation between sCD23
and sIgE is statistically significant (r = 0.77; p # 0.0001), as
determined by Spearman’s rank correlation coefficient (n = 33).
There appear to be two phases in the relationship, separated by
a threshold concentration of sCD23 (60 ng/ml/1.6 mM), above
which a steep rise in IgE secretion was observed.
Effect of exogenous sCD23 fragments on IgE secretion
We have previously shown that oligomeric sCD23 (lzCD23) above
a certain threshold concentration upregulates, whereas monomeric
sCD23 (derCD23) downregulates, IgE production from human ton-
sillar B cells (9). The IgE-potentiating ability of the more stable
triCD23 was assessed by culturing B cells with IL-4, anti-CD40,
and triCD23 (1 mM) (added at day 0) for 12 d. Although not
a naturally occurring fragment, triCD23 has been specifically
designed to mimic the trimeric state of endogenous sCD23 when
it is first cleaved off the membrane in allergic tissues. Western
blot analysis showed triCD23 did not degrade into smaller frag-
ments during the 12 d in culture (data not shown). Analysis by
ELISA on day 12 showed a 200.0% (6 27.2%) increase in IgE
secretion from cells cultured with triCD23 compared with IL-4
and anti-CD40 alone, whereas cells cultured with monomeric
derCD23 produced significantly less IgE (Fig. 5A). These effects
were isotype specific, as IgG secretion remained unaffected, and
flow cytometric analysis showed triCD23 had no effect on the
percentage of IgE+ cells (Supplemental Fig. 3), suggesting that
triCD23 preferentially promotes expression of the secreted form
of IgE.
The ability of triCD23 to rescue the inhibition of sCD23 pro-
duction and IgE secretion caused by addition of the ADAM10
inhibitor (GI254023X) was then investigated. As shown in
Fig. 5B, IgE secretion increased 2.3-fold when GI254023X
(5 mM) was cocultured with triCD23 (1 mM) compared with
GI254023X alone.
FIGURE 4. ADAM10 inhibition with GI254023X reduces mCD23
shedding, sCD23 release, and IgE secretion. Human tonsillar B cells were
cultured for 12 d with IL-4 (200 IU/ml) and anti-CD40 (1 mg/ml) in the
absence or presence of varying concentrations of GI254023X, added on
day 5 unless otherwise stated. (A) mCD23 expression was analyzed by
flow cytometry on day 12 and the fold change plotted for the percent of
mCD23+ cells (N) and CD23+ MFI (d), relative to cells cultured with IL-4/
anti-CD40 alone (n = 6). (B) GI254023X was added on days 5 (d) (n = 6),
8 (:) (n = 2), or 10 (♦) (n = 1), and supernatants were analyzed on day 12
for sCD23 (B) production and IgE secretion (C), relative to cells cultured
with IL-4/anti-CD40 alone. (D) Correlation between sCD23 and sIgE
levels after 12 d (n = 33). Values are shown in nanograms per milliliter on
the bottom x-axis and left y-axis and in micromoles on the top x-axis and
right y-axis (1 mM 190-kDa sIgE = 190 ng/ml; 1 mM 37-kDa sCD23 = 37
ng/ml). *p , 0.05, **p , 0.01.













Trimeric sCD23 colocalizes mIgE and mCD21
Having established in this study that sCD23 was involved in the
positive regulation of IgE, we next sought to identify the mech-
anism by which this may occur. Confocal microscopy was used to
test the binding of triCD23 to mIgE and mCD21 and visualize the
surface dynamics of these complexes. Human tonsillar B cells were
cultured with IL-4 and anti-CD40 for 8 d to ensure sufficient time
for the dual expression of mIgE and mCD21 (Supplemental Fig. 4)
and then stimulated for 30 min in the presence of media alone,
derCD23, or triCD23. The left and middle panels of Fig. 6A show
the uniform distribution of mIgE and mCD21 on the surface of
B cells incubated with either media alone or monomeric derCD23,
respectively. The right panel of Fig. 6A shows the redistribution
and colocalization of mIgE and mCD21, following incubation
with triCD23. Several distinct microclusters formed, and partic-
ularly strong capping of mIgE and CD21 is indicated on the
merged image in the bottom right panel of Fig. 6A.
To further investigate the role of mCD21 in the sCD23-mediated
regulation of IgE synthesis, tonsil B cells were cultured with in-
creasing concentrations of an anti-CD21 mAb (HB5 clone) for
12 d. Fig. 6B shows the addition of anti-CD21 resulted in a dose-
dependent decrease in IgE secretion. This was accompanied by an
increase in mCD23 expression and a decrease in sCD23 produc-
tion (data not shown). When cells were cultured with a combina-
tion of anti-CD21 (10 mg/ml) and triCD23 (1 mM), the IgE-stim-
ulating effects of triCD23 were blocked. Fig. 6C shows confocal
microscopy analysis of mCD21 expression. Total B cells were
cultured with IL-4 and anti-CD40 for 8 d and then stimulated
for 30 min in the presence of anti-CD21, triCD23, or anti-CD21
and triCD23. Distinct microclusters of mCD21 formed on the
surface of cells stimulated with either anti-CD21 or triCD23.
In the cells pretreated with anti-CD21 before stimulation with
triCD23, the distribution of mCD21 was more uniform. Together,
these data support the hypothesis shown in Fig. 7, whereby tri-
meric sCD23 molecules can bind both mIgE and mCD21 to
stimulate IgE synthesis.
Discussion
The cytokines IL-4 and IL-13 induce the CSR to all Ig isotypes
downstream from Cm in the H-chain locus on human chromosome
14, but can be replaced by other cytokines for switching to iso-
types other than IgE. IL-4 upregulates CD23, so that the expres-
sion of CD23 and IgE are inextricably linked (25). The role of
FIGURE 5. Effect of exogenous sCD23 fragments on IgE secretion. (A)
Human tonsillar B cells were cultured for 12 d with IL-4 (200 IU/ml) and
anti-CD40 (1 mg/ml) alone, + triCD23 (1 mM/84 mg/ml), or + derCD23 (3
mM/48 mg/ml). Supernatants were analyzed on day 12 for IgE secretion,
relative to cells cultured with IL-4/anti-CD40 alone (n = 6). (B) Human
tonsillar B cells were cultured for 12 d with IL-4/anti-CD40 alone, +
triCD23 (1 mM), + GI254023X (5 mM), or + triCD23 and GI254023X.
Supernatants were analyzed on day 12 for IgE secretion, relative to cells
cultured with IL-4/anti-CD40 alone (n = 2). *p , 0.05, **p , 0.01,
***p , 0.001.
FIGURE 6. triCD23 colocalizes both mIgE and mCD21 to upregulate IgE secretion. (A) Human tonsillar B cells were cultured for 8 d with IL-4 (200 IU/
ml) and anti-CD40 (1 mg/ml) and stimulated for 30 min with media alone, derCD23 (3 mM/48 mg/ml), or triCD23 (1 mM/84 mg/ml). Cells were stained
with mouse anti-CD21, plus secondary anti-mouse-Alexa 594 (red), anti-IgE-FITC (green), and the nuclear stain Hoescht (blue). Cells were visualized by
confocal microscopy and images show a single field of view, with the bottom panel showing a three-color overlay. The white arrow indicates strong capping
of mIgE with mCD21 (n = 1, representative of 3). Scale bar, 5 mm. (B) Human tonsillar B cells were cultured for 12 d with IL-4/anti-CD40 alone, + anti-
CD21 (0.1, 1, or 10 mg/ml), + triCD23 (1 mM), or + anti-CD21 (aCD21; 10 mg/ml) and triCD23. IgE secretion was analyzed by ELISA on day 12, relative
to cells cultured with IL-4/anti-CD40 alone (n = 2). (C) Cells were cultured as described in (A) and stimulated with anti-CD21 (10 mg/ml), triCD23 (1 mM),
or anti-CD21 and triCD23. Cells were stained for mCD21 (red) and the nucleus (blue), as previously described for (A), and visualized by confocal mi-
croscopy (n = 1). Scale bar, 5 mm.













CD23 in the regulation of IgE in the human system appears to be
more complex than in the mouse (2).
Negative regulation of IgE synthesis through mCD23 occurs in
murine B cells in vivo (13, 39) and in human B cells in vitro (15).
In human B cells, this requires the cross-linking of mCD23 (e.g.,
by Abs or Ag–IgE complexes). In the current study, we focused on
a suggested mechanism by which sCD23 positively regulates IgE
synthesis exclusively in human B cells (9, 29). In analyzing this
mechanism, it is necessary to consider that there are multiple
forms of sCD23, several potential ligands, and various complexes
with different affinities and topological constraints associated with
binding to their ligands in solution and particularly on cells.
sCD23 is released from cells by the action of an endogenous
metalloprotease, identified as ADAM10 (17, 18), and accumulates
in the supernatant of B cells following IL-4– and anti-CD40–
stimulated CSR to IgE (23, 40, 41). In this study, we have used
CD23 siRNA and an ADAM10 inhibitor (GI254023X) to confirm
that mCD23 expression and cleavage to release sCD23 is required
for the enhancement of IgE synthesis in primary human B cells.
Short-term inhibition of CD23 mRNA with siRNA led to a
significant reduction in the frequency and MFI of CD23+ cells
until day 7 following transfection. By day 12, but not at the ear-
lier time points of days 5 and 7, CD23 siRNA-transfected cells
showed significantly reduced sCD23 production, which correlated
with reduced IgE secretion, implicating sCD23 in the upregulation
of human IgE synthesis (Figs. 1–3).
To further investigate the role of sCD23, ADAM10 was inhib-
ited using GI254023X. It has been previously been shown that
inhibition of ADAM10 in vivo (20, 42), and the addition of
GI254023X to human tonsil B cells (18), results in decreased
sCD23 production. However, subsequent effects on IgE were not
analyzed. In this study, addition of GI254023X resulted in in-
creased mCD23 expression, reduced sCD23 production, and re-
duced IgE secretion. Inhibition of sCD23 production and IgE
secretion could still achieved when GI254023X was added pro-
gressively later in the incubation period, albeit to lesser extents,
indicating that the ADAM10 inhibitor is regulating secretion of
IgE by a postswitch event (Fig. 4). Because mCD23 is not cleaved,
but is actually elevated in these conditions, the observed inhibi-
tion of IgE synthesis firmly points to positive regulation medi-
ated through sCD23. Derepression of negative signaling through
mCD23 does not appear to play a major role. When sIgE binds to
mCD23, it blocks metalloprotease cleavage and the release of
sCD23 (16). However, this is not a complication in the present
system, as the sIgE concentrations in the medium (,10210 M) are
well below the KD of the IgE–mCD23 interaction. As in previous
work with alternative matrix metalloprotease inhibitors and IL-4–
stimulated human PBLs (23), we conclude that sCD23 is required
to maintain IgE synthesis in human B cells.
We confirmed the findings from previous studies (9, 23, 26) that
addition of recombinant trimeric sCD23 (triCD23) to primary
human B cells enhances IgE synthesis (Fig. 5A). We now also
show that when B cells are incubated with GI254023X in the
presence of triCD23, a relief from GI254023X-mediated IgE
suppression is observed (Fig. 5B), confirming the positive regu-
lation of IgE synthesis by sCD23. However, the level of IgE
synthesis was not fully restored to that of cells cultured only with
triCD23. This might be explained by off-target effects of the
ADAM10 inhibitor. Further studies are required to investigate
this possibility.
mIgE and mCD21 are the prime candidates for mediating the
stimulatory effects of sCD23. We show in this study that mCD21
expression declines in the first few days of incubation with IL-4
and anti-CD40 and reaches a plateau on day 5 (Supplemental
Fig. 4). Loss of mCD21 is probably due to the shedding of soluble
fragments (43), and further shedding may be prevented by the
binding of sCD23 to mCD21 and mIgE. Although the concen-
trations of endogenous sCD23 (Fig. 4D) are far lower than the
KD for the 1:1 interaction with mCD21 or mIgE (KD = 10
26 and
1028 M, respectively) (9, 29), the avidity effect of binding of three
sCD23 heads as a trimer to multiple mCD21 and/or mIgE mole-
cules may dramatically enhance binding affinity at the cell sur-
face. Prior binding of sCD23 to mIgE, the stronger ligand, may
enable the recruitment of mCD21 into a trimolecular complex.
The CD23 binding site for the two N-terminal domains of CD21
lies in the C-terminal tail and is sufficiently distant from the IgE
binding site to allow the simultaneous binding of both ligands in
solution (29). Indeed, the observed capping of mIgE and mCD21
on B cells stimulated with triCD23 (Fig. 6A) reveals that there are
likewise no topological constraints to prevent a trimeric CD23
molecule from coligating mIgE and mCD21 and forming the
predicted multimolecular network on the cell surface (29). In cells
in which CD23 binding to mCD21 is blocked with the addition of
an anti-CD21 mAb, triCD23 is no longer able to increase IgE
secretion (Fig. 6B).
Fig. 4D reveals that there is a remarkable relationship between
the concentration of sCD23 and sIgE after incubation of tonsil
B cells with IL-4 and anti-CD40. There appears to only be a slight
increase in sIgE at low sCD23 concentrations, up to 60 ng/ml (1.6
mM) (concentrations calculated for the 37-kDa fragment). How-
ever, above this threshold, we observed a steep rise in sIgE with
increasing concentrations of sCD23. The relationship shown in
Fig. 4D may reflect the avidity of sCD23 in the trimolecular
complexes with mIgE and mCD21 at the surface of the fluid B cell
membrane, as this curve exhibits cooperativity.
Earlier work has shown that the incubation of PBMCs with
sCD23 stimulates ongoing IgE synthesis, rather than increasing
CSR to IgE, which would require stimulation by IL-4 (or IL-13)
(41). In our system, with IL-4 and anti-CD40 stimulation, we
observed no difference in the expression of εGLT, an early marker
for CSR, in CD23 siRNA- compared with control siRNA-
transfected cells (Fig. 3D). Neither inhibition of sCD23 through
siRNA transfection nor addition of recombinant triCD23 altered
the proportion of IgE+ or IgG+ cells when measured by flow
cytometry (Supplemental Figs. 2, 3B). Additional experiments
FIGURE 7. Proposed mechanism of IgE upregulation by trimeric
sCD23. In this model, mCD23 is cleaved by ADAM10 to release trimeric
sCD23, which coligates both mIgE and mCD21 on the surface of IgE-
committed B cells to upregulate IgE synthesis, triggering the onset of al-
lergic symptoms.













with tonsil B cells have shown CSR to occur in the first few
days of the incubations (P.S. Hobson, unpublished observations).
However, recombinant sCD23 can still increase IgE synthesis
when added as late as day 9 in the incubations (M.R. Jutton,
unpublished observations). It has also been shown that the addi-
tion of a metalloprotease inhibitor terminates incremental IgE
synthesis after CSR has occurred (Fig. 4C) (23). Taken together,
these experiments indicate an isotype-specific role for sCD23 in
promoting IgE synthesis through a postswitch mechanism.
Fearon and Carter (31) showed that coligation of Ag-specific
IgM and the CD19–CD21–TAPA complex on naive B cells by Ag,
covalently linked to the C3d fragment of complement, stimulates
B cell proliferation in the immune response. The effect of a
blocking Ab against CD21 in vivo demonstrated the importance
of this mechanism for a robust T cell-dependent immune response
(44). The mechanism operates by synergistic signaling through
IgM and CD21 to augment the expression of the B cell survival
factors Bcl-XL and Bcl-2, respectively (45). CD23 expressed in
a fibroblast cell line can mimic the activity of the Ag–C3d com-
plexes in lowering the threshold of B cell proliferation by an anti-
IgM (surrogate Ag) (46). However, it is not known whether mIgE
can mimic mIgM in this mechanism. The cytoplasmic sequence
of IgE, required for survival, differs from that of IgM (and other
isotypes) (47), although mIgE is associated with the same signal
transduction proteins (the a and b subunits) as other isotypes (48).
Evidently, mIgE has some capacity for signaling, but nothing is
known about the signal transduction pathways.
It is informative to consider the sequence of events after placing
the B cells into culturewith IL-4 and anti-CD40. At first, sCD23 can
only bind to mCD21, which may elicit a proliferative response (49).
When IgE is expressed on the membrane, sCD23 appears to se-
quester the mIgE and mCD21 in raftlike structures (Fig. 6A) (29),
which resemble the fate of cross-linked IgM–CD19–CD21–TAPA
complexes in complement-enhanced IgM BCR activation (31, 50).
Whether formation of an mIgE–sCD23–mCD21 complex would
lead to similar functional consequences remains to be investigated.
In this study, two experimental approaches were taken to re-
duce sCD23 production in primary human B cells. Both techniques
culminated in reduced sCD23 production and reduced IgE se-
cretion, albeit through different actions on mCD23 (reduced ex-
pression or inhibition of cleavage). Each approach has its limi-
tations, but they are different from each other, and the combined
results conclusively demonstrate that sCD23 stimulates IgE syn-
thesis in human B cells.
Our results suggest that sCD23 may be an active partner, rather
than an innocent bystander, in regulating IgE synthesis and
therefore a promising therapeutic target for allergic disease.
Two current strategies, the anti-CD23 mAb lumiliximab, which
showed efficacy in lowering IgE levels in asthmatic patients (10,
11), and metalloprotease inhibitors, already tested in mice (19),
are aimed primarily at mCD23. Our results, and those from others
(9, 23, 26, 41, 51), should encourage the rational design of in-
hibitors of sCD23 binding to its ligands for the treatment of al-
lergy and asthma.
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CAPSULE	  
Background:	   Immunoglobulin	   E	   (IgE)	   has	   two	  cellular	   receptors,	   FcεRI	   and	   CD23,	   that	  mediate	  distinct	  functional	  effects.	  
Results:	  We	  have	  identified	  the	  CD23	  binding	  site	  on	   IgE	   and	   show	   that	   FcεRI	   and	   CD23	  allosterically	  compete	  for	  binding.	  
Conclusion:	   A	   mechanism	   of	   communication	  exists	   within	   the	   IgE	   molecule	   to	   prevent	  simultaneous	   engagement	   with	   the	   two	  receptors.	  
Significance:	   Competition	   between	   IgE's	  receptors	  explains	  ligand	  cross-­‐regulation.	  	  
SUMMARY	  
IgE,	   the	   antibody	   that	   mediates	   allergic	  
responses,	   acts	   as	   part	   of	   a	   self-­regulating	  
protein	  network.	  	  Its	  unique	  effector	  functions	  
are	   controlled	   through	   interactions	   of	   its	   Fc	  
region	   with	   two	   cellular	   receptors,	   FcεRI	   on	  
mast	  cells	  and	  basophils	  and	  CD23	  on	  B	  cells.	  	  
IgE	  cross-­linked	  by	  allergen	  triggers	  mast	  cell	  
activation	   via	   FcεRI,	   while	   IgE-­CD23	  
interactions	  control	  IgE	  expression	  levels.	  	  We	  
have	  determined	  the	  CD23	  binding	  site	  on	  IgE,	  
using	   a	   combination	   of	   NMR	   chemical	   shift	  
mapping	   and	   site-­directed	   mutagenesis.	   	   We	  
show	  that	  the	  CD23	  and	  FcεRI	  interaction	  sites	  
are	  at	  opposite	  ends	  of	  the	  Cε3	  domain	  of	  IgE,	  
but	   that	   receptor	   binding	   is	   mutually	  
inhibitory,	   mediated	   by	   an	   allosteric	  
mechanism.	   	   This	   prevents	   CD23-­mediated	  
cross-­linking	   of	   IgE	   bound	   to	   FcεRI	   on	   mast	  
cells	   and	   resulting	   antigen-­independent	  
anaphylaxis.	   	   The	  mutually	   inhibitory	   nature	  
of	   receptor	   binding	   provides	   a	   degree	   of	  
autonomy	   for	   the	   individual	   activities	  
mediated	   by	   IgE-­FcεRI	   and	   IgE-­CD23	  
interactions.	  ____________________________________________________	  	  Immunoglobulin	   E	   (IgE)	   is	   the	   antibody	  isotype	   responsible	   for	   mediating	   allergic	  reactions.	   It	   functions	   through	   interactions	  with	   its	   two	  receptors,	  FcεRI	  and	  CD23	  (also	  known	  as	  FcεRII).	  The	  binding	  of	  IgE	  to	  FcεRI	  is	   essential	   for	   type	   I	   hypersensitivity,	  while	  the	   interaction	   between	   CD23	   and	   IgE	   is	  crucial	   for	   IgE-­‐mediated	   facilitated	   allergen	  binding,	   processing	   and	   presentation	   (1).	  Through	   interactions	   with	   membrane	   IgE,	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soluble	   CD23	   fragments	   can	   up-­‐	   or	   down-­‐regulate	   synthesis	   of	   IgE,	   depending	   on	   the	  oligomerization	   state	   of	   CD23	   (2).	   IgE	  expression	   can	   also	   be	   controlled	   by	   a	  negative	   feedback	   mechanism	   through	   an	  interaction	   of	   IgE-­‐allergen	   complexes	   with	  membrane-­‐bound	   CD23	   on	   IgE+	   B	   cells	   (3).	  Since	   CD23	   both	   positively	   and	   negatively	  regulates	   IgE	   expression,	   a	   critical	   role	   for	  CD23	  in	  IgE	  homeostasis	  has	  been	  proposed.	  	  High-­‐resolution	   structures	   have	   been	  determined	  for	  Fc	  fragments	  of	  IgE	  (4,5),	  the	  extracellular	  region	  of	  FcεRIα	   (6),	   the	  C-­‐type	  lectin	   domain	   of	   CD23	   (7,8),	   and	   complexes	  of	   IgE-­‐Fc-­‐FcεRIα	   (4,9).	   The	   structures	   of	   the	  complex	   explain	   the	   1:1	   stoichiometry	  observed	   for	   the	   IgE-­‐Fc-­‐FcεRIα	   interaction;	  one	   FcεRIα	   molecule	   engages	   two	   IgE	   Cε3	  domains	   simultaneously	   near	   the	   Cε2-­‐Cε3	  domain	   interface.	   In	   contrast,	   the	  stoichiometry	   of	   binding	   CD23	   to	   IgE	   is	   2:1	  (10),	   with	   a	   biphasic	   affinity,	   trimeric	   CD23	  apparently	   binding	  with	   an	   affinity	   an	   order	  of	   magnitude	   higher	   than	   monomeric	   CD23	  (11).	  	  The	   structure	   of	   IgE	   is	   noteworthy	   for	   a	  marked	   bend	   between	   the	   second	   and	   third	  constant	  domains	  of	  the	  Fc	  region.	  It	  has	  been	  suggested	   that	   this	   bend	   imparts	  conformational	   constraints	   on	   the	   Fab	   arms,	  which	  might	   favor	  cross-­‐linking	  of	  mast	  cell-­‐bound	   IgE	   by	   allergens	   with	   specific	  disposition	   of	   epitopes	   (12).	   The	   IgE	   Fc	  region	   shows	   an	   intriguing	   mixture	   of	  structural	   rigidity	   and	   conformational	  flexibility,	   with	   the	   aforementioned	   rigid	  bend	   between	   the	   Cε2	   and	   Cε3	   domains	   (5)	  and	  an	  unusual	  degree	  of	   intrinsic	  structural	  lability	   within	   the	   Cε3	   domain	   (13).	  Conformational	  flexibility	  around	  the	  Cε3-­‐Cε4	  interface	   has	   been	   noted	   previously	   (14);	  motions	   around	   an	   axis	   at	   this	   interface	  control	   whether	   both	   Cε3	   domains	   are	   in	   a	  
correct	  orientation	  to	  bind	  simultaneously	  to	  the	  FcεRIα	   receptor.	   If	   only	   one	  Cε3	  domain	  binds	   to	   FcεRIα	   then	   the	   affinity	   is	   about	  10,000-­‐fold	   weaker	   than	   when	   both	   Cε3	  domains	  are	  engaged	  (15).	  	  In	  this	  study	  we	  define	  the	  CD23	  binding	  site	  on	   the	   Cε3	   domain	   of	   IgE	   using	   NMR	  spectroscopy	   and	   site-­‐directed	   mutagenesis.	  We	   show	   that	   the	   CD23	   and	   FcεRI	   binding	  sites	   occur	   on	   opposite	   ends	   of	   the	   Cε3	  domain	  of	  IgE.	  We	  demonstrate	  that	  allosteric	  inhibition	   prohibits	   simultaneous	   binding	   of	  these	  two	  receptors,	  and	  that	  this	  mechanism	  prevents	  engagement	  and	  cross-­‐linking	  of	  IgE	  bound	  to	  mast	  cells	  by	  soluble	  CD23.	  
	  
EXPERIMENTAL	  PROCEDURES	  
Protein	   expression	   and	   purification.	  Recombinant	   human	   IgE-­‐Fc	   (comprised	   of	  domains	   Cε2-­‐Cε4)	   (5),	   the	  αγ-­‐fusion	   protein	  (the	   FcεRIα	   extracellular	   region	   fused	   to	   an	  IgG4	   Fc)	   (10),	   soluble	   FcεRIα (13),	   derCD23	  (7)	   and	   the	   Cε3	   domain	   (13)	   were	   each	  produced	   and	   purified	   as	   described	  previously.	  MAb	  7.12	  was	  produced	  from	  a	  B	  cell	  hybridoma	  (16).	  Primers	  for	  site-­‐directed	  mutagenesis	   were	   obtained	   from	   Sigma-­‐Genosys	   (Sigma	   Lifescience),	   and	  mutagenesis	   was	   performed	   using	   the	  QuikChange	   II	   Kit	   (Stratagene).	   Mutant	  constructs	  were	  expressed	  and	  purified	  using	  the	  same	  methods	  as	  the	  wildtype	  proteins.	  
NMR	   spectroscopy.	   NMR	   spectroscopy	   was	  performed	   on	   protein	   samples	   in	   a	   buffer	  containing	   25mM	   Tris,	   125	   mM	   NaCl,	   4mM	  CaCl2,	   pH	   6.8,	   at	   protein	   concentrations	  between	   120	   and	   900	   µM.	   Data	   were	  collected	   at	   25oC	   on	   Bruker	   spectrometers	  equipped	   with	   CryoProbes	   operating	   at	   500	  and	  700	  MHz.	  For	  chemical	  shift	  perturbation	  experiments,	   unlabelled	   derCD23	   ligands	  were	  concentrated	  to	  2mM	  and	  then	  titrated	  in	   small	   aliquots	   to	   samples	   of	   200µM	   15N-­‐labelled	   Cε3	   until	   saturation	   was	   seen.	   The	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NMR	   chemical	   shifts	   of	   the	   urea	   denatured	  and	   native	   state	   Cε3	   domain	   are	   available	  from	   the	   BioMagResBank	   database	   under	  accession	  numbers	  18482	  and	  18483.	  
Surface	   plasmon	   resonance.	   	   All	   experiments	  were	   performed	   on	   a	   Biacore	   T100	  instrument	   (GE	   Healthcare),	   essentially	   as	  described	  previously	  (7,9).	  All	  measurements	  were	  done	  independently	  at	  least	  twice,	  using	  standard	   double	   reference	   subtraction	  methods	   for	   data	   analysis	   (17).	   Specific	  binding	   surfaces	   were	   prepared	   using	  standard	   amine	   coupling	   methods	   for	  derCD23	   and	   the	  αγ-­‐fusion	  protein,	  whereas	  IgE-­‐Fc	   was	   biotinylated	   and	   captured	   on	   a	  streptavidin	  surface.	  Coupling	  densities	  were	  kept	   low	   (<100	   RU)	   to	   minimize	   potential	  avidity	  effects.	  Ligands	  in	  HBS	  (10mM	  HEPES,	  pH	   7.4,	   150mM	   NaCl,	   4mM	   CaCl2,	   0.005%	  surfactant	   p20)	   were	   injected	   at	   25	   µl/min	  with	  a	  1-­‐min	  association	  phase	  followed	  by	  a	  15-­‐min	  dissociation	  phase.	  For	   the	  sandwich	  binding	  experiments,	  approximately	  90RU	  of	  IgE-­‐Fc	  was	  captured	  on	  an	  αγ-­‐fusion	  protein	  surface	   during	   a	   1-­‐min	   injection	   of	   a	   10nM	  IgE-­‐Fc	   sample;	   after	   a	   3-­‐min	   stabilization	  period,	  0-­‐100µM	  derCD23	  was	  injected	  for	  1-­‐min	  followed	  by	  a	  15-­‐min	  dissociation	  phase.	  
FRET	   assay.	   Inhibition	   assays	   were	  performed	   by	   competing	   1µM	   terbium-­‐chelate	   labelled	   derCD23	   and	   0-­‐20µM	   Alexa	  647-­‐labelled	   IgE-­‐Fc	   with	   a	   range	   of	  concentrations	   of	   unlabelled	   αγ-­‐fusion	  protein.	   Protein	   mixtures	   were	   prepared	   in	  Lanthascreen	  buffer	  (Invitrogen)	  in	  triplicate,	  in	   384-­‐well	   plates	   (Greiner	   Bio-­‐One),	   and	  equilibrated	   overnight	   at	   room	   temperature.	  FRET	   measurements	   were	   made	   on	   an	  Artemis	   plate	   reader	   (Berthold	  Technologies).	   TR-­‐FRET	   ratios	   were	  calculated	   for	   each	   well	   as	   the	   emission	   of	  acceptor	  at	  665nm	  divided	  by	  the	  emission	  of	  donor	   at	   620nm	   and	   then	   multiplied	   by	  10,000.	   Apparent	   KD	   and	   Bmax	   values	   were	  
derived	   from	   non-­‐linear	   curve	   fitting	   of	  inhibition	  titrations.	  
Mast	   cell	   degranulation	   assay.	   	   The	   human	  mast	   cell	   line	   LAD-­‐2	   (NIH)	   was	   primed	   by	  addition	   of	   2.5nM	   IgE	   (NIBSC)	   or	   a	   buffer-­‐only	  control	   for	  one	  hour,	  before	  addition	  of	  cross-­‐linking	  reagents.	  Polyclonal	  rabbit	  anti-­‐human	   IgE	   (Dako)	   was	   added	   at	   20nM	   and	  soluble	  CD23	   constructs	   at	   0.1,	   1	   and	  10µM,	  and	   incubated	   for	   1	   hour	   at	   37oC.	  Supernatants	   were	   harvested	   and	   tested	   for	  
β-­‐hexosaminidase	   release,	   as	   described	  previously	   (18).	   Controls	   included	   cells	  treated	  with	  wash	  buffer	  plus	  1%	  Triton-­‐X	  for	  total	   release,	   with	   buffer-­‐only	   to	   measure	  background	   release,	   typically	   about	   10%	   of	  total	   release,	   with	   2.5nM	   IgE-­‐only,	   and	   with	  10µM	  CD23-­‐only.	   The	   level	   of	   degranulation	  measured	   for	   Triton-­‐X	   treated	   cells	   was	  defined	   as	   100%	   release	   and	   all	   samples	  were	  compared	  to	  that.	  
B	   cell	   activation	   assays.	   	   Human	   tonsillar	   B	  cells	   were	   activated	   with	   IL-­‐4	   (200IU/ml)	  (R&D	  Systems),	  anti-­‐CD40	  antibody	  (1µg/ml)	  (G28.5;	   ATCC),	   and	   either	   1µM	   derCD23	   or	  1µM	  triCD23,	  as	  described	  previously	  (19).	  	  
RESULTS	  	  In	   an	   earlier	   study,	   we	   identified	   the	   IgE	  binding	   site	   on	   CD23	   using	   NMR	   chemical	  shift	   perturbation	   studies	   (7).	   Here	   we	  performed	   the	   reciprocal	   NMR	   binding	  experiment,	   mapping	   the	   interaction	   site	   of	  CD23	  onto	  the	  Cε3	  domain	  from	  IgE.	  Using	  an	  approach	   described	   by	   Schulman	   et	   al.	   (20),	  we	  assigned	   the	  backbone	   resonances	  of	   the	  molten	   globule	   Cε3	   domain	   by	   first	  performing	   resonance	   assignments	   of	   Cε3	  denatured	   in	   6M	   urea	   and	   then,	   through	  gradual	   titration	   of	   buffer	   conditions,	  tracking	  those	  resonances	  to	  the	  native	  state	  Cε3	   domain.	   Next,	   we	   titrated	   unlabelled	  monomeric	   CD23	   protein	   (derCD23)	   against	  an	   15N-­‐labelled	   Cε3	   sample	   and	   used	   the	  assigned	   NMR	   spectra	   to	   identify	   residues	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that	   were	   affected	   by	   addition	   of	   ligand.	  Similar	  to	  what	  was	  observed	  on	  derCD23	  in	  the	  reciprocal	  titration	  (7),	  a	  small	  number	  of	  Cε3	   residues	   showed	   peak	   shifting	   and	   line	  broadening	  during	  the	  derCD23	  titration	  (Fig.	  1A),	   consistent	   with	   an	   interaction	   showing	  intermediate	  and	  fast/intermediate	  exchange	  kinetics.	   When	   mapped	   onto	   the	   surface	   of	  the	  protein,	  the	  identified	  residues	  from	  three	  discontinuous	   sequences	   (amino	   acids	   405-­‐407,	   409-­‐411	   and	   413	   from	   the	   E-­‐F	   helix,	  amino	  acids	  377-­‐380	   from	  the	  C-­‐D	   loop,	  and	  residue	  436	  from	  the	  C-­‐terminal	  region)	  form	  a	   contiguous	   surface	   representing	   the	  binding	   site	   on	   Cε3	   for	   CD23	   (Figure	   1B).	   A	  plot	   of	   change	   in	   peak	   intensity	   versus	  residue	  number	  can	  be	  seen	  in	  Figure	  S1.	  	  	  This	   region	   is	   at	   the	   end	   of	   the	   Cε3	  domain,	  near	   to	   the	   interface	  with	  Cε4,	   in	  contrast	   to	  the	   interaction	  site	   for	  FcεRI,	  which	   is	  at	   the	  other	  end	  of	  Cε3	  near	   the	   interface	  with	  Cε2	  (4,9)	   (Fig.	   1B).	   Among	   other	  immunoglobulin-­‐receptor	   interactions,	   sites	  analogous	   to	   the	   Cε3-­‐Cε4	   interface	   are	  utilized	   in	  the	   interactions	  of	  FcαRI	  with	  IgA	  (21),	   CHIR-­‐AB1	   with	   IgY	   (22),	   and	   FcRn,	  protein	  A	  and	  protein	  G	  with	   IgG	  (23-­‐25).	   	  A	  comparison	   of	   the	   CD23	   binding	   surface	   on	  IgE	   with	   the	   analogous	   IgA	   and	   IgG	   binding	  surfaces	   shows	   areas	   of	   overlap	   but	   a	  nonconserved	   interaction	   motif,	   in	   contrast	  to	   the	   striking	   conservation	   of	   interaction	  surfaces	   for	   IgE-­‐FcεRIα	   and	   IgG-­‐FcγR	  complexes	  (4).	  	  The	   identification	   of	   this	   CD23	   interaction	  site	  on	   IgE	  provides	  a	   structural	  explanation	  for	   the	   experimentally	   observed	   2:1	  (CD23:IgE)	  stoichiometry	  (10),	  as	  the	  dimeric	  IgE-­‐Fc	   can	   bind	   to	   two	   separate	   CD23	   lectin	  head	   domains.	   The	   two	   CD23	   interactions	  were	  shown	  to	  have	  slightly	  different	  binding	  affinities	   and	   thermodynamic	   characteristics	  (10),	  as	  was	  also	  observed	  for	   the	  FcαRI-­‐IgA	  
interaction	   (21).	   The	   two	   binding	   affinities	  imply	  an	  asymmetry	  of	  the	  two	  CD23	  binding	  sites,	   which	   may	   possibly	   be	   allosterically	  induced.	   CD23's	   capacity	   for	   inducing	   a	  conformational	   change	   in	   IgE	   is	   discussed	  further	  below.	  	  Following	   the	   NMR	   mapping	   of	   interaction	  epitopes	   for	   both	   proteins,	   we	   used	   site-­‐directed	   mutagenesis	   to	   validate	   the	  interaction	  site	   in	   the	  context	  of	   the	   full	   IgE-­‐Fc	   construct	   and	   to	   define	   the	   energetic	  contributions	   of	   individual	   residues.	   Ten	  mutants	   from	   derCD23	   and	   eleven	   mutants	  from	  IgE-­‐Fc	  (domains	  Cε2-­‐4)	  were	  produced,	  purified	   and	   characterized;	   their	   binding	  affinities	  were	  measured	  using	  an	  SPR	  assay	  (7).	   Table	   1	   summarizes	   the	   results	   of	   the	  site-­‐directed	  mutagenesis	   studies.	   Mutations	  on	   both	   proteins	   that	   affect	   binding	   are	  entirely	   consistent	   with	   the	   NMR-­‐defined	  interaction	   sites.	   Charged	   residues	   have	   the	  largest	   energetic	   effect	   on	   binding.	   CD23	  mutations	  D227A,	  E257A,	  R224A	  and	  R188A	  all	   show	   a	   change	   in	   binding	   free	   energy	  (ΔΔG)	   of	   about	   +6	   kJ	   mol-­‐1	   (Table	   1).	  Uncharged	   residues	   also	   contribute	   to	   the	  binding	   energy;	   a	   prominently	   exposed	  tyrosine	   residue	   (Y189)	   in	   the	   center	   of	  CD23's	   IgE	   binding	   site	   makes	   a	   substantial	  contribution	   to	   binding	   energy.	   The	   CD23	  binding	  surface	  on	  IgE	   is	  also	  predominantly	  electrostatic,	  with	  residues	  D409,	  E412,	  R376	  and	   K380	   showing	   the	   largest	   effects	   on	  CD23	   binding	   energetics.	   Because	   the	   NMR	  data	   indicated	  a	  site	  on	  Cε3	  very	  near	   to	   the	  Cε4	   interface	   (Fig.	   1B)	   and	   because	   binding	  sites	   from	   several	   other	   immunoglobulin-­‐receptor	   interactions	   involve	  sites	  analogous	  to	   the	   Cε3-­‐Cε4	   interface	   (21-­‐23),	   we	   also	  made	   a	   pair	   of	  mutations	   in	   the	   F-­‐G	   loop	   of	  the	   Cε4	   domain,	   close	   to	   the	   CD23	   binding	  site	   in	   Cε3.	   However,	   neither	   Q535A	   nor	  Q538A	  appear	  to	  affect	  CD23	  binding,	  leading	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us	   to	   believe	   that	  CD23's	   binding	   surface	   on	  IgE	  is	  largely	  restricted	  to	  residues	  from	  Cε3.	  	  Earlier	   studies	   indicated	   that	   soluble	   CD23	  can	  compete	  with	  FcεRI	  binding,	  and	  this	  was	  attributed	   to	   steric	   competition	   for	   an	  overlapping	   binding	   site	   within	   the	   Cε3	  domain	  (26,27).	  However,	  our	  data	  show	  that	  the	  CD23	  and	  FcεRI	  binding	  sites	  are	  spatially	  distinct	   and	   suggest	   that	   the	   mechanism	   of	  mutual	   inhibition	   must	   be	   allosteric	   in	  nature.	   We	   performed	   a	   set	   of	   competitive	  binding	   assays	   to	   confirm	   this	  experimentally.	   Firstly,	   using	   an	   SPR	   assay,	  we	   showed	   that	   derCD23	   can	  bind	   to	   IgE-­‐Fc	  immobilized	   to	   an	   SPR	   chip	   but	   cannot	   bind	  to	   IgE-­‐Fc	   captured	   by	   immobilized	   FcεRIα	  (Fig.	  2A,B);	  a	  positive	  control,	  a	  Fab	  fragment	  of	   the	   anti-­‐IgE	   antibody	   7.12	   (16),	   directed	  against	   the	   Cε2	   domain,	   did	   bind	   to	   FcεRIα-­‐captured	   IgE-­‐Fc	   (data	   not	   shown).	   Secondly,	  we	   showed	   that	   IgE-­‐Fc	   can	   bind	   to	  immobilized	  derCD23,	  but	  an	  IgE-­‐Fc-­‐sFcεRIα	  complex	  cannot	  bind	   to	  derCD23	  (Fig.	  2C,D).	  These	   data	   indicate	   that	   CD23	   and	   FcεRI	  interactions	  with	  IgE	  are	  mutually	  inhibitory.	  Finally,	   we	   also	   tested	   the	   ability	   of	   the	  receptors	   to	   compete	   for	   binding	   to	   IgE	   in	   a	  solution	   TR-­‐FRET	   experiment	   (28).	   This	  assay	   can	   be	   performed	   under	   equilibrium	  binding	  conditions,	  allowing	  a	  different	  set	  of	  mechanistic	   properties	   to	   be	   tested	   than	   in	  the	   kinetic	   SPR	   experiments.	   Under	  equilibrium	   conditions,	   different	   inhibition	  patterns	   are	   observed	   for	   competitive	   and	  allosteric	   inhibitors.	   A	   competitive	   inhibitor	  affects	   the	   apparent	   binding	   affinity,	   with	  inhibitor	  I	  reducing	  the	  apparent	  affinity	  by	  a	  ratio	   of	   (1+[I]/KI);	   whereas	   an	   allosteric	  inhibitor	   affects	   the	   apparent	   Bmax	   of	   the	  interaction	  without	  changing	  the	  apparent	  KD	  (29).	   Soluble	   FcεRIα	   inhibits	   the	   IgE-­‐Fc-­‐derCD23	   interaction	   (Fig.	   2E)	   and	   derCD23	  inhibits	   the	   IgE-­‐Fc-­‐FcεRIα	   interaction	   (Fig.	  2F),	   and	   both	   inhibitors	   result	   in	   a	   decrease	  
of	   apparent	   interaction	   Bmax	   values	   without	  affecting	   the	  apparent	  KD	  of	   the	   interactions.	  These	  experiments	  confirm	  mutual	  inhibition	  by	   the	   two	   IgE	   receptors	   and	   offer	  experimental	   evidence	   that	   an	   allosteric	  mechanism	  is	  involved.	  	  Given	   the	   location	   of	   the	   CD23	   binding	   site,	  the	  most	  obvious	  mechanism	  for	  allostery	  is	  a	  conformational	   change	   around	   the	   interface	  between	   the	   Cε3	   and	   Cε4	   domains.	   Crystal	  structures	   of	   IgE-­‐Fc	   and	   IgE-­‐Fc-­‐FcεRIα	  complexes	  indicate	  that	  the	  Cε3	  domains	  can	  exist	   in	  "open"	  and	  "closed"	  states,	  with	  only	  an	  open	  state	  being	  capable	  of	  binding	  FcεRI	  (4,9,14).	   A	   detailed	   study	   of	   the	   open	   and	  closed	  states	  concluded	  that	  it	  is	  the	  motions	  around	   the	   Cε3	  A-­‐B	   helix,	   sitting	   at	   the	   Cε3-­‐Cε4	   interface,	   that	   control	   the	   orientation	   of	  the	  two	  Cε3	  domains	  (14).	  Indeed,	  Wurzburg	  
et	   al.	   suggested	   that	   the	   Cε3-­‐Cε4	   domain	  interface	   might	   serve	   as	   a	   drug	   target	   for	  allosteric	   inhibitors	   of	   FcεRI	   binding.	   It	  appears	   that	  nature	  has	   already	  utilized	   this	  approach	  to	  modulate	  FcεRI	  binding	  of	  IgE	  by	  CD23.	  	  Soluble	   trimeric	   CD23	   has	   been	   shown	   to	  bind	   to	   and	   cross-­‐link	   membrane	   IgE	   on	   B	  cells,	   resulting	   in	   B	   cell	   activation	   (19).	  However,	   it	   is	   essential	   that	   trimeric	   CD23	  not	   cross-­‐link	   IgE	   bound	   to	   FcεRI	   on	   the	  surface	   of	   mast	   cells.	   If	   this	   were	   to	   occur	  then	  high	  levels	  of	  CD23	  would	  result	  in	  mast	  cell	  activation	  in	  the	  absence	  of	  allergens.	  Our	  data	   from	   binding	   experiments	   (Fig.	   2B)	  predict	   that	   soluble	   CD23	   cannot	   directly	  cross-­‐link	   IgE	   bound	   to	   FcεRI	   on	  mast	   cells.	  We	   tested	   this	   prediction	   in	   a	   mast	   cell	  degranulation	   assay	   using	   the	   FcεRI+	   LAD-­‐2	  human	  mast	   cell	   line.	   In	   this	   assay,	   cells	   are	  first	   primed	   by	   adding	   IgE,	   followed	   by	  addition	   of	   potential	   cross-­‐linking	   reagents	  and	  measurement	  of	   release	  of	   the	  mast	   cell	  granule-­‐associated	   enzyme	   β-­‐
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hexosaminidase.	  An	  anti-­‐IgE	  antibody	  results	  in	  FcεRI-­‐mediated	  activation	  of	   the	  mast	  cell	  and	  robust	  β-­‐hexosaminidase	  release,	  but	  the	  addition	  of	  either	  the	  monomeric	  derCD23	  or	  a	   trimeric	   CD23	   construct	   (triCD23)	   fails	   to	  induce	   mast	   cell	   degranulation	   (Fig.	   3A).	   In	  contrast,	  trimeric	  CD23	  effectively	  cross-­‐links	  IgE	  on	  B	  cells,	  resulting	  in	  activation	  of	  these	  cells	  and	  increased	  production	  of	  soluble	  IgE	  (19)	  (Fig.	  3B).	  
	  
DISCUSSION	  Immunoglobulins	  have	  evolved	  two	  separate	  sites	  for	  binding	  to	  receptors.	  One	  site	  is	  near	  the	   hinge	   region	   in	   IgG	   and	   at	   the	   Cε2-­‐Cε3	  interface	   in	   IgE,	   while	   the	   other	   is	   at	   the	  interface	   of	   the	   C-­‐terminal	   domain	   and	   the	  penultimate	  domain:	  the	  Cε3-­‐Cε4	  interface	  in	  IgE.	   A	   mechanism	   of	   communication	   has	  evolved	   within	   the	   IgE	   molecule	   between	  these	   two	   distant	   sites	   to	   prevent	  simultaneous	  engagement	  of	  CD23	  and	  FcεRI.	  This	   may	   be	   a	   unique	   property	   of	   IgE;	   it	   is	  known,	  for	  example,	  that	  IgG	  binding	  of	  either	  FcRn	   or	   protein	   A	   at	   the	   Cγ2-­‐Cγ3	   interface	  does	  not	  affect	  binding	  of	  FcγRIIa	  at	  the	  hinge	  
region	  (30).	  Since	  IgE	  and	  CD23	  both	  exist	  in	  membrane	   bound	   and	   soluble	   forms,	   and	  soluble	  FcεRIα	  has	  also	  recently	  been	  shown	  to	   exist	   at	   functionally	   relevant	  concentrations	   (31),	   there	   is	   considerable	  potential	   for	   receptor	   cross-­‐regulation.	  Mutually	   exclusive	   receptor	   binding	   assures	  independent	  functions	  for	  IgE-­‐FcεRI	  and	  IgE-­‐CD23	  interactions.	  	  IgE	   is	   a	   clinically	   important	   drug	   target.	   An	  anti-­‐IgE	   antibody	   (omalizumab)	   is	   an	  effective	   therapy,	   currently	   used	   in	   the	  treatment	  of	  moderate	  to	  severe	  asthma	  that	  is	   not	   controlled	   by	   corticosteroids.	  Omalizumab	  binds	   to	   the	   Cε3	  domain	   of	   IgE	  and	   competitively	   inhibits	   FcεRI	   binding,	  although	   its	   in	   vivo	   activity	   relies	   on	   more	  than	   just	   inhibition	   of	   this	   interaction	   (32).	  Results	  presented	  here	  demonstrate	   that	   IgE	  is	   amenable	   to	   allosteric	   inhibition,	   an	  approach	   that	   may	   have	   significant	  advantages	   over	   competitive	   inhibition	   (33),	  and	  lay	  the	  foundation	  for	  the	  development	  of	  allosteric	   modulators	   of	   IgE-­‐receptor	  interactions.	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FIGURE	  LEGENDS	  
	  
Figure	  1.	  NMR	  mapping	  of	  the	  CD23	  and	  IgE	  interaction	  surfaces.	  (A)	  Increasing	  amounts	  of	  unlabelled	  derCD23	  were	  added	  to	  a	  200µM	  sample	  of	  15N-­‐labelled	  Cε3;	  five	  spectra	  of	  the	  titration	  are	  overlaid	  (red,	  zero	  derCD23;	  magenta,	  50µM;	  blue,	  100µM;	  cyan,	  150µM;	  green,	  200	  µM).	  Insets	  show	  magnified	  views	  of	  the	  indicated	  regions.	  (B)	  The	  NMR-­‐derived	  derCD23	  interaction	   site	   on	   Cε3	  was	  mapped	   onto	   the	   structure	   of	   IgE-­‐Fc	   (1F6A	   [6])	   and	   shown	   as	  surface	   representation.	   For	   comparison,	   the	   residues	   of	   IgE	   that	   interact	   with	   FcεRI	   are	  indicated	   in	   green.	   (C)	   The	   IgE	   interaction	   surface	   on	   CD23	  was	   defined	   previously	   [7]	   and	  shown	  here	  as	  a	  surface	  representation.	  The	  interacting	  surfaces	  of	  IgE	  and	  CD23	  are	  coloured	  according	  to	  electrostatic	  potential	  and	  coded	  such	  that	  regions	  with	  a	  potential	  <−4	  kBT	  are	  red,	  whereas	  those	  >4	  kBT	  are	  blue	  (kB,	  Boltzmann	  constant;	  T,	  absolute	  temperature).	  	  
Figure	   2.	   Competition	   binding	   experiments	   between	   derCD23	   and	   sFcεRIα 	   for	   IgE-­Fc.	  The	  binding	  of	  derCD23	  was	  tested	  against	  (A)	  IgE-­‐Fc	  immobilized	  on	  a	  sensor	  surface	  and	  (B)	  IgE-­‐Fc	   captured	   on	   an	   FcεRIα-­‐immobilized	   surface;	   the	   start	   of	   the	   derCD23	   injection	   is	  indicated	   with	   an	   arrow.	   DerCD23	   binding	   to	   immobilized	   IgE-­‐Fc	   with	   a	   KD	   of	   2.3µM;	   no	  measureable	   binding	   was	   observed	   for	   derCD23	   to	   IgE-­‐Fc	   complexed	   to	   FcεRIα.	   (C)	   The	  binding	  of	  IgE-­‐Fc	  to	  immobilized	  derCD23	  was	  compared	  with	  (D)	  the	  binding	  of	  a	  complex	  of	  IgE-­‐Fc/sFcεRIα	  to	  the	  same	  surface;	  the	  start	  of	  the	  injection	  of	  the	  complex	  is	  indicated	  with	  an	  arrow.	  	  IgE-­‐Fc	  binds	  to	  derCD23	  with	  a	  KD	  of	  2.4µM,	  but	  the	  IgE-­‐Fc/sFcεRIα	  complex	  does	  not	   bind	   to	   derCD23.	   All	   SPR	   binding	   experiments	  were	   performed	  using	   identical	   two-­‐fold	  serial	  dilutions	  of	  ligands,	  from	  40µM	  to	  78nM.	  (E)	  Binding	  between	  terbium-­‐labelled	  derCD23	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and	  Alexa	  647-­‐labelled	   IgE-­‐Fc	  was	  measured	   in	  a	  solution	  TR-­‐FRET	  assay	   in	   the	  presence	  of	  increasing	   concentrations	   of	   unlabelled	   αγ-­‐fusion	   protein	   as	   inhibitor;	   zero	   (black),	   0.5nM	  (red),	  2.5nM	  (blue)	  and	  5nM	  (green).	  (F)	  Binding	  between	  terbium-­‐labelled	  αγ-­‐fusion	  protein	  and	   Alexa	   647-­‐labelled	   IgE-­‐Fc	   was	   measured	   with	   increasing	   concentrations	   of	   unlabelled	  derCD23	  as	  inhibitor;	  zero	  (black),	  25µM	  (red),	  50µM	  (blue)	  and	  185µM	  (green).	  	  
Figure	  3.	  Soluble	  CD23	  does	  not	  cross-­link	  IgE	  bound	  to	  FcεRI	  on	  mast	  cells.	  The	  ability	  of	  soluble	  CD23	  to	  engage	  IgE	  on	  B	  cells	  and	  mast	  cells	  was	  tested.	  (A)	  After	  preincubation	  of	  IgE,	  the	  addition	  of	  anti-­‐IgE	  antibody	  results	   in	  activation	  of	   the	  FcεRIα+	  LAD-­‐2	  mast	  cell	   line,	  as	  measured	  by	  release	  of	  β-­‐hexosaminidase.	  Neither	  monomeric	  derCD23	  nor	  trimeric	  triCD23	  is	  able	  to	  cross-­‐link	  IgE	  and	  activate	  mast	  cells	  in	  this	  assay.	  (B)	  In	  contrast,	  triCD23	  effectively	  cross-­‐links	  mIgE	  on	  the	  surface	  of	  IgE+	  human	  tonsillar	  B	  cells,	  resulting	  in	  activation	  of	  these	  cells	  and	  increased	  secretion	  of	  IgE.	  B	  cell	  cultures	  were	  activated	  with	  IL-­‐4	  and	  anti-­‐CD40,	  and	  soluble	  CD23	  was	  added	  at	  1µM;	  supernatants	  were	  harvested	  12	  days	  after	  activation,	  tested	  for	  IgE	  levels	  and	  compared	  with	  levels	  for	  cells	  treated	  with	  IL-­‐4/anti-­‐CD40	  alone	  (*=p<0.05;	  **=p<0.01).	  The	  regulatory	  activities	  of	  soluble	  CD23	  on	  IgE+	  B	  cells	  are	  described	  in	  detail	  in	  (19).	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Table	  1.	  	  Effects	  of	  mutations	  on	  the	  IgE-­‐CD23	  interaction	  
	  	   IgE-­‐Fc	  	  mutation	   KD	  	  (µM)	   ΔΔG	  (kJ	  mol-­‐1)	   derCD23	  	  mutation	   KD	  (µM)	   ΔΔG	  (kJ	  mol-­‐1)	  wildtype	   2.3	   -­‐	   wildtype	   2.3	   -­‐	  D409A	   26.3	   +6.0	   D227A	   30.9	   +6.4	  E412A	   24.2	   +5.8	   E257A	   26.7	   +6.1	  R376A	   19.7	   +5.3	   R224A	   26.2	   +6.0	  K380A	   13.3	   +4.3	   R188A	   25.0	   +5.9	  K435A	   5.0	   +1.9	   Y189A	   15.6	   +4.7	  K352A	   3.8	   +1.2	   K276A	   10.9	   +3.9	  R351A	   2.6	   +0.3	   L226A	   6.6	   +2.6	  D347A	   2.5	   +0.2	   D236A	   5.8	   +2.3	  P439A	   2.5	   +0.2	   D192A	   4.3	   +1.6	  Q535A	   2.5	   +0.2	   E265A	   2.5	   +0.2	  Q538A	   2.4	   +0.1	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FIGURE	  1	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FIGURE	  2	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FIGURE	  3	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Antibodies are assembled by a highly orchestrated series of recombination events during B cell development. One of these
events, class switch recombination, is required to produce the IgG, IgE and IgA antibody isotypes characteristic of a
secondary immune response. The action of the enzyme activation induced cytidine deaminase is now known to be essential
for the initiation of this recombination event. Previous studies have demonstrated that the immunoglobulin switch regions
acquire distinct histone modifications prior to recombination. We now present a high resolution analysis of these histone
modifications across the IgE switch region prior to the initiation of class switch recombination in primary human B cells and
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methylation of lysine 4. Distinct peaks of modified histones are found across the switch region, most notably at the 59 splice
donor site of the germline (I) exon, which also accumulates AID. These data suggest that acetylation and K4 tri-methylation
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Introduction
Antibodies, which are essential components of vertebrate
adaptive immunity, are produced as a result of complex genome
rearrangements and mutation events in the B cell receptor loci. In
developing B lymphocytes, V(D)J recombination at immunoglob-
ulin heavy and light chain loci results in a diverse repertoire of
antigen binding specificities necessary for the recognition of a
spectrum of foreign antigens. During the immune response,
somatic hypermutation (SHM) and affinity maturation refine these
specificities through the introduction of mutations into the variable
regions while class switch recombination (CSR) exchanges the
constant regions of the immunoglobulin heavy chains (IgH) to
produce the different antibody isotypes, or classes. The germline
IgH locus consists of a linear array of constant region (CH) genes
spanning over one hundred kilobases, with Cm, which encodes
IgM, proximal to the rearranged V(D)J gene segments [1]. With
the exception of Cd, each downstream CH gene contains an
individual promoter, short intervening (I) exon and a 2–10 kb
switch (S) region followed by coding region exons [2]. During
CSR, DNA double strand breaks (DSBs) are generated in the
donor (initially Sm) and downstream target switch regions [3,4].
These switch regions then recombine to place the target CH
immediately downstream of the assembled V(D)J gene segments,
allowing the expression of a new immunoglobulin isotype whilst
maintaining antigen specificity [5].
In the past few decades some of the key components and
mechanistic steps of CSR have been elucidated. The enzyme
activation induced cytidine deaminase (AID) has been shown to
play a central role in both SHM and CSR [6–8]. Extracellular
cytokine signals initiate CSR by activating transcription of
donor and target CH genes (germline transcription, GLT) [9]
and upon further signalling by CD40-ligand, or one of its
analogs [10,11], recombination ensues. AID deaminates deoxy-
cytidines within IgH switch regions, converting them to
deoxyuridines [12–14]. If there are two close-lying events on
opposite strands, the resulting U:G mismatches initiate a
cascade of activities that ultimately result in the formation of
DNA DSBs in the donor and target switch regions [15,16].
DNA repair mechanisms resolve these DSBs, ligating the donor
and target switch regions, moving the target CH exons adjacent
to the expressed V(D)J gene segments [17].
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Chromatin structure is known to play an important role in most,
if not all, vertebrate processes that require direct access to DNA,
such as transcription, replication and recombination. In many
cases, distinct post-translational modifications in the N-terminal
histone tails correlate strongly with ‘‘active’’ or ‘‘silent’’ transcrip-
tional states. For example, acetylation of histones H3 and H4
marks regions of transcriptionally active chromatin, whereas tri-
methylation of histone H3 at lysine 27 is associated with
transcriptionally silent loci [18]. Local chromatin accessibility is
changed by alterations in nucleosome positioning through ATP-
dependent remodelling activities or through the recruitment of
histone modification enzymes such as histone acetyl transferases
(HATs) or histone methyl transferases (HMTs) [19].
Several lines of evidence have suggested that switch region
chromatin structure plays a key role in promoting a permissive
environment required for AID attack. Hyperacetylation of
histones H3 and H4 and tri-methylation of histone H3 on lysine
4 (K4) and lysine 9 (K9) have previously been shown to be
associated with activated switch regions in both mice and humans
[20–25]. However, the present work is the first to examine
chromatin structure over a human switch region at high
resolution.
We have focused on the histone modifications that occur prior
to CSR to IgE in human B cells. IgE is the antibody class that
mediates the allergic response and its regulation is therefore of
considerable interest. In particular, we have investigated the
changes in chromatin structure that occur under conditions that
induce e germline gene transcription; an event that precedes, and
is necessary for, CSR to IgE [26–28]. Purified B cells from
different individuals undergo class switching at low and variable
frequencies and show considerable variation in chromatin changes
associated with this process [23]. This variability has previously
made these events difficult to analyse in the human system. Here
we have taken advantage of the availability of both cultured cells
from a human B cell line (CL-01) and purified tonsil B cells from
several donors. Although the CL-01 cell line was initially reported
to undergo CSR to IgG, IgA and IgE following cytokine and
CD40 stimulation [27,29] several laboratories, including our own,
have found that this line now appears to have lost this ability (E.
Max personal communication). While this would be a limitation
for the analysis of the combined steps of immunoglobulin class
switching (germline gene transcription, DNA recombination and B
cell differentiation into immunoglobulin-secreting plasma cells), it
reduces complexity to the single, essential, initial step of germline
gene transcription: an event that occurs in the CL-01 cells and
takes place in all primary human B cells, rather than a minor
population [28]. This combination of sample materials allows us to
robustly identify key chromatin remodelling events that occur at
the Ig locus upon stimulation of egermline transcription (eGLT) in
the human system.
Results
Effect of IL-4 stimulation on CL-01 cells
We began by using the CL-01 cell line to investigate the
chromatin changes associated with the initiation of CSR to IgE in
human B cells. These cells have been reported to initiate germline
transcription of this region in response to IL-4 [27,29,34]. In order
to investigate the human IgE switch region at high resolution,
PCR primers were designed at unique sites spanning a region from
Ie-Se (Fig. S1). Four primers sets spanning Ie-Se were used to
quantify the expression level of primary (unspliced) e germline
transcripts (Fig. 1A). As expected, unstimulated cells expressed low
levels of eGLT. Consistent with changes associated with the early
stages of CSR, addition of IL-4 to the cultures for 72 hours
resulted in a 10- to 30-fold increase in the primary transcript
expression level. At this time point the change in the level of
spliced eGLT was even greater, over 150 fold (Fig. 1B), while AID
levels increased 8 fold (Fig. 1C), compared to the unstimulated
cells.
Given the marked effect of IL-4 on transcription, we asked
whether the addition of IL-4 also altered chromatin structure and
acquisition of histone modifications over this region. The average
nucleosome density (nucleosome occupancy) across Ie-Se (Fig. 2)
was determined, as previously described [31], to investigate the
gross chromatin structure and thus general accessibility of the IgE
Figure 1. Analysis of e germline gene transcripts and AID
expression in CL-01 cells. Steady state transcript levels were
quantified by qRT-PCR using HPRT as an endogenous control. All
results are represented as changes relative to unstimulated CL-01 cells.
The mean result from 3 separate experiments is shown. Error bars
display standard deviation. Induction of (A) primary (un-spliced) e
germline gene transcripts, (B) mature (spliced) e germline transcripts
and (C) AID, in CL-01 cells following IL-4 stimulation for 72 hours. A
schematic representation of the Ig e locus is shown in panel A, with the
elements approximately to scale, indicating the location of the primer/
TaqMan probe sets used for the analysis of primary e germline gene
transcripts. Mature (spliced) e germline transcripts were detected using
a forward primer and TaqMan probe located in Ie and reverse primer in
CH e exon 1 (not shown).
doi:10.1371/journal.pone.0024571.g001
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switch region. Although nucleosome occupancy did not change
following IL-4 treatment, nucleosome density increased from Ie
towards the 39 end of Se in both the stimulated and un-stimulated
cells. The presence of the histone variant H2A.Z is known to
correlate with transcriptionally accessible chromatin structures
[35], thus the accumulation of this variant was also investigated.
Consistent with the nucleosome occupancy data, no changes in
H2A.Z levels were seen upon IL-4 stimulation (Fig. S2).
We next surveyed the switch region for a range of histone
modifications commonly associated with gene activation or
repression. Following IL-4 stimulation, there were significant
increases in the diacetylation of lysines 9 and 14 on histone H3
(AcH3) and tri-methylation of histone H3 lysine 4 (H3K4me3,
Fig. 3). Although both of these modifications were increased across
the whole Ie-Se region, they were particularly enriched near the
DNA encoding the Ie exon 59 splice donor site and were markedly
less abundant 39 of Ie and at the 59 end of Se. IL-4 stimulation
resulted in no significant change in histone H4 acetylation (AcH4)
or histone H3K4 di-methylation (H3K4me2, Fig. S3), although
these modifications were enriched in the vicinity of the Ie splice
donor in both conditions. Little or no change was observed upon
stimulation in H3 tri-methylation at K9 (H3K9me3), K27
(H3K27me3) or K36 (H3K36me3) (Fig. S3). However
H3K9me3 and H3K27me3 levels were slightly depleted relative
to input (values,1), indicating that these characteristic marks of
inactive chromatin modifications are under-represented in this
region.
Effect of IL-4 and CD40 stimulation on CL-01 cells
Although IL-4 stimulation is sufficient to initiate eGLT
expression (Figs. 1A and 1B), a ‘‘second signal’’ such as CD40
ligation, is required to initiate class switch recombination [10,36].
IL-4 stimulation of CL-01 cells results in greatly increased tri-
methylation of lysine 4 and acetylation of histone H3 around Ie
(Fig. 3). We wished to determine whether the addition of the
second signal altered the pattern of accumulation of these histone
modifications over Se. In addition to the increase in H3
acetylation and K4 tri-methylation (Fig. 3), previous studies had
demonstrated increased tri-methylation of histone H3 lysine 9 at
switch regions following stimulation of CSR [23] [25]; therefore
these modifications were chosen for further analysis following
culture of CL-01 cells with IL-4 and anti-CD40 antibody (Fig. S4).
No further changes in histone modifications were seen upon
addition of anti-CD40 (and IL-4) to the cultures, compared to IL-
4 alone. As for the IL-4 stimulated cells, AcH3 and H3K4me3
levels increased dramatically near the Ie exon 59 splice site but
Figure 2. Nucleosome occupancy over Se in CL-01 cells.
Nucleosome occupancy over Se was assessed in a mononucleosome
chromatin fraction and compared to genomic DNA. The relative
abundance of each primer location following ChIP was determined by
qPCR. The mean result from 3 separate chromatin preparations is
shown. Error bars display standard deviation. Data from un-stimulated
cells is shown by squares and solid lines and stimulated cells by circles
and dashed lines. A schematic representation of the Ig e locus is shown,
with the elements approximately to scale, indicating the position of
each primer/TaqMan probe set plotted on the X axis.
doi:10.1371/journal.pone.0024571.g002
Figure 3. ChIP analysis of histone modifications at the Ig e
locus in CL-01 cells following IL-4 stimulation. Levels of di-
acetylated (K9 and K14) histone H3 (top panel) and histone H3 tri-
methylated at K4 (bottom panel) were assessed by ChIP using size-
selected native chromatin to ensure high resolution. Analysis of histone
modifications was carried out in CL-01 cells cultured for 72 hours with
or without IL-4 stimulation. Mean results from 3 separate chromatin
extractions are plotted as fold enrichments over an input control. Data
from unstimulated cells is shown by squares and solid lines and
stimulated cells by circles and dashed lines. Error bars show standard
deviations. A schematic representation of the Ig e locus is shown below
the graphs, with the elements approximately to scale, indicating the
position of each primer/TaqMan probe set plotted on the X axis.
doi:10.1371/journal.pone.0024571.g003
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were increased to a lesser extent over the switch region;
H3K9me3 did not change in response to either mode of
stimulation (Fig. S4).
Effect of IL-4 and CD40 stimulation on primary human B
cells
To gain greater insights into the changes in Se chromatin
structure associated with human class switch recombination, we
extended our studies to total primary B cells purified from tonsils
from five human donors (Fig. 4). Cells were stimulated with IL-4
and anti-CD40 for 48 hours, when the highest levels of germline
transcripts were observed in these cells (data not shown). In
primary human B cells, stimulation with IL-4 and anti-CD40
results in CSR to IgG and IgE [28,37,38]. In order to investigate
whether histone modification occurs differentially at IgG versus
IgE, histone H3 acetylation and K4 tri-methylation were also
measured at the Ic1 promoter and a unique site within the c1
switch region. Extensive sequence similarity within the IgG
subtypes prevented a high resolution analysis of this gene. For
comparison, histone modifications were also investigated at two
genes not expressed in B cells: myf4 (a transcription factor involved
in myocyte differentiation) and NeuroD1 (a transcription factor
involved in neurogenesis).
Although specific distribution patterns were variable in the
primary B cells, histone H3 acetylation (AcH3) levels increased (up
to 20-fold) in all samples over Ie and Se following stimulation with
IL-4 and anti-CD40 (Fig. 4). As was seen in the CL-01 cells, in
samples 1, 4 and 5, a distinct peak of acetylation was seen at the Ie
exon 59 splice site; no such peak was seen in sample 2 or 3,
although acetylation levels did increase significantly following
stimulation. With the exception of the Ie primers in sample 3,
acetylation levels tended to be low 59 of I exons but were
significantly higher across the switch regions. In all samples except
sample 3, acetylation levels were higher at the c1 primer sets than
the corresponding e region. By comparison, H3 acetylation was
low at the non-B cell genes.
Figure 4. ChIP analysis of histone modifications at the Ig e locus in primary human B cells. Levels of pan-acetylated histone H3, histone
H3 tri-methylated at K4, RNA polymerase II (RNAP) and AID were assessed by ChIP using formaldehyde crosslinked chromatin from primary human B
cells stimulated with IL-4 and anti-CD40 for 48 hours. Results from the individual donors for Se primers sets are plotted alongside those for 59Ic1 and
Sc1 and two non-B cell expressed genes (Myf4 and NeuroD1) for comparison. Data from unstimulated cells is shown by squares and solid lines and
stimulated cells by circles and dashed lines. A schematic representation of the Ig e locus is shown below the graphs, with the elements approximately
to scale, indicating the position of each primer/TaqMan probe set. Additional (non-IgE) probes are also annotated on the X axis. N.D. – not
determined.
doi:10.1371/journal.pone.0024571.g004
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Histone H3 lysine 4 tri-methylation levels across the e locus
were also increased upon stimulation of primary human B cells, in
the three out of four donors (1, 3 and 4) for whom data were
available (Fig. 4), again in agreement with the CL-01 data (Fig. 3).
As observed for H3 acetylation, levels of stimulation were variable
in the different donors. In two donors (1 and 4, to a greater or
lesser extent, respectively) a peak of H3K4 tri-methylation is see at
the Ie exon 59 splice site (Fig. 4). As was also observed for H3
acetylation, H3K4 tri-methylation was higher at the 39 end of Se
than was seen in the CL-01 cells. Elevation of H3K4me3 levels
was also observed at the c1 locus and was as much as two-fold
higher than at the e locus. Compared to the switch regions, levels
of H3K4 tri-methylation were reduced at Myf4 and NeuroD1 in
stimulated B cells.
We also profiled AID and RNA polymerase II (RNAP) binding
patterns in primary B cells. In four individual experiments, we
detected increased but variable RNAP and AID occupancy across
the e and c1 loci upon stimulation (Fig. 4). As was true of the
histone modifications, a trend towards a peak of AID and RNAP
was seen at the Ie exon 59 splice site in samples 1, 2 and 5.
Interestingly, sample 3 showed little AID accumulation despite
displaying robust H3 acetylation, H3K4 tri-methylation and
RNAP accumulation. In stimulated B cells AID and RNAP levels
were higher at c1 than e, while levels were lower at Myf4 and
NeuroD1.
To further investigate the chromatin structure of the IgE switch
region prior to CSR, CpG DNA methylation across Se was
analysed by bisulphite modification in primary human B cells
isolated from 3 donors (Fig. S5). Levels of DNA methylation were
not significantly changed following IL-4 and anti-CD40 stimula-
tion of B cells. Further, CpG sites located just upstream of the I
exon 59 splice site (site 176) exhibited reduced levels of methylation
compared to surrounding regions while the sites at the 39 end of Se
(sites 2081–2313) had slightly reduced levels of methylation than
the 59 end. Two further sites, one within Ie (98) and one at the 59
end of Se (580), also displayed noticeably lower levels of
methylation than their surrounding sites.
Discussion
In this study, we sought to identify changes in chromatin
conformation within the human immunoglobulin heavy chain e
locus upon stimulation by treatments known to activate class
switching to IgE. We initially took advantage of the CL-01 human
B cell line to measure changes in histone modifications associated
with the first stages of class switching in a highly reproducible
system. These results were then used as reference points for the
much more variable responses obtained with primary human B
cells.
Measurements of nucleosome distribution across the e switch
region at high resolution (one primer/probe set every 220 bp on
average) in CL-01 cells revealed that, although the density of
nucleosomes (occupancy) generally increased towards the 39 end of
Se this pattern of distribution was not affected by IL-4 stimulation
(Fig. 2). Reduced nucleosome occupancy at transcription start sites
is thought to be associated, in part, with increased levels of the
histone variant H2A.Z [35]. However, we found that levels of
H2A.Z were largely constant across Se (Fig. S2), and not higher at
the promoter, nor did they change significantly upon IL-4
stimulation.
The presence of nucleosomes in the switch region does not
preclude AID attack; AID can readily deaminate deoxycytidine
residues on transcriptionally active nucleosomal DNA in vitro [39].
However, the observed relative depletion of nucleosomes in the
promoter region in unstimulated and IL-4 stimulated cells reveals
that this region has increased accessibility to trans-acting factors
(transcription factors, polymerase and AID) even before the
activation of germline gene transcription. This conclusion is
consistent with, and supports, our previous findings showing
detectable levels of e germline gene transcripts in resting B cells [28].
Cerutti and co-workers first made use of the CL-01 cell line to
study human B cell activities, utilising CD40-ligand-expressing
cells or an anti-CD40 mAb, to stimulate class switching to IgG and
IgE. However, we have been unable to stimulate these cells to
undergo class switching. This result confirms findings from other
groups that, over time, these cells have lost their ability to undergo
class switching. Despite their inability to undergo the later stages of
recombination, we find that CL-01 cells nonetheless display
characteristic remodelling of the chromatin at the IgE locus,
including increases in histone H3 acetylation and tri-methylation
of H3 at K4 (Fig. 3). The data demonstrate that these chromatin
changes occur independently of recombination, a finding sup-
ported by the primary B cell data where chromatin changes in the
bulk population are clearly visible despite a low frequency of cells
switching to IgE.
That histone H3 acetylation and H3K4 tri-methylation was
observed at the e locus in both the CL-01 and primary B cells is
not surprising; these chromatin marks generally correlate strongly
with transcriptional activation [19], which is observed in every B
cell upon IL-4 and CD40 stimulation [28]. Our current high
resolution mapping of these histone modifications extends our
previous findings [23] and is largely in agreement with several
previous reports identifying changes in these histone modifications
in response to CSR induction, although these were in all cases
carried out at low resolution and in mice [20–22,24,25]. Tri-
methylation of H3K4 is commonly detected proximal to
transcription start sites in transcriptionally active genes [18,40].
However, because H3K4me3 has been detected in human Se
(Figs. 3 and 4) and murine Sc1 [24], as well as recombining VH
genes [41,42], our data supports the hypothesis that H3K4me3 is
also a mark of recombinationally active chromatin. Indeed, the
V(D)J recombinase RAG2 contains an H3K4me3-binding PHD
domain that is required for its proper function [43–45]. It is
possible that a yet undiscovered PHD-containing cofactor is
involved in the proper targeting of AID to H3K4me3-enriched
activated switch regions.
We did not observe the significant changes in histone H4
acetylation or tri-methylation of histone H3 at lysine 9 within
switch regions that had previously been reported in murine
[21,22,25] and human B cells [23]. This demonstrates that
analyses of histone modifications at single points over large loci
can give misleading impressions of general levels of enrichments
over these regions. Additionally, different constant regions could
utilize different histone modifications to promote CSR. Previous
studies have described switch recombination at c loci, while we
particularly noted H3K9me3 accumulation at Sm and Sc regions
[23]. Our present high resolution analysis however has focused on
Se. Wang et al. [24] also observed induction of H3K36me3 just 39
of murine Sc1 in stimulated splenic B cells. We did not detect a
corresponding increase in H3K36me3 levels at the 39 end of Se in
CL-01 cells (Fig. S3). In addition to target identity and species-
specific differences, the size of the respective switch regions could
explain this difference. Because mouse Sc1 is approximately 10 kb
in size, the observed elevation in H3K36me3 could simply reflect
its association with transcriptional elongation [18,46–48], not a
specific feature of switch region chromatin. Se is approximately
2 kb in length and thus may be too close to the transcription start
site to accumulate detectable H3K36 tri-methylation marks.
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The histone modifications associated with silent heterochroma-
tin, tri-methylated H3K27 and K9, are already depleted at Se
before stimulation. Similarly, marks of active chromatin, H4
acetylation and H3K4me2 are elevated in this region before
stimulation. None of these modifications are significantly affected
by IL-4 stimulation, but provide an environment permissive for
AID deposition and action. These results support a model in
which the chromatin structure is ‘‘poised’’ within the switch
regions prior to cytokine stimulation [28].
In our primary human B cell studies we observed quantitative
differences in the enrichment of acetylated H3 and H3K4me3
between activated Se and Sc1 (Fig. 4). Broadly, the elevated levels
of these histone modifications at Sc1 compared to Se correlated
with greater RNAP occupancy and to a lesser extent AID
distribution. While it would have been desirable to perform a high-
resolution analysis of Sc1, the high degree of sequence repetition
at the IgG genes prevented this. Thus, we cannot discount the
possibility that these differences do not reflect the ‘‘general’’ level
of modification across the c1 locus. However, at least in places,
Sc1 is more highly modified than anywhere within Se. These
findings suggest that transcriptional activity, and in turn AID
accumulation, at the switch regions is likely to be facilitated by the
extent of histone modification over the genes; this could explain
the preferential switching to c compared to e CH genes in response
to IL-4 and CD40 signalling.
In both the CL-01 cells (Fig. 3) and primary human B cells
(Fig. 4) the nucleosomes near the Ie exon 59 splice site are
extensively modified and this coincided with a localised reduction
in DNA methylation and accumulation of RNAP and AID in
human B cells. A growing body of literature reveals a link between
chromatin structure and splicing [49]. Interestingly, Sims et al.
[50] found that the H3K4me3-binding chromatin remodelling
factor CHD1, which binds spliceosomal components, is required
for efficient RNA splicing. These data may go some way toward
explaining the interesting earlier findings that implicated the
requirement for the GLT splice site for successful CSR [51] and
supports the recent observation that AID associates with paused
RNA polymerase through an interaction with the spliceosome
factor spt5 [52]. It is possible that the altered chromatin structure
over the splice site may not only recruit complexes that are
essential for germline gene transcript processing, but also
complexes responsible for the process of DNA cleavage and
recombination.
The use of the CL-01 model system allowed us to obtain highly
reproducible data for changes associated with IL-4/anti-CD40
stimulation, which included increased histone H3 acetylation and
H3K4 tri-methylation. In the corresponding studies in primary B
cells, the specific distribution patterns varied among donors, but
comparison to the CL-01 data makes it clear that the overall
trends in primary B cells are similar to those in CL-01 cells. In the
five donors investigated, no correlation could be seen between the
levels of histone modification at Se at 48 hours and IgE secretion
at 12 days. Cell death is significant in the long-term (12 day)
cultures (Supplemental Table S1), yet this does not appear to be a
limiting factor for IgE production. We suggest that while histone
modification is necessary for CSR it is not sufficient, and other
factors must be involved in determining the success of CSR in
individual B cells.
Abnormal IgE production is associated with a range of
pathologies, including asthma, allergic rhinitis, Hyper-IgE and
Hyper-IgM Syndromes. The development of therapeutic ap-
proaches to controlling these disease states necessitates the
elucidation of mechanisms underlying CSR to IgE in human
systems. Our findings suggest that approaches that specifically
target the chromatin structural state in the switch region could be
employed, for example by manipulating the chromatin structure of
Se using methods that would not affect switching to other CH
genes [53].
Materials and Methods
Primary Human B Cell purification
Human B cells were isolated from tonsils collected from patients
undergoing routine tonsillectomies at the Evelina Children’s
Hospital (Guy’s and St. Thomas’ NHS Foundation Trust - ethics
approval from Guy’s Research Ethics Committee). The patients
were all aged between 2 and 14, had no history of asthma, any
known allergies or long standing medical conditions (except
tonsillitis) and were not taking any medications. The patients’
parents or legal guardians gave informed written consent for
participation in this study. Total B cells were isolated from the
tonsil as previously described [30]. B cell purity was assessed by
flow cytometry using fluorescently-labelled antibodies (DakoCyto-
mation) and a FACSCaliburTM flow cytometer (BD Biosciences).
B cell populations were routinely .95% CD19+, with ,5%
contaminating CD3+ T cells. Generally, around 60% of these cells
expressed IgM, with ,2% IgG or IgE expressing cells (data not
shown).
Cell culture
B cells were cultured in 24-well plates (Nunc) at 0.56106 cells/
mL in RPMI medium (Invitrogen Ltd.), supplemented with
transferrin (35 mg/mL, Sigma-Aldrich Company Ltd.), insulin
(5 mg/mL, Sigma-Aldrich Company Ltd.), penicillin (100 IU/
mL), streptomycin (100 mg/mL), glutamine (2 mM) (all Invitrogen
Ltd.) and 10% foetal bovine serum (FBS) (Hyclone, Perbio
Biosciences Ltd.). Where indicated, media were supplemented
with 1 mg/mL anti-CD40 antibody (G28.5, ATCC) and 200 IU/
mL of recombinant human IL-4 (R&D Systems Ltd.). Unless
specified in the text, cells were cultured for 48 hours prior to
extraction of chromatin (see below) and for 12 days for analysis of
IgE production. At the 48 hour time point cell viability is routinely
80–90%, as judged by trypan blue exclusion. Cell viability
following 12 days in culture, as judged by flow cytometry, was
more variable and is displayed for each donor in Supplemental
Table S1.
CL-01 cells were cultured in RPMI 1640 medium with
Glutamax (Invitrogen Ltd.) supplemented with 5% FBS (ATCC)
and antibiotics. Where indicated, cells were cultured with 200 IU/
mL of recombinant human IL-4 (R&D Systems Ltd.) and 1 mg/
mL anti-CD40 monoclonal antibody (mAb) (G28.5, ATCC). To
determine whether CSR had taken place after 7 days stimulation
with IL-4 and anti-CD40, cells were stained for extracellular IgG
or IgE and analysed by flow cytometry and the secretion of soluble
IgE and IgG was investigated by ELISA [28]. No surface bound or
secreted IgE or IgG was detected from the CL-01 cells following
stimulation (data not shown). The CL-01 cells were also stimulated
with IL-4 in combination with trimeric CD40-ligand [27],
however CSR to IgG and IgE could not be detected (data not
shown).
Detection of IgE
Secretion of IgE was analysed by ELISA as previously described
[28]. Briefly, Maxisorp plates (Nalge Europe Ltd.) were coated
with polyclonal mouse anti-human IgE (DakoCytomation) in
sodium carbonate buffer (pH 9.8) overnight at 4uC. Unbound sites
were blocked with 2% non-fat milk powder (Marvel) in PBS/
0.05% Tween (Sigma-Aldrich Company Ltd.). Samples were
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added and the plates were incubated for 16 hours at 4uC; NIP-IgE
(JW8/5/13, ECACC, UK) was used to construct a standard curve.
IgE was detected by mouse anti-human IgE conjugated to HRP
(DakoCytomation) diluted 1/1000 in PBS/Tween 20 0.05%/1%
non-fat milk powder for 4 hours at room temperature and
revealed with OPD (Sigma-Aldrich Company Ltd.), with a
minimum detection limit of 2 ng/mL. Surface IgE was detected
by flow cytometry using a goat anti-human IgE antibody (Vector
Laboratories Inc., Burlingame, USA). The percentage of IgE+ cells
and amount of IgE secreted for each sample are shown in
Supplemental Table S1.
RNA extraction and quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from 26106 cells using the RNeasy
RNA isolation kit (Qiagen). Genomic DNA contamination was
removed from 10 mg of total RNA using the Turbo DNA-free Kit
(Ambion). cDNA was generated using the SuperScript III First-
Strand Synthesis SuperMix for qRT-PCR (Invitrogen Ltd.). qRT-
PCR was performed using the ABI-7900HT machine and
TaqMan Universal PCR Mastermix (Applied Biosystems). Rela-
tive transcript levels were determined by comparing Ct values
from equivalent amounts of cDNA derived from untreated cells to
those from other experimental samples, all normalized to the
endogenous reference gene human HPRT (Applied Biosystems)
(DDCt analysis). Supplemental Table S2 and S3 list oligonucle-
otides used in qRT-PCR experiments.
Nucleosome Occupancy Analysis
Mono-, di- and tri-nucleosome fractions of native chromatin
were prepared and DNA extracted as previously described [31].
Genomic DNA was isolated using the DNeasy Blood & Tissue Kit
(Qiagen) and used as a reference for quantitative PCR (qPCR).
DNA samples were quantified using the Quant-iT PicoGreen
dsDNA reagent (Invitrogen Ltd.). 2 ng of DNA were subjected to
qPCR using multiple primer/probe sets and qPCR was performed
as described for qRT-PCR. Relative nucleosome abundance was
calculated using the formula: 2Ct(genomic)-Ct(nucleosomal).
Native chromatin immunoprecipitation
Native (non-formaldehyde-crosslinked) chromatin immunoprecipita-
tions (ChIPs) were performed and analysed in the IL-4 stimulated
CL-01 experiments as previously described [31]. Antibodies used
in this study included: anti-acetyl H3 (Millipore, 06-599), anti-
acetyl H4 (Millipore, 06-598), anti-H3K4me2 (Millipore, 07-030),
anti-H3K4me3 (Millipore, CS200580), anti-H3K9me3 (Abcam,
ab8898), anti-H3K27me3 (Millipore, 07-449), anti-H3K36me3
(Abcam, ab9050), anti-H2AZ (Millipore, 07-954), anti-RNA
Polymerase II (Covance, 8WG16) and anti-AID (Abcam, ab5197).
Formaldehyde crosslinked chromatin
immunoprecipitation
All ChIP experiments analyzing chromatin from cells cultured
with IL-4 and anti-CD40 mAb stimulation (CL-01 and primary
human B cells) were performed by formaldehyde crosslinking,
MNase-treatment and sonication of chromatin. Briefly, 16108
cells were fixed at 20uC for 4 minutes in 1% formaldehyde in
10 mL of culture medium. The cross-linking reaction was stopped
by the addition of glycine to a final concentration of 125 mM. The
cells were spun and the cell pellet resuspended in 16 PBS
containing 125 mM glycine and incubated at 20uC for 5 minutes.
Nuclei were isolated as detailed for primary human B cells [23]
and CL-01 [31]. MNase digestion and chromatin extraction were
performed as previously described [23]. Chromatin was sonicated
to aid DNA fragmentation to a 100 bp–500 bp range. 10 mg of
chromatin were diluted in 0.4 mL modified RIPA buffer (140 mM
NaCl, 10 mM Tris pH 7.5, 1 mM EDTA, 0.5 mM EGTA, 1%
Triton X-100, 0.01% SDS, 0.1% NaDeoxycholate) and incubated
overnight at 4uC with 3–5 mg of the appropriate antibody and
25 mL of Protein G-magnetic beads (Active Motif) in the presence
of protease inhibitor cocktail and 5 mM sodium butyrate (Sigma-
Aldrich Company Ltd.). Beads were washed twice in IPWB1
(20 mM Tris pH 8.0, 50 mM NaCl, 2 mM EDTA, 1% Triton X-
100, 0.1% SDS) and twice in IPWB2 (10 mM Tris pH 8.0,
150 mM NaCl, 1 mM EDTA, 1% NP-40, 250 mM LiCl, 1%
Sodium Deoxycholate). Beads were resuspended in 100 mL of 10%
Chelex 100 Resin (Bio-rad), boiled for 5 minutes, RNase-treated
for 60 minutes at 37uC and proteinase K-treated for 30 minutes at
55uC. Samples were boiled for 10 minutes and DNA-containing
supernatant was isolated for qPCR analysis. Equivalent volumes of
isolated ChIP DNA and input DNA were subjected to qPCR. A
standard curve was generated to convert the differences in Ct
values to percent of input.
qPCR analysis of ChIP experiments
Following extraction and purification of DNA from ChIPs,
qPCR was performed to determine enrichment of target
sequences. All primers used bound uniquely to the genome. Se
and negative control primer sets were designed using Primer
Express (Applied Biosystems) and checked for unique alignment to
the genome by BLAST analysis. Because of the repetitive nature of
the human IgG genes a novel primer design strategy was
employed to identify unique primer/probe pairs. Briefly, the c1
switch region sequence was incrementally divided into short
overlapping oligonucleotides of 18 to 25 bp in length. Oligonu-
cleotides having a GC content of 40 to 60% and containing no
repeats of greater than 4 nucleotides were selected for further
analysis. UNAfold analysis was performed to exclude oligonucle-
otides that could form homo-dimers at 45uC or with annealing
temperatures outside of the desired range (59 to 63u). Oligonu-
cleotides that bound uniquely to Sc1 were identified using
FASTA. Finally, suitable oligonucleotide pairs were identified
that produced amplicons of less than 190 bp in length and had a
difference in annealing temperatures of less than 2uC. Primer pairs
were checked for unique alignment by BLAST and probes
designed using the Universal ProbeLibrary Assay Design Centre
(Roche Applied Science). The location of all the IgE and IgG
primer sets (relative to the I exon) is shown in Supplemental Table
S3, and displayed graphically (Fig. S1). qPCR analysis was carried
out as described above. Sufficient DNA was recovered from the
native CL-01 cell histone ChIPs to allow accurate quantification of
recovered samples using the Quant-iT PicoGreen assay (Invitro-
gen Ltd.); fold enrichment values have therefore been displayed for
these ChIPs in Figures 1, 3, S2 and S3. Insufficient DNA was
recovered from crosslinked Polymerase and AID ChIPs to allow
accurate quantification. For all crosslinked ChIPs, recovered DNA
was quantified using a standard curve, generated from genomic
DNA serial dilutions, and expressed as percent recovery compared
to input.
Bisulphite modification analysis
Genomic DNA was extracted from 16107 cells using a WizardH
genomic DNA extraction kit (Promega, Madison, USA). CpG
methylation site mapping was performed by bisulphite modifica-
tion (BSM) of DNA, adapted from Frommer et al. [32], followed
by PCR amplification and sequencing. 10 mg of genomic DNA
were digested with Kpn I (New England Biolabs UK Ltd.) and
purified by phenol extraction, followed by ethanol precipitation.
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DNA was denatured by treatment with 0.2 M NaOH at 37uC for
15 minutes. To this, was added 30 ml of 10 mM hydroquinone
and 520 ml of 3 M sodium bisulphite pH 5 (both freshly prepared;
Sigma-Aldrich Company Ltd.). Samples were incubated in the
dark for 16 hours at 50uC prior to salt removal using the Wizard
DNA clean-up system (Promega). DNA was desulphonated in a
final concentration of 0.3 M NaOH at room temperature for
15 minutes, neutralised by adding 1 volume of 6 M ammonium
acetate, precipitated with 3 volumes of ethanol and resuspended in
20 mL TE buffer.
Primers for the amplification of BSM DNA were designed using
MethPrimer [33]. All PCR reactions were carried out on 2 ml of
BSM DNA in a 50 ml reaction volume containing 1.5 mM MgCl2
and Hotstart Platinum Taq (Invitrogen Ltd.). PCR-amplified
products were cloned using the TOPOH cloning system (Invitro-
gen Ltd.) and individual colonies sequenced. 20 sequences were
collected for each CpG site. The following primer pairs were used
for the amplification of BSM modified DNA: E1F TTTG-
TTGATTGGGATTATTAAGTT A, E1R CAAACAACCTCT-
CCCTCACAACTAC; E2F TTTTTTTTGTATGGGGA TAT-
AGGAA, E2R CCCAACTCAAACCTAACTCAACTAA; E3F
AGTTGAATTA GGTTGATTTGGATTT, E3R AACCTACT-




Table S1 IgE production and cell viability of B cell
cultures. IgE production and cell viability of each primary
human B cell culture was determined following 12 days
stimulation with IL-4 and anti-CD40. Secreted IgE was deter-
mined by ELISA, the % of IgE+ cells and cell viability were
determined by flow cytometry. UD. – Undetected.
(DOCX)
Table S2 qRT PCR Assays. Details of the assays used for
quantitative RT-PCR analyses are given; AID and HPRT were
detected by proprietary assays from Applied Biosystems. eGLT
assays were designed ‘‘in-house’’ and used MGB dual labelled
probes (Applied Biosystems).
(DOCX)
Table S3 qPCR assays. Details of the assays used for
quantitative PCR analysis of ChIPs and unspliced (primary)
eGLT assays are given; Se assays were designed ‘‘in-house’’ and
used dual labelled probes, c1, NeuroD1 and Myf4 assays were
designed to use dual labelled Universal Probe Library probes
(Roche). The approximate genomic location of each assay is given.
(PDF)
Figure S1 Location of qPCR primer sets across the IgE
locus. The location of the IgE qPCR primer sets is displayed on a
graphical represention (to scale) of the IgE locus.
(TIF)
Figure S2 ChIP analysis of H2A.Z deposition at the Ig e
locus in CL-01 cells. H2A.Z deposition over Se was
investigated in CL-01 by ChIP using size-selected native
chromatin. Cells were harvested following 72 hours culture with
or without IL-4. Mean results from 3 separate chromatin
extractions are plotted as fold enrichments over an input control.
Data from unstimulated cells is shown by open squares and solid
lines, stimulated cells are open circles and dashed lines. Error bars
show standard deviations. A schematic representation of the Ig e
locus, with the elements approximately to scale, is shown below the
graph indicating the position of each primer/TaqMan probe set
plotted on the X axis.
(TIF)
Figure S3 ChIP analysis of histone modifications at the
Ig e locus in CL-01 cells following IL-4 stimulation.
Histone modification over Se was investigated in CL-01 by ChIP
using size-selected native chromatin. Cells were harvested
following 72 hours culture with or without IL-4. Mean results
from 3 separate chromatin extractions are plotted as fold
enrichments over an input control. Data from unstimulated cells
is shown by open squares and solid lines, stimulated cells are open
circles and dashed lines. Error bars show standard deviations. A
schematic representation of the Ig e locus, with the elements
approximately to scale, is shown below each graph indicating the
position of each primer/TaqMan probe set plotted on the X axis.
The following histone modifications are shown: AcH4, di-methyl
H3K4, tri-methyl H3K36, tri-methyl H3K9 and tri-methyl
H3K27.
(TIF)
Figure S4 ChIP analysis of histone modifications at the
Ig e locus in CL-01 cells following IL-4 and anti-CD40
stimulation. Histone modification over Se was investigated in
CL-01 by ChIP using size-selected native (non-crosslinked)
chromatin. Cells were harvested following 72 hours culture with
or without IL-4 and anti-CD40. Mean results from 3 separate
chromatin extractions are plotted as fold enrichments over an
input control. Data from unstimulated cells is shown by open
squares and solid lines; stimulated cells are open circles and dashed
lines. Error bars show standard deviations. A schematic represen-
tation of the Ig e locus, with the elements approximately to scale, is
shown below each graph indicating the position of each primer/
TaqMan probe set plotted on the X axis.
(TIF)
Figure S5 Analysis of DNA CpG methylation over Se and
Sc1. CpG methylation was analysed across Se by bisulphite
modification of DNA followed by sequencing. Genomic DNA was
extracted from tonsil B cells isolated from three donors, 20
sequences were collected for each CpG site. The percentage of
methylated deoxcytidines found across the three donors is plotted;
error bars show the standard deviation in the data between the
three donors. The location of the CpG site is shown on the x axis:
Numbers refer to the distance (bp) from the Ie start site and the
location is displayed on the graphical representation of the IgE
locus below; long vertical lines show each CpGs analysed, short
lines show the location of CpGs that could not be analysed
(distance from Ie is given below the graphic). The locations of 5
sites that have especially low levels of methylation are emphasised.
(TIF)
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